{
    "headline": "Real-world evidence: Driving a new drug-development paradigm in oncology",
    "link": "https://www.mckinsey.com/industries/life-sciences/our-insights/real-world-evidence-driving-a-new-drug-development-paradigm-in-oncology",
    "content": "<!DOCTYPE html><html dir=\"ltr\" lang=\"en\"><head><meta charset=\"utf-8\"><meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\"><meta http-equiv=\"X-UA-Compatible\" content=\"IE=edge\"><iframe src=\"javascript:void(0)\" title=\"\" role=\"presentation\" style=\"width: 0px; height: 0px; border: 0px; display: none;\"></iframe><script>var McKinsey = {\"ArticleTemplate\":\"Legacy\",\"DaysSinceCMSPublication\":\"600\",\"DisplayDate\":\"7/24/2018\",\"OriginalPublicationDate\":\"6/1/2018\",\"SitecoreId\":\"{FE170B38-BD48-4955-8ABA-7173563E1F6B}\",\"Title\":\"Real-world evidence: Driving a new drug-development paradigm in oncology\",\"ArticleType\":\"Article\",\"ContentType\":\"Article\",\"ServerNumber\":\"\",\"IsPageRestricted\":\"true\",\"UserID\":\"\",\"RegistrationDate\":\"\",\"LoginStatus\":\"logged_out\",\"JobTitle\":\"\",\"CompanyName\":\"\",\"blogTags\":null}; var pageMetaInformation = {\"CurrentLanguage\":\"en\",\"AlternateLanguages\":[{\"DisplayName\":\"English\",\"LanguageCode\":\"en\",\"Url\":\"/industries/life-sciences/our-insights/real-world-evidence-driving-a-new-drug-development-paradigm-in-oncology\"}],\"NavigationLink\":\"industries\",\"ActiveItemId\":\"{BB8498AC-8CC4-4BFB-8832-53C76F3E61CF}\",\"OfficeCode\":\"\",\"MiniSiteId\":\"{CDBF3A89-AE60-459E-ACF8-786E31307534}\"};</script><link rel=\"icon\" href=\"/favicon.ico\"><link href=\"https://www.mckinsey.com/redesign/resources/css/styles-rc.css\" rel=\"stylesheet\"><link rel=\"manifest\" href=\"/manifest.json\"><link rel=\"dns-prefetch\" href=\"//cdn.dynamicyield.com\"><link rel=\"dns-prefetch\" href=\"//st.dynamicyield.com\"><link rel=\"dns-prefetch\" href=\"//rcom.dynamicyield.com\"><link rel=\"dns-prefetch\" href=\"//cdn.cookielaw.org\"><link rel=\"preconnect\" href=\"//assets.adobedtm.com\"><link rel=\"preconnect\" href=\"//connect.facebook.net\"><link rel=\"preconnect\" href=\"//static.hotjar.com\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/bower/Bower-Bold.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/regular/McKinseySans-Regular.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/medium/McKinseySans-Medium.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/light/McKinseySans-Light.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/italic/McKinseySans-Italic.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/light-italic/McKinseySans-LightItalic.woff2\" type=\"font/woff2\" crossorigin=\"\"><link rel=\"preload\" as=\"font\" href=\"/next-static/fonts/mckinsey-sans/medium-italic/McKinseySans-MediumItalic.woff2\" type=\"font/woff2\" crossorigin=\"\"><meta name=\"apple-itunes-app\" content=\"app-id=674902075\"><link rel=\"apple-touch-icon\" sizes=\"57x57\" href=\"/next-static/images/mck-touch-icon-57x57.png\"><link rel=\"apple-touch-icon\" sizes=\"72x72\" href=\"/next-static/images/mck-touch-icon-72x72.png\"><link rel=\"apple-touch-icon\" sizes=\"114x114\" href=\"/next-static/images/mck-touch-icon-114x114.png\"><link rel=\"apple-touch-icon\" sizes=\"144x144\" href=\"/next-static/images/mck-touch-icon-144x144.png\"><link rel=\"apple-touch-icon\" sizes=\"152x152\" href=\"/next-static/images/mck-touch-icon-152x152.png\"><link rel=\"apple-touch-icon\" sizes=\"167x167\" href=\"/next-static/images/mck-touch-icon-167x167.png\"><link rel=\"apple-touch-icon\" sizes=\"180x180\" href=\"/next-static/images/mck-touch-icon-180x180.png\"><meta content=\"no-referrer-when-downgrade\" name=\"referrer\"><meta content=\"McKinsey &amp; Company\" property=\"og:site_name\" name=\"site_name\"><meta content=\"Real-world evidence: Driving a new drug-development paradigm in oncology\" property=\"og:title\" name=\"title\"><meta content=\"The potential for real-world evidence is expanding, particularly in oncology drug development. To compete, some companies are investing in robust real-world data and analytic capabilities.\" property=\"og:description\" name=\"description\"><meta content=\"https://www.mckinsey.com/industries/life-sciences/our-insights/real-world-evidence-driving-a-new-drug-development-paradigm-in-oncology\" name=\"url\" property=\"og:url\"><meta content=\"index,follow,all\" name=\"robots\"><meta content=\"https://www.mckinsey.com/~/media/mckinsey/industries/life%20sciences/our%20insights/real%20world%20evidence%20driving%20a%20new%20drug%20development%20paradigm%20in%20oncology/real-world-evidence-driving-new-drug-1536x1536-800.jpg\" property=\"og:image\" name=\"image\"><meta content=\"{FE170B38-BD48-4955-8ABA-7173563E1F6B}\" name=\"sid\"><link href=\"https://www.mckinsey.com/industries/life-sciences/our-insights/real-world-evidence-driving-a-new-drug-development-paradigm-in-oncology\" rel=\"canonical\"><meta content=\"Life Sciences\" name=\"practice-name\"><meta content=\"N20\" name=\"practice-code\"><meta content=\"summary_large_image\" name=\"twitter:card\"><meta content=\"@mckinsey\" name=\"twitter:site\"><title>Real-world evidence: Driving a new drug-development paradigm in oncology | McKinsey</title><meta content=\"Insights &amp; Publications\" name=\"sections\"><meta content=\"Real-world evidence: Driving a new drug-development paradigm in oncology\" name=\"twitter:title\"><meta content=\"The potential for real-world evidence is expanding, particularly in oncology drug development. To compete, some companies are investing in robust real-world data and analytic capabilities.\" name=\"twitter:description\"><meta content=\"Article\" property=\"contenttype\" name=\"contenttype\"><meta content=\"https://www.mckinsey.com/~/media/mckinsey/industries/life%20sciences/our%20insights/real%20world%20evidence%20driving%20a%20new%20drug%20development%20paradigm%20in%20oncology/real-world-evidence-driving-new-drug-1536x1536-800.jpg?mw=677&amp;car=42:25\" name=\"twitter:image\"><meta content=\"Real-world evidence: Driving a new drug-development paradigm in oncology\" name=\"twitter:image:alt\"><meta content=\"true\" name=\"mobileready\"><meta content=\"public\" name=\"accesslevel\"><meta content=\"false\" name=\"excludefromclientlink\"><meta content=\"article\" name=\"articletype\"><meta content=\"Arnaub Chatterjee | Sastry Chilukuri | Edd Fleming | Adam Knepp | Saif Rathore | Joe Zabinski\" name=\"authors-name\"><meta content=\"2018-07-24T00:00:00Z\" name=\"itemdate\"><meta content=\"Life Sciences | Article | July 24, 2018\" name=\"searchresults-tags\"><script type=\"application/ld+json\">{\"@context\":\"https://schema.org\",\"@type\":\"Article\",\"url\":\"https://www.mckinsey.com\",\"publisher\":{\"@type\":\"Organization\",\"name\":\"McKinsey & Company\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https://www.mckinsey.com/~/media/Thumbnails/Mck_Logo\"}},\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https://www.mckinsey.com/industries/life-sciences/our-insights/real-world-evidence-driving-a-new-drug-development-paradigm-in-oncology\"},\"datePublished\":\"2018-06-01T00:00:00Z\",\"dateCreated\":\"2018-07-18T20:41:57Z\",\"dateModified\":\"2018-07-24T00:00:00Z\",\"heading\":\"Real-world evidence: Driving a new drug-development paradigm in oncology\",\"image\":\"https://www.mckinsey.com/~/media/mckinsey/industries/life%20sciences/our%20insights/real%20world%20evidence%20driving%20a%20new%20drug%20development%20paradigm%20in%20oncology/real-world-evidence-driving-new-drug-1536x1536-800.jpg\",\"description\":\"The potential for real-world evidence is expanding, particularly in oncology drug development. To compete, some companies are investing in robust real-world data and analytic capabilities.\",\"author\":[{\"@type\":\"Person\",\"name\":\"Arnaub Chatterjee\"},{\"@type\":\"Person\",\"name\":\"Sastry Chilukuri\"},{\"@type\":\"Person\",\"name\":\"Edd Fleming\"},{\"@type\":\"Person\",\"name\":\"Adam Knepp\"},{\"@type\":\"Person\",\"name\":\"Saif Rathore\"},{\"@type\":\"Person\",\"name\":\"Joe Zabinski\"}]}</script><meta charset=\"utf-8\"><meta name=\"next-head-count\" content=\"58\"><meta name=\"next-font-preconnect\"><script src=\"\" id=\"onetrust-wrapperchecker\" data-nscript=\"beforeInteractive\">function OptanonWrapperChecker() {}</script><link rel=\"preload\" href=\"/_next/static/css/2fad2c5744177bb8.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/2fad2c5744177bb8.css\" data-n-g=\"\"><link rel=\"preload\" href=\"/_next/static/css/dc5a0fd9c531d8ae.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/dc5a0fd9c531d8ae.css\" data-n-p=\"\"><link rel=\"preload\" href=\"/_next/static/css/529ed6e2fac958b2.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/529ed6e2fac958b2.css\"><link rel=\"preload\" href=\"/_next/static/css/cb9982a1c7acea8c.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/cb9982a1c7acea8c.css\"><link rel=\"preload\" href=\"/_next/static/css/72fc56b1fbe032aa.css\" as=\"style\"><link rel=\"stylesheet\" href=\"/_next/static/css/72fc56b1fbe032aa.css\"><noscript data-n-css=\"\"></noscript><script defer=\"\" nomodule=\"\" src=\"/_next/static/chunks/polyfills-5cd94c89d3acac5f.js\"></script><script src=\"https://cdn.cookielaw.org/scripttemplates/otSDKStub.js\" data-document-language=\"true\" type=\"text/javascript\" data-domain-script=\"915b5091-0d7e-44d2-a8c4-cf08267e52fe\" defer=\"\" data-nscript=\"beforeInteractive\"></script><script defer=\"\" src=\"/_next/static/chunks/281.674cd4210cb46873.js\"></script><script defer=\"\" src=\"/_next/static/chunks/3769.eb77385153f1a4b1.js\"></script><script defer=\"\" src=\"/_next/static/chunks/6731.9bccca8a7edb0704.js\"></script><script defer=\"\" src=\"/_next/static/chunks/2991.4cb0aa2f9f53e653.js\"></script><script src=\"/_next/static/chunks/webpack.47afe4b83145c95f.js\" defer=\"\"></script><script src=\"/_next/static/chunks/framework.62bbe2ca94854a85.js\" defer=\"\"></script><script src=\"/_next/static/chunks/main.51e10588adc949ca.js\" defer=\"\"></script><script src=\"/_next/static/chunks/pages/_app.e3dd57df2dc16789.js\" defer=\"\"></script><script src=\"/_next/static/chunks/3b1baa31.cd6cdac6158774d8.js\" defer=\"\"></script><script src=\"/_next/static/chunks/7d0bf13e.8f3383787afb45af.js\" defer=\"\"></script><script src=\"/_next/static/chunks/1354.c34ddc4bd7c986c8.js\" defer=\"\"></script><script src=\"/_next/static/chunks/408.9bf4e4647a127fd0.js\" defer=\"\"></script><script src=\"/_next/static/chunks/pages/%5B%5B...path%5D%5D.99501948ed14e00a.js\" defer=\"\"></script><script src=\"/_next/static/AymXir4ImcRSnB3UIpSL6/_buildManifest.js\" defer=\"\"></script><script src=\"/_next/static/AymXir4ImcRSnB3UIpSL6/_ssgManifest.js\" defer=\"\"></script><script src=\"/_next/static/AymXir4ImcRSnB3UIpSL6/_middlewareManifest.js\" defer=\"\"></script>\n<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push([\"addVar\",{\"rua.upush\":\"false\",\"rua.cpush\":\"false\",\"rua.upre\":\"false\",\"rua.cpre\":\"false\",\"rua.uprl\":\"false\",\"rua.cprl\":\"false\",\"rua.cprf\":\"false\",\"rua.trans\":\"SJ-b7ca1abb-ecba-4149-9919-3f315fab5f35\",\"rua.cook\":\"true\",\"rua.ims\":\"false\",\"rua.ufprl\":\"false\",\"rua.cfprl\":\"false\",\"rua.isuxp\":\"false\",\"rua.texp\":\"norulematch\",\"rua.ceh\":\"false\",\"rua.ueh\":\"false\",\"rua.ieh.st\":\"0\"}]);</script>\n                              <script>!function(a){var e=\"https://s.go-mpulse.net/boomerang/\",t=\"addEventListener\";if(\"False\"==\"True\")a.BOOMR_config=a.BOOMR_config||{},a.BOOMR_config.PageParams=a.BOOMR_config.PageParams||{},a.BOOMR_config.PageParams.pci=!0,e=\"https://s2.go-mpulse.net/boomerang/\";if(window.BOOMR_API_key=\"TURRK-8ADJT-WDUC5-TC32E-KV9ND\",function(){function n(e){a.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!a.BOOMR||!a.BOOMR.version&&!a.BOOMR.snippetExecuted){a.BOOMR=a.BOOMR||{},a.BOOMR.snippetExecuted=!0;var i,_,o,r=document.createElement(\"iframe\");if(a[t])a[t](\"load\",n,!1);else if(a.attachEvent)a.attachEvent(\"onload\",n);r.src=\"javascript:void(0)\",r.title=\"\",r.role=\"presentation\",(r.frameElement||r).style.cssText=\"width:0;height:0;border:0;display:none;\",o=document.getElementsByTagName(\"script\")[0],o.parentNode.insertBefore(r,o);try{_=r.contentWindow.document}catch(O){i=document.domain,r.src=\"javascript:var d=document.open();d.domain='\"+i+\"';void(0);\",_=r.contentWindow.document}_.open()._l=function(){var a=this.createElement(\"script\");if(i)this.domain=i;a.id=\"boomr-if-as\",a.src=e+\"TURRK-8ADJT-WDUC5-TC32E-KV9ND\",BOOMR_lstart=(new Date).getTime(),this.body.appendChild(a)},_.write(\"<bo\"+'dy onload=\"document._l();\">'),_.close()}}(),\"\".length>0)if(a&&\"performance\"in a&&a.performance&&\"function\"==typeof a.performance.setResourceTimingBufferSize)a.performance.setResourceTimingBufferSize();!function(){if(BOOMR=a.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var e=\"false\"==\"true\"?1:0,t=\"cookiepresent\",n=\"ajsxrwycc6kamzy2osvq-f-f8269841e-clientnsv4-s.akamaihd.net\",i=\"false\"==\"true\"?2:1,_={\"ak.v\":\"39\",\"ak.cp\":\"19387\",\"ak.ai\":parseInt(\"285213\",10),\"ak.ol\":\"0\",\"ak.cr\":27,\"ak.ipv\":4,\"ak.proto\":\"h2\",\"ak.rid\":\"4b36fd\",\"ak.r\":49473,\"ak.a2\":e,\"ak.m\":\"a\",\"ak.n\":\"essl\",\"ak.bpcip\":\"2.101.120.0\",\"ak.cport\":63914,\"ak.gh\":\"2.21.6.28\",\"ak.quicv\":\"\",\"ak.tlsv\":\"tls1.3\",\"ak.0rtt\":\"\",\"ak.0rtt.ed\":\"\",\"ak.csrc\":\"-\",\"ak.acc\":\"\",\"ak.t\":\"1729787051\",\"ak.ak\":\"hOBiQwZUYzCg5VSAfCLimQ==WyvmSEJXGjYqdGqv5wKed3wFfquSWXPVIP62p5Sj06al8tjT1ZK6r3DwivT8fS75BYdkQFY9sYEdURrwRiCUvWsUt2gFsYbLPgs74CvmcYwXnRLdwj/WLACIeEeBmdWK6r9/yasQ2y6VYU2d51k6vbQ9NzLRDnEhl49CIb04FqU/24Xsx9eJEQpiD/nvZ/F/IMk74f8u45iy0vfSR9yM5x7EByFlGt9LDcuYAT5DhJ+Tr1ju5ZoSq2moVrV/TnG2zQQ2KYeO++Ql5skX/GHwhUKGrvrwm+aSwC8Grd4RtrSsdTn4+mNmWNXhm8HLahLOSs3pN5CWArSrPA3EaGE6J3obWzGM8RAwAEZY43Vn/gKYT9mtEJseNqDV1N9sE1NtKtGRJohiO2rMXB9dRteWElXoxj52ASL660UT9CHViy0=\",\"ak.pv\":\"570\",\"ak.dpoabenc\":\"\",\"ak.tf\":i};if(\"\"!==t)_[\"ak.ruds\"]=t;var o={i:!1,av:function(e){var t=\"http.initiator\";if(e&&(!e[t]||\"spa_hard\"===e[t]))_[\"ak.feo\"]=void 0!==a.aFeoApplied?1:0,BOOMR.addVar(_)},rv:function(){var a=[\"ak.bpcip\",\"ak.cport\",\"ak.cr\",\"ak.csrc\",\"ak.gh\",\"ak.ipv\",\"ak.m\",\"ak.n\",\"ak.ol\",\"ak.proto\",\"ak.quicv\",\"ak.tlsv\",\"ak.0rtt\",\"ak.0rtt.ed\",\"ak.r\",\"ak.acc\",\"ak.t\",\"ak.tf\"];BOOMR.removeVar(a)}};BOOMR.plugins.AK={akVars:_,akDNSPreFetchDomain:n,init:function(){if(!o.i){var a=BOOMR.subscribe;a(\"before_beacon\",o.av,null,null),a(\"onbeacon\",o.rv,null,null),o.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><style type=\"text/css\">.mdc-c-button___U4iY2_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;border:var(--mdc-size-border-width-1) solid #0000;border-radius:0;color:var(--text-color-default);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);padding:0;text-align:center}.mdc-c-button___U4iY2_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--primary___Ed-lT_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;background-color:var(--button-primary-background);border:var(--mdc-size-border-width-1) solid #0000;border-radius:0;color:var(--button-primary-text);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-32);min-width:200px;padding:0;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);text-align:center;transition:all .12s linear}@media (hover:hover){.mdc-c-button--primary___Ed-lT_990311c:hover{background-color:var(--button-primary-background-hover);border:var(--mdc-size-border-width-1) solid var(--button-primary-border-hover);box-shadow:0 7px 14px 0 #0003;color:var(--button-primary-text-hover);outline:none;transform:translateY(-2px)}}.mdc-c-button--primary___Ed-lT_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--primary___Ed-lT_990311c .mdc-c-icon___1vWkz_990311c:before{color:var(--button-primary-text)}.mdc-c-button--primary___Ed-lT_990311c .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-primary-text);color:var(--button-primary-background)}@media (hover:hover){.mdc-c-button--primary___Ed-lT_990311c:hover .mdc-c-icon___1vWkz_990311c:before{color:var(--button-primary-text-hover)}.mdc-c-button--primary___Ed-lT_990311c:hover .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-primary-text-hover);color:var(--button-primary-background-hover)}}.mdc-c-button--primary___Ed-lT_990311c:focus .mdc-c-icon___1vWkz_990311c:before{color:var(--button-primary-text)}.mdc-c-button--primary___Ed-lT_990311c:focus .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-primary-text);color:var(--button-primary-background)}.mdc-c-button--secondary___Boipq_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;background-color:var(--button-primary-background);background-color:var(--button-secondary-background);border:var(--mdc-size-border-width-1) solid var(--button-secondary-border);border-radius:0;color:var(--button-primary-text);color:var(--button-secondary-text);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-32);min-width:200px;padding:0;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);text-align:center;transition:all .12s linear}@media (hover:hover){.mdc-c-button--secondary___Boipq_990311c:hover{background-color:var(--button-primary-background-hover);background-color:var(--button-secondary-background-hover);border:var(--mdc-size-border-width-1) solid var(--button-primary-border-hover);border:var(--mdc-size-border-width-1) solid var(--button-secondary-border-hover);box-shadow:0 7px 14px 0 #0003;color:var(--button-primary-text-hover);color:var(--button-secondary-text-hover);outline:none;transform:translateY(-2px)}}.mdc-c-button--secondary___Boipq_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--secondary___Boipq_990311c .mdc-c-icon___1vWkz_990311c:before{color:var(--button-secondary-text);line-height:1}.mdc-c-button--secondary___Boipq_990311c .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-secondary-text);color:var(--mdc-color-neutral-white)}@media (hover:hover){.mdc-c-button--secondary___Boipq_990311c:hover .mdc-c-icon___1vWkz_990311c:before{color:var(--button-secondary-text-hover)}.mdc-c-button--secondary___Boipq_990311c:hover .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-secondary-text-hover);color:var(--button-secondary-background-hover)}}.mdc-c-button--secondary___Boipq_990311c:focus .mdc-c-icon___1vWkz_990311c:before{color:var(--button-secondary-text)}.mdc-c-button--secondary___Boipq_990311c:focus .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-secondary-text);color:var(--button-secondary-icon-focus)}.mdc-c-button--tertiary___zPM6q_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:var(--button-primary-background);background-color:initial;border:var(--mdc-size-border-width-1) solid var(--button-tertiary-border);border-radius:0;color:var(--button-primary-text);color:var(--button-tertiary-text);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-32);min-width:200px;padding:0;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);text-align:center;transition:all .12s linear}@media (hover:hover){.mdc-c-button--tertiary___zPM6q_990311c:hover{background-color:var(--button-primary-background-hover);background-color:var(--button-tertiary-background-hover);border:var(--mdc-size-border-width-1) solid var(--button-primary-border-hover);border:var(--mdc-size-border-width-1) solid var(--button-tertiary-border-hover);box-shadow:0 7px 14px 0 #0003;color:var(--button-primary-text-hover);color:var(--button-tertiary-text-hover);outline:none;transform:translateY(-2px)}}.mdc-c-button--tertiary___zPM6q_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--tertiary___zPM6q_990311c .mdc-c-icon___1vWkz_990311c:before{color:var(--button-tertiary-text)}.mdc-c-button--tertiary___zPM6q_990311c .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-tertiary-text);color:var(--button-tertiary-text-hover)}@media (hover:hover){.mdc-c-button--tertiary___zPM6q_990311c:hover .mdc-c-icon___1vWkz_990311c:before{color:var(--button-tertiary-text-hover)}.mdc-c-button--tertiary___zPM6q_990311c:hover .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-tertiary-text-hover);color:var(--button-tertiary-text)}}.mdc-c-button--tertiary___zPM6q_990311c:focus .mdc-c-icon___1vWkz_990311c:before{color:var(--button-tertiary-text)}.mdc-c-button--tertiary___zPM6q_990311c:focus .mdc-c-icon--radial___uCcK5_990311c:before{background-color:var(--button-tertiary-text);color:var(--button-tertiary-text-hover)}.mdc-c-button--minimal___Uzgaz_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;border-bottom:var(--mdc-size-border-width-1) solid #0000;border:var(--mdc-size-border-width-1) solid #0000;border-bottom-width:var(--mdc-size-border-width-2);border-radius:0;color:var(--button-minimal-primary);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);padding:0;text-align:center}@media (hover:hover){.mdc-c-button--minimal___Uzgaz_990311c:hover{border-bottom-color:var(--button-minimal-primary)}}.mdc-c-button--minimal___Uzgaz_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--minimal___Uzgaz_990311c.mdc-c-button--size-large___jwpUy_990311c,.mdc-c-button--minimal___Uzgaz_990311c.mdc-c-button--size-small___uvMIB_990311c{padding-left:0;padding-right:0}.mdc-c-button--minimal-secondary___W0Qrc_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;border-bottom:var(--mdc-size-border-width-1) solid #0000;border:var(--mdc-size-border-width-1) solid #0000;border-bottom-width:var(--mdc-size-border-width-2);border-radius:0;color:var(--button-minimal-secondary);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);padding:0;text-align:center}@media (hover:hover){.mdc-c-button--minimal-secondary___W0Qrc_990311c:hover{border-bottom-color:var(--button-minimal-secondary)}}.mdc-c-button--minimal-secondary___W0Qrc_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--minimal-secondary___W0Qrc_990311c.mdc-c-button--size-large___jwpUy_990311c,.mdc-c-button--minimal-secondary___W0Qrc_990311c.mdc-c-button--size-small___uvMIB_990311c{padding-left:0;padding-right:0}.mdc-c-button--minimal-tertiary___YwyAF_990311c{grid-gap:var(--mdc-size-spacing-8);align-items:center;background-color:initial;border-bottom:var(--mdc-size-border-width-1) solid #0000;border:var(--mdc-size-border-width-1) solid #0000;border-bottom-width:var(--mdc-size-border-width-2);border-radius:0;color:var(--button-minimal-tertiary);cursor:pointer;display:inline-grid;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);grid-auto-flow:column;justify-content:center;line-height:var(--mdc-size-line-height-24);padding:0;text-align:center}@media (hover:hover){.mdc-c-button--minimal-tertiary___YwyAF_990311c:hover{border-bottom-color:var(--button-minimal-tertiary-hover);color:var(--button-minimal-tertiary-hover)}}.mdc-c-button--minimal-tertiary___YwyAF_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default)}.mdc-c-button--minimal-tertiary___YwyAF_990311c.mdc-c-button--size-large___jwpUy_990311c,.mdc-c-button--minimal-tertiary___YwyAF_990311c.mdc-c-button--size-small___uvMIB_990311c{padding-left:0;padding-right:0}.mdc-c-button--size-large___jwpUy_990311c{font-size:var(--mdc-size-font-18);line-height:var(--mdc-size-line-height-28);min-height:var(--mdc-size-spacing-48);padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-24)}.mdc-c-button--size-small___uvMIB_990311c{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20);min-height:var(--mdc-size-spacing-32);min-width:var(--mdc-size-spacing-72);padding:var(--mdc-size-spacing-4) var(--mdc-size-spacing-16)}.mdc-c-button--btn-compact___P-iHa_990311c{min-width:auto}.mdc-c-button--disabled___Xbyp5_990311c{border:none!important;cursor:not-allowed}.mdc-c-button--disabled___Xbyp5_990311c:active,.mdc-c-button--disabled___Xbyp5_990311c:focus,.mdc-c-button--disabled___Xbyp5_990311c:hover{border:none!important;box-shadow:none!important;outline:none!important;transform:none!important}.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--primary___Ed-lT_990311c{background-color:var(--button-primary-disabled-background);color:var(--button-disabled-text)}.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--secondary___Boipq_990311c,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--tertiary___zPM6q_990311c{background-color:var(--button-secondary-disabled-background);border:var(--mdc-size-border-width-1) solid var(--button-secondary-disabled-border)!important;color:var(--button-disabled-text)}.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--secondary___Boipq_990311c:active,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--secondary___Boipq_990311c:focus,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--secondary___Boipq_990311c:hover,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--tertiary___zPM6q_990311c:active,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--tertiary___zPM6q_990311c:focus,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--tertiary___zPM6q_990311c:hover{border:var(--mdc-size-border-width-1) solid var(--button-secondary-disabled-border)!important}.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--minimal-secondary___W0Qrc_990311c,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--minimal-tertiary___YwyAF_990311c,.mdc-c-button--disabled___Xbyp5_990311c.mdc-c-button--minimal___Uzgaz_990311c{color:var(--button-minimal-disabled)}</style><style type=\"text/css\">.mdc-c-link-cta___NBQVi_990311c,.mdc-c-link-icon___SEKyg_990311c,.mdc-c-link-inline___7DRrt_990311c,.mdc-c-link___lBbY1_990311c{align-items:center;color:currentcolor;display:inline-flex;gap:var(--mdc-size-spacing-8)}.mdc-c-link-cta___NBQVi_990311c:focus-visible,.mdc-c-link-icon___SEKyg_990311c:focus-visible,.mdc-c-link-inline___7DRrt_990311c:focus-visible,.mdc-c-link___lBbY1_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--link-color-selected);outline-offset:var(--mdc-size-border-width-4)}.mdc-c-link___lBbY1_990311c{color:var(--link-color-default);text-decoration:none}.mdc-c-link___lBbY1_990311c:focus .mdc-c-link__label___Pfqtd_990311c,.mdc-c-link___lBbY1_990311c:hover .mdc-c-link__label___Pfqtd_990311c{text-decoration-line:underline;text-decoration-thickness:calc(var(--mdc-size-spacing-4)/2);text-underline-offset:calc(var(--mdc-size-spacing-4)/2)}.mdc-c-link--secondary___TSFam_990311c{color:var(--link-color-secondary-default)}.mdc-c-link-inline___7DRrt_990311c{border-bottom:2px solid var(--link-inline-default-border-color);color:currentcolor;line-height:1;padding-left:calc(var(--mdc-size-spacing-4)/2);padding-right:calc(var(--mdc-size-spacing-4)/2);text-decoration:none;transition:.12s linear;transition-property:background-color,color}.mdc-c-link-inline___7DRrt_990311c:hover{background-color:var(--link-inline-default-background-hover-color);border-color:var(--link-inline-default-border-hover-color);color:var(--link-inline-default-hover-color);text-decoration:none}.mdc-c-link-inline--secondary___YKoOK_990311c{border-bottom-color:initial}.mdc-c-link-inline--secondary___YKoOK_990311c:hover{background-color:var(--link-inline-secondary-background-hover-color);border-bottom-color:var(--link-inline-secondary-background-hover-color);color:var(--link-inline-secondary-hover-color)}.mdc-c-link-cta___NBQVi_990311c{color:var(--link-color-text-default);display:inline-block;font-weight:var(--mdc-font-weight-medium)}.mdc-c-link-cta___NBQVi_990311c span[class$=icon]{padding-left:var(--mdc-size-spacing-8);padding-right:var(--mdc-size-spacing-16);transition:padding .4s ease-in-out;vertical-align:initial}.mdc-c-link-cta___NBQVi_990311c span[class$=icon]:before{color:var(--link-cta-icon-color)}.mdc-c-link-cta___NBQVi_990311c:active,.mdc-c-link-cta___NBQVi_990311c:focus,.mdc-c-link-cta___NBQVi_990311c:hover{color:var(--link-color-text-default-hover)}.mdc-c-link-cta___NBQVi_990311c:active span[class$=icon],.mdc-c-link-cta___NBQVi_990311c:focus span[class$=icon],.mdc-c-link-cta___NBQVi_990311c:hover span[class$=icon]{padding-left:var(--mdc-size-spacing-24);padding-right:0}.mdc-c-link-cta--size-large___udJoH_990311c{font-size:var(--mdc-size-font-20);font-weight:var(--mdc-font-weight-regular);line-height:var(--mdc-size-line-height-32)}@media (min-width:1180px){.mdc-c-link-cta--size-large___udJoH_990311c{font-size:var(--mdc-size-font-28);line-height:var(--mdc-size-line-height-40)}.mdc-c-link-cta--size-large___udJoH_990311c span[class$=icon]{padding-left:var(--mdc-size-spacing-16);padding-right:var(--mdc-size-spacing-32);transition:padding .4s ease-in-out;vertical-align:initial}.mdc-c-link-cta--size-large___udJoH_990311c span[class$=icon]:before{color:var(--link-cta-icon-color)}.mdc-c-link-cta--size-large___udJoH_990311c:active,.mdc-c-link-cta--size-large___udJoH_990311c:focus,.mdc-c-link-cta--size-large___udJoH_990311c:hover{color:var(--link-color-text-default-hover)}.mdc-c-link-cta--size-large___udJoH_990311c:active span[class$=icon],.mdc-c-link-cta--size-large___udJoH_990311c:focus span[class$=icon],.mdc-c-link-cta--size-large___udJoH_990311c:hover span[class$=icon]{padding-left:var(--mdc-size-spacing-48);padding-right:0}}.mdc-c-link-icon___SEKyg_990311c{color:var(--link-icon-color)}.mdc-c-link-icon___SEKyg_990311c:focus,.mdc-c-link-icon___SEKyg_990311c:hover{color:var(--link-icon-hover-color)}.mdc-c-link-icon___SEKyg_990311c:focus [class^=\"mdc-c-icon--radial::before\"],.mdc-c-link-icon___SEKyg_990311c:hover [class^=\"mdc-c-icon--radial::before\"]{background-color:var(--link-icon-hover-color);color:var(--link-icon-radial-hover-color)}.mdc-c-link-icon___SEKyg_990311c:focus .mdc-c-link__label___Pfqtd_990311c,.mdc-c-link-icon___SEKyg_990311c:hover .mdc-c-link__label___Pfqtd_990311c{text-decoration-line:underline}.mdc-c-link-heading___Zggl8_990311c{color:var(--link-heading-color);font-weight:var(--mdc-font-weight-medium)}.mdc-c-link-heading___Zggl8_990311c:focus,.mdc-c-link-heading___Zggl8_990311c:hover{color:var(--link-heading-hover-color);text-decoration-line:underline;text-decoration-thickness:.07em;text-underline-offset:var(--mdc-size-spacing-4)}.mdc-c-link-heading___Zggl8_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--link-color-selected);outline-offset:var(--mdc-size-border-width-4)}.mdc-c-link-heading--with-icon___ssPll_990311c{display:inline;padding-right:var(--mdc-size-spacing-8)}</style><style type=\"text/css\">.mdc-c-toast__wrapper--active___FhXwN_990311c{z-index:9999}.mdc-c-toast__wrapper--active___FhXwN_990311c>*{pointer-events:auto}.mdc-c-toast__content___aJ0xH_990311c{background:var(--mdc-color-neutral-white);box-shadow:0 7px 14px 0 #0003;max-width:min(100%,var(--mdc-breakpoint-md));padding:var(--mdc-size-spacing-16);pointer-events:auto;will-change:transform}.mdc-c-toast__alert-container___bP-MJ_990311c{padding:0!important}.mdc-c-toast__alert___xdRqn_990311c{background-color:var(--mdc-color-neutral-white)!important;border-color:var(--mdc-color-neutral-gray-06)!important;max-width:min(100%,var(--mdc-breakpoint-lg))}.mdc-c-toast__alert___xdRqn_990311c [data-component=mdc-c-icon]:focus:before,.mdc-c-toast__alert___xdRqn_990311c [data-component=mdc-c-icon]:hover:before{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-toast__message___r6An3_990311c{color:inherit;display:flex;flex:1 1 auto;justify-content:center;white-space:pre-line}</style><style type=\"text/css\">.mdc-c-module-wrapper--full-page___3XZ1n_990311c{align-items:center;display:flex;height:100dvh;justify-content:center;left:0;margin:0!important;padding:0!important;top:0;width:100vw}.mdc-c-module-wrapper--full-page___3XZ1n_990311c img:first-of-type,.mdc-c-module-wrapper--full-page___3XZ1n_990311c video:first-of-type,.mdc-c-module-wrapper--full-page___3XZ1n_990311c>.image___T6Mcc_990311c,.mdc-c-module-wrapper--full-page___3XZ1n_990311c>.mdc-c-bg-image___z77CN_990311c{height:100%;object-fit:cover;width:100%}.story-wrapper{padding:0!important}</style><style type=\"text/css\">:root .mdc-c-icon-svg___68K-O_990311c,[data-module-theme=light] .mdc-c-icon-svg___68K-O_990311c{--icon-svg-stroke-color:currentcolor;--icon-svg-fill-color:none}[data-module-theme=dark] .mdc-c-icon-svg___68K-O_990311c{--icon-svg-stroke-color:var(--mdc-color-neutral-white);--icon-svg-fill-color:none}.mdc-c-icon-svg___68K-O_990311c{display:inline-flex}.mdc-c-icon-svg___68K-O_990311c svg{fill:var(--icon-svg-fill-color)}</style><style type=\"text/css\">:root .mdc-c-icon___oi7ef_990311c,[data-module-theme=light] .mdc-c-icon___oi7ef_990311c{--icon-radial-color:var(--mdc-color-neutral-white);--icon-radial-background-color:var(--mdc-color-neutral-black);--icon-radial-background-color-hover:var(--mdc-color-palette-electric-blue)}[data-module-theme=dark] .mdc-c-icon___oi7ef_990311c{--icon-radial-color:var(--mdc-color-neutral-black);--icon-radial-background-color:var(--mdc-color-neutral-white);--icon-radial-background-color-hover:var(--mdc-color-palette-cyan)}:root .mdc-c-icon--secondary___dSlsG_990311c,[data-module-theme=light] .mdc-c-icon--secondary___dSlsG_990311c{--icon-radial-color:var(--mdc-color-neutral-black);--icon-radial-background-color:unset;--icon-radial-background-color-hover:var(--mdc-color-neutral-gray-06)}[data-module-theme=dark] .mdc-c-icon--secondary___dSlsG_990311c{--icon-radial-color:var(--mdc-color-neutral-white);--icon-radial-background-color:unset;--icon-radial-background-color-hover:var(--mdc-color-palette-cyan)}.mdc-c-icon___oi7ef_990311c{display:inline;line-height:inherit;vertical-align:middle}.mdc-c-icon___oi7ef_990311c:before{color:currentcolor;vertical-align:middle}.mdc-c-icon--outline___MU0j1_990311c:before,.mdc-c-icon--radial___y3csX_990311c:before,.mdc-c-icon-default___0TDAM_990311c:before{font-size:inherit;position:relative}.mdc-c-icon--outline___MU0j1_990311c:hover span,.mdc-c-icon--radial___y3csX_990311c:hover span,.mdc-c-icon-default___0TDAM_990311c:hover span{border-color:inherit;color:inherit}.mdc-c-icon--default___f-hQM_990311c:before{display:block}.mdc-c-icon--outline___MU0j1_990311c:before,.mdc-c-icon--radial___y3csX_990311c:before{align-items:center;border-radius:50%;display:inline-flex;flex-shrink:0;font-size:.5em;height:var(--mdc-size-icon-16);justify-content:center;width:var(--mdc-size-icon-16)}a .mdc-c-icon--outline___MU0j1_990311c:only-child:before,a .mdc-c-icon--radial___y3csX_990311c:only-child:before{transition:.12s linear;transition-property:all}a .mdc-c-icon--outline___MU0j1_990311c:hover:only-child:before,a .mdc-c-icon--radial___y3csX_990311c:hover:only-child:before{box-shadow:0 7px 14px 0 #0003;transform:translateY(-2px)}.mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--icon-radial-background-color);color:var(--icon-radial-color)}a .mdc-c-icon--radial___y3csX_990311c:hover:before,button .mdc-c-icon--radial___y3csX_990311c:hover:before{background-color:var(--icon-radial-background-color-hover)}a:focus .mdc-c-icon--radial___y3csX_990311c:before,a:hover .mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--link-icon-hover-color);color:var(--link-icon-radial-hover-color)}.mdc-c-icon--success___2CfF7_990311c.mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--mdc-color-status-dark-green);color:var(--mdc-color-neutral-white)}.mdc-c-icon--error___3PoQX_990311c:before{color:var(--mdc-color-status-dark-red)}.mdc-c-icon--error___3PoQX_990311c.mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--mdc-color-status-dark-red);color:var(--mdc-color-neutral-white)}.mdc-c-icon--info___fsGGT_990311c:before{color:var(--mdc-color-palette-electric-blue)}.mdc-c-icon--warning___iP6zl_990311c:before{color:var(--mdc-color-status-dark-yellow)}.mdc-c-icon--active___4KblW_990311c.mdc-c-icon--radial___y3csX_990311c:before{background-color:var(--icon-radial-background-color-hover)}.mdc-c-icon--active___4KblW_990311c.mdc-c-icon--outline___MU0j1_990311c:before{background-color:unset;border:var(--mdc-size-border-width-1) solid var(--icon-radial-background-color-hover);color:var(--icon-radial-background-color-hover)}a .mdc-c-icon--secondary___dSlsG_990311c.mdc-c-icon--radial___y3csX_990311c:only-child:before{transition:none}a .mdc-c-icon--secondary___dSlsG_990311c.mdc-c-icon--radial___y3csX_990311c:hover:only-child:before{box-shadow:none;transform:none}.mdc-c-icon--outline___MU0j1_990311c:before{border:var(--mdc-size-border-width-1) solid;border-radius:50%;font-size:.5em}.mdc-c-icon--size-xs___g8-q5_990311c{font-size:var(--mdc-size-icon-10)}.mdc-c-icon--size-xs___g8-q5_990311c:before{height:var(--mdc-size-icon-10);width:var(--mdc-size-icon-10)}.mdc-c-icon--size-sm___2FLYH_990311c{font-size:var(--mdc-size-icon-12)}.mdc-c-icon--size-sm___2FLYH_990311c:before{height:var(--mdc-size-icon-12);width:var(--mdc-size-icon-12)}.mdc-c-icon--size-md___yi5fA_990311c{font-size:var(--mdc-size-icon-16)}.mdc-c-icon--size-md___yi5fA_990311c:before{height:var(--mdc-size-icon-16);width:var(--mdc-size-icon-16)}.mdc-c-icon--size-lg___5rPck_990311c{font-size:var(--mdc-size-icon-24)}.mdc-c-icon--size-lg___5rPck_990311c:before{height:var(--mdc-size-icon-24);width:var(--mdc-size-icon-24)}.mdc-c-icon--size-xl___3BEee_990311c{font-size:var(--mdc-size-icon-32)}.mdc-c-icon--size-xl___3BEee_990311c:before{height:var(--mdc-size-icon-32);width:var(--mdc-size-icon-32)}.mdc-c-icon--size-xxl___cL3ZT_990311c{font-size:var(--mdc-size-icon-40)}.mdc-c-icon--size-xxl___cL3ZT_990311c:before{height:var(--mdc-size-icon-40);width:var(--mdc-size-icon-40)}.mdc-c-icon--align-right___94-AR_990311c{order:2}.mdc-c-content-icon--size-sm___2acYB_990311c,.mdc-c-content-icon--size-xs___hPSY1_990311c{font-size:var(--mdc-size-font-16)}.mdc-c-content-icon--size-md___U5-qz_990311c{font-size:var(--mdc-size-font-24)}.mdc-c-content-icon--size-lg___ALqld_990311c{font-size:var(--mdc-size-font-28)}.mdc-c-content-icon--size-xl___4LKWE_990311c{font-size:var(--mdc-size-font-36)}.mdc-c-content-icon--size-xxl___PB38p_990311c{font-size:var(--mdc-size-font-44)}</style><style type=\"text/css\">.mdc-c-heading___0fM1W_990311c{text-shadow:var(--text-shadow)}.mdc-c-heading--title___5qyOB_990311c{font-family:var(--mdc-font-family-default-primary);font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-medium);letter-spacing:.075rem;line-height:var(--mdc-size-line-height-24);text-transform:uppercase}.mdc-c-heading--title___5qyOB_990311c:lang(ar){font-family:var(--mdc-font-family-arabic-primary,var(--mdc-font-family-default-primary))}.mdc-c-heading--title___5qyOB_990311c:lang(ru){font-family:var(--mdc-font-family-russian-primary,var(--mdc-font-family-default-primary))}.mdc-c-heading--title___5qyOB_990311c:lang(vi){font-family:var(--mdc-font-family-vietnamese-primary,var(--mdc-font-family-default-primary))}.mdc-c-heading--title___5qyOB_990311c:lang(ja){font-family:var(--mdc-font-family-japanese-primary,var(--mdc-font-family-default-primary))}.mdc-c-heading--border___K8dj3_990311c{border-top:var(--mdc-size-border-width-1) solid;padding-top:var(--mdc-size-spacing-24)}.mdc-c-heading__icon___TbFKK_990311c{color:var(--link-cta-icon-color);position:absolute}</style><style type=\"text/css\">.mdc-c-description___SrnQP_990311c{text-shadow:var(--text-shadow)}.mdc-c-description___SrnQP_990311c>p:last-child{margin-bottom:0}</style><style type=\"text/css\">.mdc-c-accordion__items___yF0jA_990311c{border-bottom:var(--mdc-size-border-width-1) solid;border-top:var(--mdc-size-border-width-1) solid}.mdc-c-accordion__items--border-0___elAT7_990311c{border:none}.mdc-c-accordion__item___TaDQ0_990311c{word-break:break-word}.mdc-c-accordion__item___TaDQ0_990311c:not(:last-child){border-bottom:var(--mdc-size-border-width-1) solid}.mdc-c-accordion__title-wrapper___ujaRh_990311c{display:block!important;position:relative;text-align:inherit!important;width:100%}.mdc-c-accordion__title-wrapper___ujaRh_990311c:hover div{color:var(--button-minimal-primary)}.mdc-c-accordion__title___S2Csf_990311c{border-bottom:0;display:block;padding:var(--mdc-size-spacing-16) var(--mdc-size-spacing-48) var(--mdc-size-spacing-16) 0}.mdc-c-accordion__icon___MnUrM_990311c{position:absolute;right:var(--mdc-size-spacing-16);top:50%;transform:translateY(-50%);width:-webkit-max-content;width:max-content}.mdc-c-accordion__content-wrapper___WBkbu_990311c{padding-bottom:var(--mdc-size-spacing-16)}</style><style type=\"text/css\">.mdc-c-content-block___7p6Lu_990311c{grid-gap:var(--mdc-size-spacing-16);display:grid}.mdc-c-content-block--size-xxl___N8MW3_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-76);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-92)}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xxl___N8MW3_990311c [class^=mdc-c-heading]:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xl___USpo5_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-44);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-52)}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-xl___USpo5_990311c [class^=mdc-c-heading]:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-lg___183sK_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-36);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-44)}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-lg___183sK_990311c [class^=mdc-c-heading]:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}.mdc-c-content-block--size-md___ZNL6I_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--size-md___ZNL6I_990311c [class^=mdc-c-heading]{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36)}.mdc-c-content-block--size-sm___8ZwhU_990311c{font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24)}.mdc-c-content-block--size-sm___8ZwhU_990311c [class^=mdc-c-heading]{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-content-block--align-center___KRLtu_990311c{text-align:center}.mdc-c-content-block--align-center___KRLtu_990311c [class^=mdc-c-link-container]{justify-content:center;justify-items:center}.mdc-c-content-block--align-right___yCJP2_990311c{text-align:right}.mdc-c-content-block--align-right___yCJP2_990311c [class^=mdc-c-link-container]{justify-content:right;justify-items:right}</style><style type=\"text/css\">.mdc-c-link-container___xefGu_990311c{grid-gap:var(--mdc-size-spacing-16);align-items:flex-start;display:flex;flex-flow:column wrap}.mdc-c-link-container--display-column___X0HDD_990311c{align-items:center!important;flex-flow:row wrap;justify-content:flex-start}.mdc-c-link-container--align-center___ar3mu_990311c{align-items:center;justify-content:center}.mdc-c-link-container--align-right___6XjJx_990311c{align-items:flex-end;justify-content:flex-end}.mdc-c-link-container--display-row___LYWqK_990311c [class^=mdc-c-button]{align-self:stretch;max-width:100%}</style><style type=\"text/css\">.mdc-c-avatar___kVSTP_990311c{align-items:center;display:inline-flex;height:var(--mdc-avatar-size);justify-content:center;width:var(--mdc-avatar-size)}.mdc-c-avatar___kVSTP_990311c a{align-items:center;border-radius:inherit;color:var(--mdc-color-neutral-white);display:flex;height:100%;justify-content:center;overflow:hidden;width:100%}.mdc-c-avatar__hide___rnSnd_990311c{display:none}.mdc-c-avatar___kVSTP_990311c img{border-radius:inherit;height:inherit;width:inherit}.mdc-c-avatar--image___levct_990311c{background-color:var(--mdc-color-neutral-gray-04);border-radius:50%;display:inline-block}.mdc-c-avatar--image-placeholder___BX3C4_990311c{background-image:url(\"data:image/svg+xml;charset=utf-8,%3Csvg width='62' height='62' xmlns='http://www.w3.org/2000/svg'%3E%3Cdefs%3E%3Cfilter id='a'%3E%3CfeColorMatrix in='SourceGraphic' values='0 0 0 0 0.701961 0 0 0 0 0.701961 0 0 0 0 0.701961 0 0 0 1.000000 0'/%3E%3C/filter%3E%3C/defs%3E%3Cg filter='url(%23a)' transform='translate(-1 -1)' fill='%23B3B3B3' fill-rule='evenodd'%3E%3Cpath d='M32 1C14.906 1 1 14.907 1 32s13.906 31 31 31 31-13.907 31-31S49.094 1 32 1ZM20 28c0-6.617 5.383-12 12-12s12 5.383 12 12v3c0 6.617-5.383 12-12 12s-12-5.383-12-12v-3Zm12 33a28.847 28.847 0 0 1-17.789-6.122C17.082 49.99 22.26 47 28 47h8c5.733 0 10.911 2.99 13.788 7.879A28.845 28.845 0 0 1 32 61Z' fill='%23000'/%3E%3C/g%3E%3C/svg%3E\");background-repeat:no-repeat;background-size:contain}.mdc-c-avatar--text___Z2T5E_990311c{align-items:center;background-color:var(--mdc-color-palette-deep-blue);border-radius:50%;color:var(--mdc-color-neutral-white);display:inline-flex;font-weight:var(--mdc-font-weight-regular);justify-content:center}</style><style type=\"text/css\">.mdc-c-header__eyebrow___PZMpI_990311c{display:inline-block;font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20);margin-bottom:var(--mdc-size-spacing-8)}.mdc-c-header__block___i1Lg-_990311c{grid-gap:var(--mdc-size-spacing-16);display:grid}</style><style type=\"text/css\">.mdc-c-bg-image___GJdv1_990311c{background-size:cover;min-height:100%}.mdc-c-bg-image--opaque-bg___CauU1_990311c{background-color:var(--mdc-color-neutral-black);bottom:0;left:0;position:absolute;right:0;top:0}</style><style type=\"text/css\">.mdc-c-tooltip___iYQYf_990311c{max-width:90%;min-width:160px;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);position:absolute;text-align:center}@media (min-width:768px){.mdc-c-tooltip___iYQYf_990311c{max-width:500px}}.mdc-c-tooltip--min-width-auto___Na7Bp_990311c{min-width:auto}.mdc-c-tooltip__arrow___BvUKx_990311c{position:absolute;width:15px}.mdc-c-tooltip__arrow--static___tBroH_990311c{bottom:-14px;left:50%;transform:translateX(-50%)}.mdc-c-tooltip--light___3HIZT_990311c{background-color:var(--mdc-color-neutral-white)}.mdc-c-tooltip--light___3HIZT_990311c .mdc-c-tooltip__arrow___BvUKx_990311c span:before{color:var(--mdc-color-neutral-white)}.mdc-c-tooltip--semi-light___nUvVM_990311c{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-tooltip--semi-light___nUvVM_990311c .mdc-c-tooltip__arrow___BvUKx_990311c span:before{color:var(--mdc-color-neutral-gray-06)}.mdc-c-tooltip--dark___EVQsg_990311c{background-color:var(--mdc-color-palette-deep-blue)}.mdc-c-tooltip--dark___EVQsg_990311c .mdc-c-tooltip__arrow___BvUKx_990311c span:before{color:var(--mdc-color-palette-deep-blue)}.mdc-c-tooltip--elevated___KfVi2_990311c{box-shadow:0 7px 14px 0 #0003}</style><style type=\"text/css\">.mdc-c-brand-lines___HsR8E_990311c{height:0;width:0}.mdc-c-brand-lines__line___tr8-f_990311c{background-color:var(--mdc-color-palette-electric-blue);position:absolute}.mdc-c-brand-lines__line--left___tRtEV_990311c{left:0}.mdc-c-brand-lines__line--right___GLoBF_990311c{right:0}.mdc-c-brand-lines__line--top___4jrrn_990311c{top:0}.mdc-c-brand-lines__line--bottom___P7RVL_990311c{bottom:0}.mdc-c-brand-lines__line--horizontal___6Cq7-_990311c{height:20px;width:100%}@media (min-width:768px){.mdc-c-brand-lines__line--horizontal___6Cq7-_990311c{height:25px}}@media (min-width:1180px){.mdc-c-brand-lines__line--horizontal___6Cq7-_990311c{height:30px}}.mdc-c-brand-lines__line--vertical___ZPEOH_990311c{height:100%;width:20px}@media (min-width:768px){.mdc-c-brand-lines__line--vertical___ZPEOH_990311c{width:25px}}@media (min-width:1180px){.mdc-c-brand-lines__line--vertical___ZPEOH_990311c{width:30px}}.mdc-c-brand-lines__offset-line--left___e2-2s_990311c{left:-20px}.mdc-c-brand-lines__offset-line--right___rcjIK_990311c{right:-20px}.mdc-c-brand-lines__offset-line--top___-dgSE_990311c{top:-20px}.mdc-c-brand-lines__offset-line--bottom___R01BP_990311c{bottom:-20px}@media (min-width:768px){.mdc-c-brand-lines__offset-line--left___e2-2s_990311c{left:-25px}.mdc-c-brand-lines__offset-line--right___rcjIK_990311c{right:-25px}.mdc-c-brand-lines__offset-line--top___-dgSE_990311c{top:-25px}.mdc-c-brand-lines__offset-line--bottom___R01BP_990311c{bottom:-25px}}@media (min-width:1180px){.mdc-c-brand-lines__offset-line--left___e2-2s_990311c{left:-30px}.mdc-c-brand-lines__offset-line--right___rcjIK_990311c{right:-30px}.mdc-c-brand-lines__offset-line--top___-dgSE_990311c{top:-30px}.mdc-c-brand-lines__offset-line--bottom___R01BP_990311c{bottom:-30px}}.mdc-c-brand-lines__offset-filler___xRGlR_990311c{background-color:var(--mdc-color-palette-electric-blue);height:20px;position:absolute;width:20px}@media (min-width:768px){.mdc-c-brand-lines__offset-filler___xRGlR_990311c{height:25px}}@media (min-width:1180px){.mdc-c-brand-lines__offset-filler___xRGlR_990311c{height:30px}}@media (min-width:768px){.mdc-c-brand-lines__offset-filler___xRGlR_990311c{width:25px}}@media (min-width:1180px){.mdc-c-brand-lines__offset-filler___xRGlR_990311c{width:30px}}.mdc-c-brand-lines__offset-filler--left___Y71dP_990311c{left:-20px}.mdc-c-brand-lines__offset-filler--right___UeKiB_990311c{right:-20px}.mdc-c-brand-lines__offset-filler--top___yJSYc_990311c{top:-20px}.mdc-c-brand-lines__offset-filler--bottom___YyTtZ_990311c{bottom:-20px}@media (min-width:768px){.mdc-c-brand-lines__offset-filler--left___Y71dP_990311c{left:-25px}.mdc-c-brand-lines__offset-filler--right___UeKiB_990311c{right:-25px}.mdc-c-brand-lines__offset-filler--top___yJSYc_990311c{top:-25px}.mdc-c-brand-lines__offset-filler--bottom___YyTtZ_990311c{bottom:-25px}}@media (min-width:1180px){.mdc-c-brand-lines__offset-filler--left___Y71dP_990311c{left:-30px}.mdc-c-brand-lines__offset-filler--right___UeKiB_990311c{right:-30px}.mdc-c-brand-lines__offset-filler--top___yJSYc_990311c{top:-30px}.mdc-c-brand-lines__offset-filler--bottom___YyTtZ_990311c{bottom:-30px}}</style><style type=\"text/css\">@charset \"UTF-8\";blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c{border-left:none;padding-left:0}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-28);font-weight:var(--mdc-font-weight-regular);line-height:var(--mdc-size-line-height-40)}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c p:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c>p:first-of-type:before{content:\"\";margin-left:-.4em}blockquote.mdc-c-blockquote--is-quotes___TozKo_990311c>p:last-of-type:after{content:\"\"}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p{font-size:var(--mdc-size-font-28);line-height:var(--mdc-size-line-height-40)}@media (min-width:768px){blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-36);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-44)}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-medium___Q6-Js_990311c p:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p{font-size:var(--mdc-size-font-28);line-height:var(--mdc-size-line-height-40)}@media (min-width:768px){blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-36);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-44)}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}}@media (min-width:1180px){blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p{font-family:var(--mdc-font-family-default-secondary);font-size:var(--mdc-size-font-44);font-weight:var(--mdc-font-weight-light);line-height:var(--mdc-size-line-height-52)}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ar){font-family:var(--mdc-font-family-arabic-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ru){font-family:var(--mdc-font-family-russian-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(vi){font-family:var(--mdc-font-family-vietnamese-secondary,var(--mdc-font-family-default-secondary))}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c p:lang(ja){font-family:var(--mdc-font-family-japanese-secondary,var(--mdc-font-family-default-secondary))}}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c cite{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}@media (min-width:768px){blockquote.mdc-c-blockquote--size-large___n9Z06_990311c cite{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36)}}blockquote.mdc-c-blockquote--size-large___n9Z06_990311c cite span{font-size:var(--mdc-size-font-18);line-height:var(--mdc-size-line-height-28)}@media (min-width:768px){blockquote.mdc-c-blockquote--size-large___n9Z06_990311c cite span{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}}blockquote.mdc-c-blockquote--is-align-center___l-q5n_990311c{text-align:center}blockquote.mdc-c-blockquote--is-align-right___yD7vc_990311c{text-align:right}@media (min-width:1180px){blockquote.mdc-c-blockquote--is-not-full-width___Dyvim_990311c{margin:0 auto;width:490px}}blockquote .mdc-c-blockquote__author-name___u4L7-_990311c{display:inline-block;text-decoration:inherit}</style><style type=\"text/css\">.mdc-c-progress-bar___PW5Xi_990311c{height:calc(var(--mdc-size-spacing-40)/2);overflow:hidden;position:relative}.mdc-c-progress-bar__progress___wQRDN_990311c{-webkit-appearance:none;appearance:none;height:inherit;overflow:hidden;position:absolute;width:100%}.mdc-c-progress-bar__progress___wQRDN_990311c::-webkit-progress-bar{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-progress-bar__progress___wQRDN_990311c::-moz-progress-bar{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-progress-bar__progress___wQRDN_990311c::-moz-progress-value{background-color:var(--mdc-color-neutral-gray-54);-moz-transition:width .6s ease-in-out;transition:width .6s ease-in-out}.mdc-c-progress-bar__progress___wQRDN_990311c::-webkit-progress-value{background-color:var(--mdc-color-neutral-gray-54);-webkit-transition:width .6s ease-in-out;transition:width .6s ease-in-out}.mdc-c-progress-bar__label___JDW5s_990311c{color:var(--mdc-color-neutral-white);font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24);line-height:var(--mdc-size-line-height-20);position:absolute;top:0;transform:translate(calc(-100% - var(--mdc-size-spacing-8)));transition:left .6s ease-in-out}.mdc-c-progress-bar__label--align-outside___-YOop_990311c{color:var(--mdc-color-neutral-gray-54);padding-left:var(--mdc-size-spacing-8)}</style><style type=\"text/css\">.mdc-c-drop-down__rootmenu___yJzvz_990311c{color:var(--root-share-icon-color)!important;cursor:pointer;display:inline-grid!important;font-size:.75rem!important;font-weight:var(--mdc-font-weight-light)!important;gap:0!important;grid-auto-flow:row!important;line-height:1rem!important}.mdc-c-drop-down__rootmenu___yJzvz_990311c span:before{margin:auto}.mdc-c-drop-down__rootmenu--active___VHnk6_990311c,.mdc-c-drop-down__rootmenu___yJzvz_990311c:hover{color:var(--root-share-icon-color-hover)}.mdc-c-drop-down__menu___z9UVl_990311c{background:var(--mdc-color-neutral-white);box-shadow:var(--mdc-elevation-2);display:grid;gap:var(--mdc-size-spacing-16);padding:var(--mdc-size-spacing-24)}.mdc-c-drop-down__menu___z9UVl_990311c ul{margin:0;padding:0}.mdc-c-drop-down__menu___z9UVl_990311c ul li{list-style-type:none}.mdc-c-drop-down__menu___z9UVl_990311c ul li:not(:last-of-type){margin-bottom:var(--mdc-size-spacing-8)}.mdc-c-drop-down__menuitem___xIPFf_990311c{gap:var(--mdc-size-spacing-8)!important;line-height:1}.mdc-c-drop-down__arrow___O0eKP_990311c{position:absolute;transform:rotate(180deg)}.mdc-c-drop-down__arrow___O0eKP_990311c span{filter:drop-shadow(0 1px .5px rgba(5,28,44,.2));line-height:var(--mdc-size-line-height-24)}.mdc-c-drop-down__arrow___O0eKP_990311c span:before{color:var(--mdc-color-neutral-white)}</style><style type=\"text/css\">.mdc-c-bg-video___KqGb1_990311c{height:100%;object-fit:cover;width:100%}.mdc-c-play-pause-button___dscFo_990311c{bottom:var(--mdc-size-spacing-16);position:absolute;right:var(--mdc-size-spacing-24);z-index:var(--mdc-zindex-1)}.mdc-c-play-pause-button___dscFo_990311c span:before{background-color:var(--mdc-color-neutral-black)!important;color:var(--mdc-color-neutral-white)!important}.mdc-c-play-pause-button___dscFo_990311c span:hover:before{background-color:var(--mdc-color-palette-electric-blue)!important;box-shadow:0 7px 14px 0 #0003;transform:translateY(-2px)}</style><style type=\"text/css\">.mdc-c-alert___HJ1s1_990311c{align-items:center;display:flex;gap:var(--mdc-size-spacing-8);justify-content:space-between;opacity:var(--mdc-opacity-100);padding:var(--mdc-size-spacing-16);transition-timing-function:ease-out}.mdc-c-alert--close-alert___BZpm3_990311c{opacity:0;transition:.2s}.mdc-c-alert--success___moj-j_990311c{background-color:var(--mdc-color-status-light-green);border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-light-green)}.mdc-c-alert--error___iR23S_990311c{background-color:var(--mdc-color-status-light-red);border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-light-red)}.mdc-c-alert--info___2ifXt_990311c{background-color:var(--mdc-color-status-light-blue);border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-light-blue)}.mdc-c-alert--warning___2vdhU_990311c{background-color:var(--mdc-color-status-light-yellow);border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-light-yellow)}.mdc-c-alert__message___CA3pW_990311c{display:flex;flex:1 1 0%;flex-wrap:wrap;justify-content:space-between}.mdc-c-alert__container___OY1LN_990311c{display:flex;gap:var(--mdc-size-spacing-16)}.mdc-c-alert__alert-icon___UDJog_990311c{flex:1 0 var(--mdc-size-spacing-24)}.mdc-c-alert__close-alert___UNT03_990311c{align-self:baseline;cursor:pointer;flex:0 0 var(--mdc-size-spacing-24)}.mdc-c-alert__close-alert___UNT03_990311c span:before{background-color:initial;color:var(--mdc-color-neutral-black)}.mdc-c-alert__close-alert___UNT03_990311c:focus span:before,.mdc-c-alert__close-alert___UNT03_990311c:hover span:before{background-color:#ffffff4d}</style><style type=\"text/css\">.mdc-c-loader___W8w3-_990311c{animation:spin___HfHqf_990311c 1.4s linear infinite;border:var(--mdc-size-spacing-4) solid var(--loader-border);border-radius:50%;border-top:var(--mdc-size-spacing-4) solid var(--loader-border-top);margin:0 auto}.mdc-c-loader--size-sm___K1ZMm_990311c{height:var(--mdc-size-spacing-32);width:var(--mdc-size-spacing-32)}.mdc-c-loader--size-md___EAQRY_990311c{height:var(--mdc-size-spacing-48);width:var(--mdc-size-spacing-48)}.mdc-c-loader--size-lg___0hH02_990311c{height:var(--mdc-size-spacing-72);width:var(--mdc-size-spacing-72)}.mdc-c-loader--border-1___w1cAp_990311c{border-width:1px}.mdc-c-loader--border-2___b8kJb_990311c{border-width:2px}.mdc-c-loader--border-3___AeSHf_990311c{border-width:3px}.mdc-c-loader--border-4___AsS32_990311c{border-width:4px}.mdc-c-loader--border-5___JRHFb_990311c{border-width:5px}.mdc-c-loader--inline___laBg6_990311c{margin:0}@keyframes spin___HfHqf_990311c{0%{transform:rotate(0deg)}to{transform:rotate(1turn)}}</style><style type=\"text/css\">.mdc-c-char-counter___vIMEm_990311c{color:var(--mdc-color-neutral-gray-70);font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20);margin-left:auto}.mdc-c-char-counter--error___09qgB_990311c{color:var(--mdc-color-status-red)}</style><style type=\"text/css\">.mdc-c-form-control___ib-Ut_990311c{display:flex;flex-direction:column;gap:var(--mdc-size-spacing-8)}.mdc-c-form-control__label___ICXbu_990311c{color:var(--mdc-color-neutral-black);font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-regular);line-height:var(--mdc-size-line-height-24);margin:0}.mdc-c-form-control--error___9sMf7_990311c{color:var(--mdc-color-status-red)}.mdc-c-form-control--state-error___yU8iu_990311c .mdc-c-form-control__field___PTF2Y_990311c,.mdc-c-form-control--state-error___yU8iu_990311c .mdc-c-form-control__textarea___3V76M_990311c{border-color:var(--mdc-color-status-red);color:var(--mdc-color-status-red)}.mdc-c-form-control--state-error___yU8iu_990311c label{color:var(--mdc-color-status-red)}.mdc-c-form-control--state-error___yU8iu_990311c .mdc-c-form-control__editor___TSbUw_990311c{border:var(--mdc-size-border-width-1) solid var(--mdc-color-status-red);color:var(--mdc-color-status-red)}.mdc-c-form-control--size-sm___OAC6g_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20);min-height:var(--mdc-size-spacing-32)}.mdc-c-form-control--size-md___nT0HS_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-42)}.mdc-c-form-control--size-lg___UeotQ_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24);min-height:var(--mdc-size-spacing-48)}.mdc-c-form-control--size-xl___8xbCi_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36);min-height:var(--mdc-size-spacing-56);padding:var(--mdc-size-spacing-24)}.mdc-c-form-control--size-xxl___LoPhp_990311c .mdc-c-form-control__field___PTF2Y_990311c{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36);min-height:var(--mdc-size-spacing-64);padding:var(--mdc-size-spacing-32) var(--mdc-size-spacing-24)}.mdc-c-form-control__text-helper___gGlvN_990311c,.mdc-c-form-control__text-hint___rHwCJ_990311c{color:var(--mdc-color-neutral-gray-54)}.mdc-c-form-control__text-hint___rHwCJ_990311c{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20)}.mdc-c-form-control__text-icon___ZRGsL_990311c{line-height:var(--mdc-size-spacing-4);margin-right:var(--mdc-size-spacing-4)}.mdc-c-form-control__text-error___grncf_990311c{color:var(--mdc-color-status-red);font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20)}.mdc-c-form-control__control___oPCjw_990311c{position:relative}.mdc-c-form-control__show-icon___DcQyC_990311c{display:inline-flex;position:absolute;right:var(--mdc-size-spacing-16);top:50%;transform:translateY(-50%)}.mdc-c-form-control__show-icon--icon-left___bTByt_990311c{left:var(--mdc-size-spacing-16);right:inherit}.mdc-c-form-control__info-tooltip-wrapper___WvQ1m_990311c{align-items:center;display:flex;gap:var(--mdc-size-spacing-8)}.mdc-c-form-control___ib-Ut_990311c [class^=mdc-c-tooltip]{color:var(--mdc-color-neutral-gray-54);z-index:var(--mdc-zindex-1)}.mdc-c-form-control__textarea___3V76M_990311c{font-weight:var(--mdc-font-weight-regular);height:96px;max-height:600px}.mdc-c-form-control__textarea___3V76M_990311c.error___gKx3A_990311c{border-color:var(--mdc-color-status-red)}.mdc-c-form-control___ib-Ut_990311c .mdc-c-form-control__field--icon-right___W4s-t_990311c{padding-right:var(--mdc-size-spacing-56)}.mdc-c-form-control___ib-Ut_990311c .mdc-c-form-control__field--icon-left___YoJju_990311c{padding-left:var(--mdc-size-spacing-56)}.mdc-c-form-control__input-bottom___q3J5i_990311c{display:flex;gap:var(--mdc-size-spacing-32);justify-content:space-between}.mdc-c-form-control__input-bottom___q3J5i_990311c .mdc-c-form-control__container___1bzSs_990311c{display:flex;flex-direction:column}</style><style type=\"text/css\">.mdc-c-checkbox-control___UWECp_990311c{align-self:flex-start;cursor:pointer;display:flex;flex-direction:row;padding:var(--mdc-size-spacing-4) 0}.mdc-c-checkbox-control__wrapper___QhZEn_990311c{display:flex;flex-direction:row}.mdc-c-checkbox-control__label-container___xQnnT_990311c{display:flex;flex-direction:column;flex-grow:1;margin-left:var(--mdc-size-spacing-8)}.mdc-c-checkbox-control__hint___A79E-_990311c{overflow:hidden}.mdc-c-checkbox-control__display-name___DpsHy_990311c{font-weight:var(--mdc-font-weight-light);overflow:hidden}.mdc-c-checkbox-control__display-name___DpsHy_990311c span{border-bottom:var(--mdc-size-border-width-2) solid #0000;color:var(--mdc-color-neutral-black);font-size:var(--mdc-size-font-16);line-height:var(--mdc-size-line-height-24)}.mdc-c-checkbox-control__tooltip-content___a0MS3_990311c{margin-left:var(--mdc-size-spacing-8)}.mdc-c-checkbox-control___UWECp_990311c label.mdc-c-checkbox-control__display-name___DpsHy_990311c{text-transform:none}.mdc-c-checkbox-control___UWECp_990311c:focus-within .mdc-c-checkbox-control__checkbox___pjkv3_990311c,.mdc-c-checkbox-control___UWECp_990311c:hover .mdc-c-checkbox-control__checkbox___pjkv3_990311c{border-color:var(--mdc-color-palette-electric-blue)}.mdc-c-checkbox-control___UWECp_990311c:focus-within .mdc-c-checkbox-control__display-name___DpsHy_990311c span,.mdc-c-checkbox-control___UWECp_990311c:hover .mdc-c-checkbox-control__display-name___DpsHy_990311c span{border-color:var(--mdc-color-palette-electric-blue);color:var(--mdc-color-palette-electric-blue);cursor:pointer}.mdc-c-checkbox-control__checkbox___pjkv3_990311c{align-items:center;-webkit-appearance:none;appearance:none;background:var(--mdc-color-neutral-white);border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-black);cursor:pointer;display:flex;flex:0 0 auto;flex-shrink:0;font-family:mck-icons;justify-content:center}.mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked{background:var(--mdc-color-palette-electric-blue);border-color:var(--mdc-color-palette-electric-blue)}.mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked:after{color:var(--mdc-color-neutral-white);content:\"\\e612\"}.mdc-c-checkbox-control--size-md___-06Hq_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c,.mdc-c-checkbox-control--size-sm___z-REr_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{height:var(--mdc-size-spacing-16);width:var(--mdc-size-spacing-16)}.mdc-c-checkbox-control--size-md___-06Hq_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c,.mdc-c-checkbox-control--size-sm___z-REr_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20)}.mdc-c-checkbox-control--size-lg___1E9cE_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{height:var(--mdc-size-spacing-24);width:var(--mdc-size-spacing-24)}.mdc-c-checkbox-control--size-xl___FfdJO_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{height:var(--mdc-size-spacing-32);width:var(--mdc-size-spacing-32)}.mdc-c-checkbox-control--size-xl___FfdJO_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c{font-size:var(--mdc-size-font-20);line-height:var(--mdc-size-line-height-32)}.mdc-c-checkbox-control--size-xxl___YZHt-_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{font-size:var(--mdc-size-font-24);font-weight:bolder;height:var(--mdc-size-spacing-40);line-height:var(--mdc-size-line-height-36);width:var(--mdc-size-spacing-40)}.mdc-c-checkbox-control--size-xxl___YZHt-_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c{font-size:var(--mdc-size-font-24);line-height:var(--mdc-size-line-height-36)}.mdc-c-checkbox-control--disabled___h4gzX_990311c:focus-within .mdc-c-checkbox-control__checkbox___pjkv3_990311c,.mdc-c-checkbox-control--disabled___h4gzX_990311c:hover .mdc-c-checkbox-control__checkbox___pjkv3_990311c{border-color:var(--mdc-color-neutral-gray-30)}.mdc-c-checkbox-control--disabled___h4gzX_990311c:focus-within .mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked,.mdc-c-checkbox-control--disabled___h4gzX_990311c:hover .mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked{border-color:var(--mdc-color-status-light-blue)}.mdc-c-checkbox-control--disabled___h4gzX_990311c:focus-within .mdc-c-checkbox-control__display-name___DpsHy_990311c span,.mdc-c-checkbox-control--disabled___h4gzX_990311c:hover .mdc-c-checkbox-control__display-name___DpsHy_990311c span{border:none;color:var(--mdc-color-neutral-gray-30);cursor:not-allowed}.mdc-c-checkbox-control--disabled___h4gzX_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c{background:var(--mdc-color-neutral-gray-18);border-color:var(--mdc-color-neutral-gray-30);cursor:not-allowed}.mdc-c-checkbox-control--disabled___h4gzX_990311c .mdc-c-checkbox-control__display-name___DpsHy_990311c span{color:var(--mdc-color-neutral-gray-30)}.mdc-c-checkbox-control--disabled___h4gzX_990311c .mdc-c-checkbox-control__checkbox___pjkv3_990311c:checked{background:var(--mdc-color-status-light-blue);border-color:var(--mdc-color-status-light-blue)}.mdc-c-checkbox-group___K-viM_990311c{display:flex}.mdc-c-checkbox-group--direction-row___vFCK9_990311c{flex-direction:row;gap:var(--mdc-size-spacing-8);justify-content:flex-start}.mdc-c-checkbox-group--direction-column___VeWCA_990311c{align-items:flex-start;flex-direction:column;gap:var(--mdc-size-spacing-4)}</style><style type=\"text/css\">.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-black);cursor:pointer;font-family:mck-icons;opacity:0;position:absolute}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:checked+label .mdc-c-radial-checkbox-control__plus-icon___F697M_990311c,.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:not(:checked)+label .mdc-c-radial-checkbox-control__checkmark-icon___dv6ix_990311c{display:none}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:checked+label .mdc-c-radial-checkbox-control__checkmark-icon___dv6ix_990311c{display:block}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:checked+label .mdc-c-radial-checkbox-control__checkmark-icon___dv6ix_990311c:before{background-color:var(--mdc-color-palette-electric-blue)}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:focus+label,.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:hover+label{cursor:pointer}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:focus+label span:before,.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:hover+label span:before{box-shadow:0 7px 14px 0 #0003;transform:translateY(-2px)}.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:focus+label .mdc-c-radial-checkbox-control__plus-icon___F697M_990311c,.mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c:hover+label .mdc-c-radial-checkbox-control__plus-icon___F697M_990311c{border-color:var(--mdc-color-palette-electric-blue);color:var(--mdc-color-palette-electric-blue)}.mdc-c-radial-checkbox-control--size-md___sYwDS_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c,.mdc-c-radial-checkbox-control--size-sm___FGVel_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{height:var(--mdc-size-spacing-16);width:var(--mdc-size-spacing-16)}.mdc-c-radial-checkbox-control--size-lg___o6P1-_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{height:var(--mdc-size-spacing-24);width:var(--mdc-size-spacing-24)}.mdc-c-radial-checkbox-control--size-xl___xTUNR_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{height:var(--mdc-size-spacing-32);width:var(--mdc-size-spacing-32)}.mdc-c-radial-checkbox-control--size-xxl___uDI7N_990311c .mdc-c-radial-checkbox-control__radial-checkbox___29DwO_990311c{font-size:var(--mdc-size-font-24);font-weight:bolder;height:var(--mdc-size-spacing-40);line-height:var(--mdc-size-line-height-36);width:var(--mdc-size-spacing-40)}</style><style type=\"text/css\">.mdc-c-tag___bvVWv_990311c{align-items:center;background-color:var(--mdc-color-neutral-gray-18);border-radius:var(--mdc-size-border-radius-4);color:var(--mdc-color-neutral-black);display:flex;font-family:var(--mdc-font-family-default-primary);font-size:var(--mdc-size-font-12);font-weight:var(--mdc-font-weight-light);gap:var(--mdc-size-spacing-8);line-height:var(--mdc-size-line-height-16);padding:var(--mdc-size-spacing-8);width:-webkit-fit-content;width:-moz-fit-content;width:fit-content}.mdc-c-tag___bvVWv_990311c:lang(ar){font-family:var(--mdc-font-family-arabic-primary,var(--mdc-font-family-default-primary))}.mdc-c-tag___bvVWv_990311c:lang(ru){font-family:var(--mdc-font-family-russian-primary,var(--mdc-font-family-default-primary))}.mdc-c-tag___bvVWv_990311c:lang(vi){font-family:var(--mdc-font-family-vietnamese-primary,var(--mdc-font-family-default-primary))}.mdc-c-tag___bvVWv_990311c:lang(ja){font-family:var(--mdc-font-family-japanese-primary,var(--mdc-font-family-default-primary))}.mdc-c-tag--with-hover___OE7lc_990311c:hover{background-color:var(--mdc-color-palette-electric-blue);box-shadow:var(--mdc-elevation-8);color:var(--mdc-color-neutral-white);cursor:pointer}.mdc-c-tag--with-hover___OE7lc_990311c:focus-visible{border:var(--mdc-size-border-width-1) solid var(--mdc-color-palette-electric-blue);outline:var(--mdc-size-border-width-4) solid #2155ff66}.mdc-c-tag--checked___BnJWp_990311c{background-color:var(--mdc-color-neutral-gray-70);color:var(--mdc-color-neutral-white)}</style><style type=\"text/css\">.mdc-c-select-custom___TOhaq_990311c{max-width:100%;position:relative}.mdc-c-select-custom--fit-content-width___epwhR_990311c{width:-webkit-fit-content;width:-moz-fit-content;width:fit-content}.mdc-c-select-custom__select-button___5fnAN_990311c{background-color:var(--mdc-color-neutral-white);border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-black);color:var(--mdc-color-neutral-black);cursor:pointer;grid-auto-flow:column;justify-content:space-between;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-8) var(--mdc-size-spacing-8) var(--mdc-size-spacing-16);transition:all .12s linear}.mdc-c-select-custom__select-button--expanded___eNvKm_990311c{background-color:var(--mdc-color-palette-electric-blue);border:0;color:var(--mdc-color-neutral-white)}.mdc-c-select-custom__label___8vCRC_990311c{text-wrap:nowrap;overflow:hidden;text-overflow:ellipsis}.mdc-c-select-custom__list___xXyVs_990311c{background-color:var(--mdc-color-neutral-white);box-shadow:var(--mdc-elevation-8);margin:0;max-width:90vw;min-width:100%;padding:0;position:absolute;width:-webkit-max-content;width:max-content;z-index:1}.mdc-c-select-custom__list--collapsed___jyYdT_990311c{display:none}.mdc-c-select-custom__list--right___SwAN0_990311c{right:0}@media (min-width:768px){.mdc-c-select-custom__list___xXyVs_990311c{max-width:max(50vw,100%)}}.mdc-c-select-custom__list-item___7DeLO_990311c{cursor:pointer;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16)}.mdc-c-select-custom__list-item___7DeLO_990311c:focus,.mdc-c-select-custom__list-item___7DeLO_990311c:hover{background-color:var(--mdc-color-neutral-gray-06)}.mdc-c-select-custom__list-item--select-all___7U9Az_990311c{border-bottom:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-gray-10)}.mdc-c-select-custom__footer___dMcSY_990311c{box-shadow:var(--mdc-elevation-8);padding:var(--mdc-size-spacing-16)}.mdc-c-select-custom___TOhaq_990311c [class^=mdc-c-button]{min-width:-webkit-fit-content;min-width:-moz-fit-content;min-width:fit-content}</style><style type=\"text/css\">.mdc-c-datepicker___706mw_990311c{color:var(--mdc-color-neutral-gray-80);position:relative}.mdc-c-datepicker__input___-ZW4z_990311c{padding-right:var(--mdc-size-spacing-32)!important}.mdc-c-datepicker__popper___AOPhF_990311c{background-color:var(--mdc-color-neutral-white);box-shadow:var(--mdc-elevation-4);font-family:var(--mdc-font-family-default-primary);padding:var(--mdc-size-spacing-16) var(--mdc-size-spacing-24);z-index:var(--mdc-zindex-10)}.mdc-c-datepicker__popper___AOPhF_990311c:lang(ar){font-family:var(--mdc-font-family-arabic-primary,var(--mdc-font-family-default-primary))}.mdc-c-datepicker__popper___AOPhF_990311c:lang(ru){font-family:var(--mdc-font-family-russian-primary,var(--mdc-font-family-default-primary))}.mdc-c-datepicker__popper___AOPhF_990311c:lang(vi){font-family:var(--mdc-font-family-vietnamese-primary,var(--mdc-font-family-default-primary))}.mdc-c-datepicker__popper___AOPhF_990311c:lang(ja){font-family:var(--mdc-font-family-japanese-primary,var(--mdc-font-family-default-primary))}.mdc-c-datepicker__popper-header___9HTov_990311c{align-items:center;display:flex;justify-content:space-between}.mdc-c-datepicker__popper-header___9HTov_990311c button{background:none;border:0;cursor:pointer;height:var(--mdc-size-spacing-40);outline:none;width:var(--mdc-size-spacing-40)}.mdc-c-datepicker__popper-header___9HTov_990311c button:hover{background-color:var(--mdc-color-neutral-gray-06);border-radius:50%}.mdc-c-datepicker__popper-year-nav___sRMUD_990311c{align-items:center;display:flex;flex:1;font-size:var(--mdc-size-font-16);font-weight:var(--mdc-font-weight-medium);gap:var(--mdc-size-spacing-8);justify-content:center;line-height:var(--mdc-size-line-height-24)}.mdc-c-datepicker__popper-year-nav___sRMUD_990311c select{border:none;cursor:pointer;outline:none;padding:0 var(--mdc-size-spacing-32) 0 0;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content}.mdc-c-datepicker__year-select___YPSz2_990311c{align-self:normal}.mdc-c-datepicker__reset-btn___tdJ-r_990311c{margin-right:var(--mdc-size-spacing-32)}.mdc-c-datepicker___706mw_990311c .react-datepicker__calendar-icon{color:var(--mdc-color-neutral-gray-80);cursor:pointer;position:absolute;right:var(--mdc-size-spacing-16);top:var(--mdc-size-spacing-8)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day-names{display:flex;font-size:var(--mdc-size-font-14);font-weight:var(--mdc-font-weight-medium);line-height:var(--mdc-size-line-height-20)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day,.mdc-c-datepicker___706mw_990311c .react-datepicker__day-name{height:var(--mdc-size-spacing-40);line-height:var(--mdc-size-spacing-40);outline:none;text-align:center;width:var(--mdc-size-spacing-40)}.mdc-c-datepicker___706mw_990311c .react-datepicker__month{font-size:var(--mdc-size-font-14);line-height:var(--mdc-size-line-height-20)}.mdc-c-datepicker___706mw_990311c .react-datepicker__week{display:flex}.mdc-c-datepicker___706mw_990311c .react-datepicker__day{cursor:pointer}.mdc-c-datepicker___706mw_990311c .react-datepicker__day:hover{background-color:var(--mdc-color-neutral-gray-10)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--outside-month{color:var(--mdc-color-neutral-gray-30)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--today{border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-gray-80);font-weight:var(--mdc-font-weight-bold)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--in-range,.mdc-c-datepicker___706mw_990311c .react-datepicker__day--in-selecting-range{background-color:var(--mdc-color-status-light-blue)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--range-end,.mdc-c-datepicker___706mw_990311c .react-datepicker__day--selected{background-color:var(--mdc-color-palette-electric-blue);color:var(--mdc-color-neutral-white);font-weight:var(--mdc-font-weight-bold)}.mdc-c-datepicker___706mw_990311c .react-datepicker__day--range-end:hover,.mdc-c-datepicker___706mw_990311c .react-datepicker__day--selected:hover{background-color:var(--mdc-color-status-dark-blue)}.mdc-c-datepicker___706mw_990311c .react-datepicker__today-button{display:flex;justify-content:space-between;padding-top:var(--mdc-size-spacing-8);width:100%}.mdc-c-datepicker___706mw_990311c .react-datepicker__aria-live{border:0;-webkit-clip-path:circle(0);clip-path:circle(0);height:0;overflow:hidden;padding:0;position:absolute;white-space:nowrap;width:0}</style><style type=\"text/css\">.mdc-c-modal__backdrop___-KX-s_990311c{align-items:center;animation-duration:.4s;animation-name:animatetop___aWqMX_990311c;background-color:#000c;inset:0;justify-content:center;overflow:auto;position:fixed;z-index:var(--mdc-zindex-20)}.mdc-c-modal__backdrop--bottom___le1-H_990311c{animation-name:animatebottom___4ILUZ_990311c}.mdc-c-modal__backdrop--hide___LW7W8_990311c{opacity:0}@keyframes animatetop___aWqMX_990311c{0%{opacity:0;top:-300px}to{opacity:1;top:0}}@keyframes animatebottom___4ILUZ_990311c{0%{bottom:-300px;opacity:0}to{bottom:0;opacity:1}}.mdc-c-modal__content___os-1D_990311c{box-sizing:border-box;margin:96px auto auto;max-width:624px;padding:var(--mdc-size-spacing-64);position:relative;width:100%}@media (max-width:1179px){.mdc-c-modal__content___os-1D_990311c{margin-top:var(--mdc-size-spacing-80)}}@media (max-width:767px){.mdc-c-modal__content___os-1D_990311c{margin:0;max-width:100%;min-height:100%;padding:var(--mdc-size-spacing-40)}}.mdc-c-modal__content--align-top___BfmM5_990311c{margin-top:0}.mdc-c-modal__content--align-bottom___-T7nI_990311c{animation-name:animatebottom___4ILUZ_990311c;bottom:0;position:absolute}.mdc-c-modal__content--full-width___hDjtB_990311c{max-width:100%}.mdc-c-modal__content--spacing-compact___5fP7H_990311c{padding:var(--mdc-size-spacing-40)}.mdc-c-modal__content___os-1D_990311c .mdc-c-modal__close-button___ZYOFu_990311c{position:absolute;right:var(--mdc-size-spacing-8);top:var(--mdc-size-spacing-8)}@media (min-width:768px){.mdc-c-modal__content___os-1D_990311c .mdc-c-modal__close-button___ZYOFu_990311c{right:var(--mdc-size-spacing-16);top:var(--mdc-size-spacing-16)}}.mdc-c-modal__content___os-1D_990311c .mdc-c-modal__header___Fts7-_990311c{margin-bottom:var(--mdc-size-spacing-32)}.mdc-c-modal__content___os-1D_990311c .mdc-c-modal__header___Fts7-_990311c p{font-size:var(--mdc-size-font-18);line-height:var(--mdc-size-line-height-28)}</style><style type=\"text/css\">:root .mdc-c-tabs___7eVdv_990311c,[data-module-theme=light] .mdc-c-tabs___7eVdv_990311c{--paddle-bg-right:linear-gradient(to right,#0000,var(--mdc-color-neutral-white) 50%);--paddle-bg-left:linear-gradient(to left,#0000,var(--mdc-color-neutral-white) 50%)}[data-module-theme=dark] .mdc-c-tabs___7eVdv_990311c{--paddle-bg-right:linear-gradient(to right,#0000,var(--mdc-color-palette-deep-blue) 50%);--paddle-bg-left:linear-gradient(to left,#0000,var(--mdc-color-palette-deep-blue) 50%)}.mdc-c-tabs___7eVdv_990311c{position:relative}.mdc-c-tabs__tablist-wrapper___dBa0k_990311c{overflow-x:scroll}.mdc-c-tabs__tablist-wrapper___dBa0k_990311c::-webkit-scrollbar{height:0;width:0}.mdc-c-tabs__tablist___I130n_990311c{grid-gap:var(--mdc-size-spacing-24);display:grid;grid-auto-flow:column;justify-content:start;margin:0;margin-bottom:calc(var(--mdc-size-border-width-1)*-1);padding:0;width:-webkit-max-content;width:max-content}.mdc-c-tabs__tablist--centered___UQ0o8_990311c{justify-content:center}.mdc-c-tabs__tab___IXSdl_990311c{border:0;border-bottom:var(--mdc-size-border-width-4) solid #0000;display:block;font-family:var(--mdc-font-family-default-primary);font-weight:var(--mdc-font-weight-light);padding:var(--mdc-size-spacing-16) var(--mdc-size-spacing-4);width:-webkit-max-content;width:max-content}.mdc-c-tabs__tab___IXSdl_990311c:lang(ar){font-family:var(--mdc-font-family-arabic-primary,var(--mdc-font-family-default-primary))}.mdc-c-tabs__tab___IXSdl_990311c:lang(ru){font-family:var(--mdc-font-family-russian-primary,var(--mdc-font-family-default-primary))}.mdc-c-tabs__tab___IXSdl_990311c:lang(vi){font-family:var(--mdc-font-family-vietnamese-primary,var(--mdc-font-family-default-primary))}.mdc-c-tabs__tab___IXSdl_990311c:lang(ja){font-family:var(--mdc-font-family-japanese-primary,var(--mdc-font-family-default-primary))}.mdc-c-tabs__tab--is-active___G72D-_990311c{border-bottom-color:var(--button-minimal-tertiary-hover)}.mdc-c-tabs__tabpanel___chsU7_990311c{border-top:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-gray-18);padding:var(--mdc-size-spacing-16) 0}.mdc-c-tabs__paddles___msvdU_990311c .mdc-c-tabs__paddle___Y09Ta_990311c{background-image:var(--paddle-bg-left);border:0;min-width:var(--mdc-size-spacing-16);padding:var(--mdc-size-spacing-16) var(--mdc-size-spacing-24) var(--mdc-size-spacing-16) var(--mdc-size-spacing-8);position:absolute;top:0}.mdc-c-tabs__paddles___msvdU_990311c .mdc-c-tabs__paddle--right___KtnNh_990311c{background-image:var(--paddle-bg-right);padding-left:var(--mdc-size-spacing-24);padding-right:var(--mdc-size-spacing-8);right:0}.mdc-c-tabs__paddle___Y09Ta_990311c:focus,.mdc-c-tabs__tab___IXSdl_990311c:focus{outline:none}.mdc-c-tabs__paddle___Y09Ta_990311c:focus-visible,.mdc-c-tabs__tab___IXSdl_990311c:focus-visible{outline:var(--mdc-size-border-width-4) solid var(--button-focus-default);outline-offset:calc(var(--mdc-size-border-width-4)*-1)}</style><style type=\"text/css\">.mdc-c-typeahead___31M3S_990311c{position:relative}.mdc-c-typeahead__menu___kINRW_990311c{background-color:var(--mdc-color-neutral-white);border:var(--mdc-size-border-width-1) solid var(--mdc-color-neutral-gray-30);box-shadow:var(--mdc-elevation-2);margin-top:var(--mdc-size-spacing-4);padding:0;width:100%;z-index:1}.mdc-c-typeahead__menu___kINRW_990311c ul{list-style:none;margin:0;padding:0}.mdc-c-typeahead__menu___kINRW_990311c ul li{cursor:pointer;padding:var(--mdc-size-spacing-8) var(--mdc-size-spacing-16)}.mdc-c-typeahead__menu-item--active___q5GP9_990311c{background-color:var(--mdc-color-neutral-gray-03);outline:none}</style><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/08dfc05290ce60e1.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-3464\" src=\"/_next/static/chunks/3464.caabbe0cce2df796.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-2453\" src=\"/_next/static/chunks/2453.5bbec710ffd42462.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/7f0894b6dca7827f.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-2169\" src=\"/_next/static/chunks/2169.db1ed0d7c6e757b7.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/46b1c7e4e497c465.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-5317\" src=\"/_next/static/chunks/5317.7ad5e77119c7b9d7.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-895\" src=\"/_next/static/chunks/895.63b261a2b180ec79.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-7044\" src=\"/_next/static/chunks/7044.d5c57fbc84841f29.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-906\" src=\"/_next/static/chunks/906.033c0adf90096a05.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-9829\" src=\"/_next/static/chunks/9829.1c1a2c713fe60a17.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/d4aec97cc669860d.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-3305\" src=\"/_next/static/chunks/3305.922e1efcae077965.js\"></script><link rel=\"stylesheet\" type=\"text/css\" href=\"/_next/static/css/5c2a9bc874cbce83.css\"><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-1649\" src=\"/_next/static/chunks/1649.100f3837f09cbcf8.js\"></script><script charset=\"utf-8\" data-webpack=\"_N_E:chunk-1230\" src=\"/_next/static/chunks/1230.de91f4807c3ee7d1.js\"></script></head><body style=\"\"><div id=\"__next\" data-reactroot=\"\"><div class=\"Layout_mck-c-skipbar__K684J\"><a data-component=\"mdc-c-link\" href=\"#skipToMain\" class=\"mdc-c-button___U4iY2_990311c mdc-c-button--primary___Ed-lT_990311c mdc-c-button--size-medium\"><span class=\"mdc-c-link__label___Pfqtd_990311c\">Skip to main content</span></a></div><main class=\"mck-o-container--outer\" data-layer-region=\"body\" role=\"main\" id=\"skipToMain\"><div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"dark\" data-module-background=\"deep-blue\" data-module-category=\"AnchoredHero\" class=\"ArticleDefault_mck-c-article-default__SfYQE\"><style>\n    .background-image-article-default {\n      background-image: url('/~/media/mckinsey/industries/life%20sciences/our%20insights/real%20world%20evidence%20driving%20a%20new%20drug%20development%20paradigm%20in%20oncology/real-world-evidence-driving-new-drug-1536x1536-800.jpg?cq=50&mw=767&car=4:3&tco=800&cpy=Center');\n      background-position: center center;\n      width: auto;\n    }\n  \n          @media screen and (min-width: 768px){\n            \n    .background-image-article-default {\n      background-image: url('/~/media/mckinsey/industries/life%20sciences/our%20insights/real%20world%20evidence%20driving%20a%20new%20drug%20development%20paradigm%20in%20oncology/real-world-evidence-driving-new-drug-1536x1536-800.jpg?cq=50&mw=1536&car=42:25&tco=800&cpy=Center');\n      background-position: center center;\n      width: auto;\n    }\n  \n          }\n        \n          @media screen and (min-width: 1180px){\n            \n    .background-image-article-default {\n      background-image: url('/~/media/mckinsey/industries/life%20sciences/our%20insights/real%20world%20evidence%20driving%20a%20new%20drug%20development%20paradigm%20in%20oncology/real-world-evidence-driving-new-drug-1536x1536-800.jpg?cq=50&mw=1536&car=2:1&tco=800&cpy=Center');\n      background-position: center center;\n      width: auto;\n    }\n  \n          }\n        </style><div data-component=\"mdc-c-background-image\" class=\"mdc-c-bg-image___GJdv1_990311c background-image-article-default ArticleDefault_mck-c-article-default__parallax-container__fZ7Iq\"></div><div class=\"ArticleDefault_mck-c-article-default__gradient__Uu21n\"></div><div class=\"ArticleDefault_mck-c-article-default__wrapper-content__XOe9C\"><div class=\"mck-o-container\"><div class=\"mck-o-container--wrapped mck-o-container--mobile-spacing mdc-u-grid mdc-u-grid-col-lg-12\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c mdc-u-grid-col-lg-start-1 mdc-u-grid-col-lg-span-10\"><div><h1 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-2 mck-u-animation-slide-down ArticleDefault_mck-c-article-default__heading__bv6rL\"><div>Real-world evidence: Driving a new drug-development paradigm in oncology</div></h1></div><div data-component=\"mdc-c-description\" class=\"mdc-c-description___SrnQP_990311c mdc-u-ts-10 mck-u-animation-blur-in-800 ArticleDefault_mck-c-article-default__description__sjoe9\"><div><time datetime=\"2018-07-24T00:00:00Z\">July 24, 2018</time> | Article</div></div></div></div></div></div></div><div class=\"mck-o-container\"><div class=\"mck-o-container--wrapped mck-o-container--mobile-spacing mdc-u-grid mdc-u-grid-gutter-xxl\"><section data-layer-region=\"article-body-header\" class=\"mdc-u-grid mdc-u-grid-col-md-12 mck-u-animation-blur-in-400 byline-share-container\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-8 mdc-u-grid-col-lg-start-3 mdc-u-grid-col-lg-end-8 mdc-u-ts-9\"><span>By </span><span>Arnaub Chatterjee</span>,  <span>Sastry Chilukuri</span>,  <span>Edd Fleming</span>,  <span>Adam Knepp</span>,  <span>Saif Rathore</span><span>,  and </span><span>Joe Zabinski</span></div><div class=\"mdc-u-grid-col-md-start-8 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-8 mdc-u-grid-col-lg-end-11 ArticleContent_mck-c-article-content__share-tools__kWRRw\"></div></section><section class=\"mdc-u-grid mdc-u-grid-col-md-12 mck-u-animation-blur-in-400\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-3 mdc-u-grid-col-lg-end-11\"><div data-component=\"mdc-c-description\" class=\"mdc-c-description___SrnQP_990311c mdc-u-ts-5\"><div class=\"mck-u-links-inline\">The potential for real-world evidence is expanding, particularly in oncology drug development. To compete, some companies are investing in robust real-world data and analytic capabilities.</div></div></div></section><main data-layer-region=\"article-body\" class=\"mdc-u-grid mdc-u-grid-gutter-xxl\"><div class=\"mdc-u-grid mdc-u-grid-col-1 mdc-u-grid-col-md-12\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-3 mdc-u-grid-col-lg-end-11\"><div class=\"mdc-o-content-body mck-u-dropcap\"><div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"DownloadsSidebar_mck-c-downloads-sidebar__iFmyt mck-o-xs-right-span\"><div data-layer-region=\"downloads-right-rail\"><h3 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-c-heading--title___5qyOB_990311c mdc-c-heading--border___K8dj3_990311c\">DOWNLOADS</h3><div><div data-component=\"mdc-c-link-container\" class=\"mdc-c-link-container___xefGu_990311c\"><a data-component=\"mdc-c-link\" href=\"#/download/%2F~%2Fmedia%2Fmckinsey%2Findustries%2Flife%20sciences%2Four%20insights%2Freal%20world%20evidence%20driving%20a%20new%20drug%20development%20paradigm%20in%20oncology%2Freal-world-evidence-driving-a-new-drug-development-paradigm-in-oncology-final.pdf%3FshouldIndex%3Dfalse\" class=\"DownloadsSidebar_mck-c-downloads-sidebar__download-link__fPqFQ mdc-c-link___lBbY1_990311c\" target=\"_self\" data-layer-event-prefix=\"Download Link\" data-layer-action=\"click\" data-layer-report-type=\"Article\" data-layer-file-name=\"real-world-evidence-driving-a-new-drug-development-paradigm-in-oncology-final\" data-layer-report-name=\"real-world-evidence-driving-a-new-drug-development-paradigm-in-oncology-final>Article\"><span data-component=\"mdc-c-icon\" class=\"mdc-c-icon___oi7ef_990311c mdc-c-icon--size-md___yi5fA_990311c mck-download-icon\"></span><span class=\"mdc-c-link__label___Pfqtd_990311c\">Article (PDF-1 MB)</span></a></div></div></div></div>\n<p><em>Note: some examples referenced in this white paper, including therapies, indications, and biopharmaceutical manufacturers, remain under review by regulatory agencies or health authorities; to preserve confidentiality, these are presented without identification.</em></p>\n<p><strong>Evidence generation in oncology</strong> is at a key inflection point. Given the rapid pace of scientific innovation, historical approaches to drug development are increasingly burdensome, with randomized controlled trials remaining incredibly costly and time intensive to conduct, and having a low certainty of success. Biopharmaceutical companies will collectively invest $50 billion to support oncology research and development in 2018, with an approximately 3 percent probability of success for any individual product from preclinical through registration phases.<a rel=\"#footnote1\" class=\"link-footnote\" href=\"#\"><sup>1</sup></a> <span style=\"display:none\" id=\"footnote1\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">1.</span><span class=\"footnote-text\">Bjrn Albrecht, Sandra Andersen, Keval Chauhan, Daina Graybosch, and Philippe Menu, <a href=\"/industries/life-sciences/our-insights/pursuing-breakthroughs-in-cancer-drug-development\">Pursuing breakthroughs in cancer-drug development</a>, January 2018; Andrew W. Lo, Kien Wei Siah, and Chi Heem Wong, Estimation of clinical trial success rates and related parameters, <em>Biostatistics</em>, 2018, mit.edu.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span> Despite this investment, many completed trials fail to answer critical questions for payers and healthcare providers, exacerbating the wide evidence gap that already exists between clinical research.</p>\n<p>Patients, providers, and payers lack answers to fundamental questions: What treatment is best for me?, How do patients treated in the real world perform on this therapy?, What is the value of this therapy relative to other treatment options? The evidence gap persists despite a richness of available data, novel analytic methods, and inexpensive computing and genomic sequencing power. Real-world evidence (RWE)insights generated from data collected during routine clinical practiceprovides a platform with which to close the evidence gap between clinical research and practice.</p>\n<p>The role of RWE in drug development is expanding, driven in part by biotechnology and pharmaceutical manufacturers embrace of digital solutions to realize gains in speed and efficiency from innovation. RWE teams have taken root across the pharmaceutical industry with industry-wide investments in talent and technical infrastructure. Successful biopharmaceutical companies have coupled investment with the belief that RWE is a critical component of development and life-cycle management, and committed to this by building RWE-generation capabilities on a large scale. Providers have similarly embraced RWE to inform clinical practice, and clinical guidelines (for example, National Comprehensive Cancer Network) increasingly incorporate RWE-generated insights. Recognizing the need for a more flexible framework for therapy evaluation, regulators are developing approaches to incorporate RWE in their decision making, as outlined in frameworks such as the 21st Century Cures Act. These changes are accompanied by the emergence of high-quality data providers, including those with distinct data sources and analytic approaches.</p>\n<div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"mck-c-disruptor1up mck-o-md-center mck-u-inline-module-border-top mck-u-inline-module-border-bottom mck-u-screen-only\" data-layer-region=\"disruptor-1up\"><div class=\"mdc-u-grid mdc-u-grid-gutter-md mdc-u-grid-col-lg-12 mdc-u-grid-col-md-12 \"><div class=\"mdc-u-grid-col-md-span-12\"><header data-component=\"mdc-c-header\" class=\"mdc-c-header\"><div class=\"mdc-c-header__block___i1Lg-_990311c\"><h3 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c\"><div>Would you like to learn more about our <a href=\"/industries/life-sciences/how-we-help-clients\">Life Sciences Practice</a>?</div></h3></div></header><div data-component=\"mdc-c-link-container\" class=\"mdc-c-link-container___xefGu_990311c mdc-c-link-container--display-column___X0HDD_990311c mck-c-disruptor1up__content Disruptor1Up_mck-c-disruptor1up__content--links__VV4lE mdc-u-grid-gutter-md\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/how-we-help-clients/research-and-development\" class=\"mdc-c-link-cta___NBQVi_990311c\"><span class=\"mdc-c-link__label___Pfqtd_990311c\">Visit our Research &amp; Development page</span><span data-component=\"mdc-c-icon\" class=\"mdc-c-icon___oi7ef_990311c mck-link-arrow-right-icon\"></span></a></div></div></div></div>\n<p>The potential for RWE is perhaps greatest in oncology. Cancer will soon overtake cardiovascular disease as the leading cause of death in the United States,<a rel=\"#footnote2\" class=\"link-footnote\" href=\"#\"><sup>2</sup></a> <span style=\"display:none\" id=\"footnote2\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">2.</span><span class=\"footnote-text\">Leading Causes of Death, Centers for Disease Control and Prevention, March 2017, cdc.gov.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span> with a similarly increasing disease burden in other geographies. Governmental support for addressing the burden of cancer has increased and includes record levels of federal funding (the National Cancer Institute is the most heavily funded of the 27 National Institutes of Health) and regulatory support through the creation of the Oncology Center of Excellence within the Food and Drug Administration (FDA).<a rel=\"#footnote3\" class=\"link-footnote\" href=\"#\"><sup>3</sup></a> <span style=\"display:none\" id=\"footnote3\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">3.</span><span class=\"footnote-text\">HHS FY2016 Budget in Brief, Department of Health &amp; Human Services, February 2015, hhs.gov.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span> Clinical breakthroughs have led to the development of novel modalities of therapy (that is, chimeric antigen receptor T (CAR-T)/cell therapy) that offer the potential for cure-like responses, but at financial costs that raise questions regarding the role and, ultimately, the value of such therapy. RWE is well positioned to help address these questions in a manner aligned with the interests of all stakeholders. Effectively deployed, RWE can accelerate the pace of discoveryand patient impactof new oncology therapies.</p>\n<h2>How is RWE driving impact?</h2>\n<p>Robust RWE has applications across the entire drug development life cycle, presenting numerous opportunities for biopharmaceutical companies to shorten development time lines, reduce the costs of clinical trials, and improve the probability of technical and regulatory success (PTRS). There are several applications for RWE <em>throughout clinical development</em>, including:</p>\n<ul>\n    <li><em>Early discovery.</em> Oncology development is increasingly personalized and precise, with narrower and more nuanced indications characterized by genomic alterations and signatures. RWE can derisk elements of early discovery by focusing on identification of high-responding patient cohorts. Using robust genomic sequencing data and longitudinal clinical data, RWE analyses can identify biomarkers of therapeutic response and resistance to optimize a drug development strategy. For example, a top ten pharmaceutical company recently utilized a clinico-genomic database with tumor sequencing information from over 2,000 patients with advanced nonsmall cell lung cancer to identify and characterize genomic profiles of patients with rapid progression or otherwise poor prognosis.<a rel=\"#footnote4\" class=\"link-footnote\" href=\"#\"><sup>4</sup></a> <span style=\"display:none\" id=\"footnote4\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">4.</span><span class=\"footnote-text\">Vineeta Agarwala et al, Identification of resistance mechanisms to EGFR treatment in the real world using a clinicogenomic database, AACR Annual Meeting, Chicago, IL, In 2018 ASCO Annual Meeting, June 1-4, 2018; Chicago, Illinois, April 16, 2018, abstractsonline.com.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span> Application of such findings can inform biomarker targets of interest and, in the future, may support more targeted drug development.</li>\n    <li><em>Trial design and feasibility.</em> Targeted use of RWE derived from electronic health records (EHR) supports the design and optimization of clinical trials. RWE can be used to design a protocol that is generalizable to standard of care, assess the impact of eligibility criteria on trial feasibility, and inform the selection of trial sites. For example, a top five oncology drug developer designed a dosing study protocol with high external validity by using RWE to understand how standard of care was delivered in a metastatic cancer population in routine clinical practice. This included adjusting the frequency of assessments of diagnostic imaging and laboratory tests to match the patterns observed in the patient population in the real world. The resulting protocol was designed to be less onerous to patients and investigators, and to lower the cost to the sponsor while producing reliable evidence.</li>\n    <li><em>Trial execution.</em> Of particular relevance to oncology is the adoption of external control arms which may reduce trial size (that is, required number of patients), duration, and cost. In some scenarios, randomization of patients to standard of care will prolong recruitment, and may be difficult to recruit for if early signals show substantial benefit over standard of care. The traditional control arm, which provides a comparator to the experimental therapy, may evolve into an external control derived from historical or contemporaneous populations treated in a real-world setting. This opportunity is particularly striking in cases of rare malignancies where patient recruitment remains a challenge. External control arms may also serve as comparators to early-phase single-arm trials used for registration purposes, as seen in 11 of the last 12 oncology-related approvals through the FDAs Breakthrough Therapy Designation Pathway.<a rel=\"#footnote5\" class=\"link-footnote\" href=\"#\"><sup>5</sup></a> <span style=\"display:none\" id=\"footnote5\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">5.</span><span class=\"footnote-text\">2016 novel drugs summary, US Food &amp; Drug Administration, January 2017, fda.gov; 2017 new drug therapy approvals, US Food &amp; Drug Administration, January 2018, fda.gov.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span> Pfizer recently validated such an approach for a subset of clinical trial patients with HER2-negative/hormone-receptor-positive metastatic breast cancer. The real-world control arm replicated the clinical outcomes (progression-free survival and overall survival) observed in a subset of patients enrolled in a standard of care phase III control arm.<a rel=\"#footnote6\" class=\"link-footnote\" href=\"#\"><sup>6</sup></a> <span style=\"display:none\" id=\"footnote6\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">6.</span><span class=\"footnote-text\">C.H. Bartlett et al, Concordance of real world progression free survival (PFS) on endocrine therapy as first line treatment for metastatic breast cancer using electronic health record with proper quality control versus conventional PFS from a phase 3 trial, San Antonio Breast Cancer Symposium, December 59, 2017, San Antonio, Texas, cancerres.aacrjournals.org.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span> Important questions regarding experimental design, appropriate use of external control arms, and role in the regulatory approval process remain to be elucidated.</li>\n</ul>\n<p>As therapies move from investigation to regulatory approval and uptake, RWE can address additional evidence gaps. Postapproval, we see additional RWE applications, including:</p>\n<ul>\n    <li>\n    <p><em>Postmarketing studies.</em> Real-world perspectives were first incorporated in the regulatory process through the mandate for postmarketing studies. These requirements have traditionally been satisfied through prospective patient registries or chart reviews, approaches requiring significant resources and time to enroll sufficient patients. As oncology therapies are increasingly approved through the FDAs Breakthrough Therapy Designation Pathway, the number and scope of resource intensive postmarketing studies is growing. RWE derived from retrospective capture of high-quality data sources represents an alternative means of satisfying this regulatory requirement that is faster, cheaper, and more representative of real-world populations. A recent example of the increased regulatory role of postmarketing studies was the FDAs Breakthrough Therapy Pathway designation and approval of osimertinib for second-line or later EGFR T790M+ nonsmall cell lung cancer.<a rel=\"#footnote7\" class=\"link-footnote\" href=\"#\"><sup>7</sup></a> <span style=\"display:none\" id=\"footnote7\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">7.</span><span class=\"footnote-text\">TAGRISSO (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer, AstraZeneca, November 13, 2015, astrazeneca.com.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span> Upon approval, the FDA requested that AstraZeneca provide overall response-rate data from one or more real-world cohorts of a minimum of 100 patients who have been selected for treatment on the basis of an EGFR T790M mutation positive result.<a rel=\"#footnote8\" class=\"link-footnote\" href=\"#\"><sup>8</sup></a> <span style=\"display:none\" id=\"footnote8\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">8.</span><span class=\"footnote-text\">Postmarket requirements and commitments, US Food &amp; Drug Administration, April 25, 2018, Retrieved from accessdata.fda.gov.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span> While the FDA has previously required postmarketing studies to assess effectiveness and safety in real-world populations, the approval of osimertinib is notable in that RWE is explicitly requested by name in order to maintain the label. A top-ten oncology developer has gone a step further and adopted a portfolio-wide RWD approach using EHR data to track the effectiveness and safety of their on-market oncology products in near real time.</p>\n    <p>As regulators explore how to incorporate RWE into approval processes, the conditional approach taken with osimertinib may represent an emerging regulatory mechanism. For instance, regulators may increase the use of postmarketing requirements to address evidence gaps from traditional clinical trials as guidelines solidify the use of RWE in this setting. This approach would be of the greatest value in understanding therapy performance in populations typically excluded from clinical trials (for example, mild chronic kidney disease, mild hepatic dysfunction, presence of brain metastases) where the risk-treatment benefit has not been studied.</p>\n    <p>Postmarketing studies are also critical in ex-US markets, and here too, RWE has been proven effective in addressing evidence gaps. For example, a European Health Technology Assessment authority recently requested data to evaluate the safety of a top-five oncology therapy manufacturers new medication in patients with limited cardiac function. The patient population was excluded from the therapys registration trials, so a retrospective analysis of real-world patients was submitted to clarify the safety profile associated with the use of the therapy in this patient subset. This analysis informed the specific European countrys national coverage decision without the need for an additional costly trial.<a rel=\"#footnote9\" class=\"link-footnote\" href=\"#\"><sup>9</sup></a> <span style=\"display:none\" id=\"footnote9\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">9.</span><span class=\"footnote-text\">An observational study of cardiac events in patients with HER2-positive metastatic breast cancer who have a left ventricular ejection fraction (LVEF) between 40%-49% prior to initiating treatment with Kadcyla, European Network of Centers for Pharmacoepidemiology and Pharmacovigilance, April 27, 2018.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span> As the ability to generate high-quality RWE expands, providers will be able to understand the performance of therapies in specific population segments, allowing clinicians and governing bodies (for example, guideline developers) to deliver more tailored therapy recommendations to patients.</p>\n    </li>\n    <li><em>Indication expansion.</em> Oncology therapies approved for a specific indication are frequently used for the treatment of related malignancies. RWE provides a means of leveraging the series of natural experiments that occur as part of off-label use to clarifyand where possible, broadenindications or guidelines for previously approved therapies. Using high-quality RWE to secure broader indications or coverage helps biopharmaceutical companies by reducing obligations for costly randomized controlled trials. In doing so, the impact and scope of biopharmaceutical companies development budgets is increased. Indication expansion has tangible benefits for patients who often depend on labels to ensure treatment coverage. Moreover, indication expansion via RWE also benefits providers by creating a richer evidence dossier that can inform clinical practice.<a rel=\"#footnote10\" class=\"link-footnote\" href=\"#\"><sup>10</sup></a> <span style=\"display:none\" id=\"footnote10\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">10.</span><span class=\"footnote-text\">Derrick Gingery, Pink sheet: US FDA looks to proactively update old generic drug labels under pilot, Friends of Cancer Research, January 28, 2018, focr.org.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span> The value of this benefit is demonstrated in Friends of Cancer Researchs recent efforts to promote label updates for generic therapies whose labels no longer fully reflect how a therapy is used in practice. In an example from a commercial setting, a top-ten oncology drug developer recently submitted EHR-derived patient narrativesbrief summaries of specific events experienced by patients during clinical trialsto support an indication expansion for a rare biomarker defined population. Aside from small populations, RWE can inform treatment in populations historically excluded from randomized controlled trials, including elderly patients and those with comorbidities.</li>\n    <li><em>Market access and reimbursement.</em> In the face of increasing therapy costs, payers are increasingly asking for evidence of clinical value before providing coverage. These pressures are more prominent in oncology, where multiple high-cost agents with similar mechanisms of action compete for market share. For example, the PD-(L)1 inhibitor class includes five on-market therapies and several under development.<a rel=\"#footnote11\" class=\"link-footnote\" href=\"#\"><sup>11</sup></a> <span style=\"display:none\" id=\"footnote11\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">11.</span><span class=\"footnote-text\">Kenji Chamoto et al, Cancer immunotherapies targeting the PD-1 signaling pathway, Journal of Biomedical Science, 2017, Volume 24, Number 26, jbiomedsci.biomedcentral.com.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span> RWE provides a means for demonstration of value, ranging from confirming randomized trial benefits in real-world populations to a fuller characterization of resource impact. In the case of PD-(L)1s, RWE may be utilized as a means of differentiation. More recently, RWE has been used to facilitate value-based and other novel contracting structures by providing a mutually agreed upon measurement methodology for biopharmaceutical companies and providers. Novartiss decision to utilize an outcomes-based pricing contract with CMS for their CAR-T breakthrough Kymriah illustrates this emerging trend.<a rel=\"#footnote12\" class=\"link-footnote\" href=\"#\"><sup>12</sup></a> <span style=\"display:none\" id=\"footnote12\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">12.</span><span class=\"footnote-text\">Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice, Novartis, August 30, 2017, novartis.com.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span></li>\n</ul>\n<h2>Defining quality RWE</h2>\n<p>While RWE promises to unlock significant value across the drug development life cycle, realizing its potential hinges on the quality of the data underlying RWE analyses. This raises the question of how stakeholders should define high-quality RWE. <span>Poor-quality data risks incorrect conclusions</span> through noise and/or potential bias. Clearly defining what data are considered sufficient, and for what purposes, is necessary to ensure confidence in RWE. Data used for hypothesis generation or internal development decision making purposes may not require the same quality standard as data directly informing patient, provider, payer, or regulator behavior.</p>\n<p>Regulatory grade RWE, or evidence derived from data and analyses intended for review by regulators such as the FDA and the European Medicines Agency, or for national payer reviews (Health Technology Assessment authorities), must withstand the highest level of scrutiny (that is, potential review by the FDA Office of Scientific Investigations). Regulatory guidance regarding the specific aspects of high-quality data and analytics is still in development. In the absence of official guidance, principles suggested by otherstraceable/auditable, complete, transparent, generalizable, timely, and scalable<a rel=\"#footnote13\" class=\"link-footnote\" href=\"#\"><sup>13</sup></a> <span style=\"display:none\" id=\"footnote13\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">13.</span><span class=\"footnote-text\">Amy P. Abernethy and Rebecca A. Miksad, Harnessing the power of real-world evidence (RWE): A checklist to ensure regulatory-grade data quality, Clinical Pharmacology and Therapeutics, February 2018, Volume 103, Issue 2, pp. 202-205.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span>provide a good starting point. Ideally, such standards will be developed in a collaboration between biopharmaceutical companies, regulators, and RWE data providers. FDA demonstration projects with RWE providers such as ASCOs CancerLinQ and Flatiron Health, and industry roundtables through the Duke-Margolis Center for Health Policy Research RWE Collaborative represent ongoing efforts in this space.<a rel=\"#footnote14\" class=\"link-footnote\" href=\"#\"><sup>14</sup></a> <span style=\"display:none\" id=\"footnote14\" class=\"tooltip\"><span class=\"footnote-content\"><span class=\"footnote-number\">14.</span><span class=\"footnote-text\">Scott Gottlieb, Implementing the 21st Century Cures Act: An update from FDA and NIH, testimony before the Subcommittee on Health, Energy, and Commerce Committee, US House of Representatives, November 30, 2017, fda.gov.</span><span class=\"clear\"></span></span><span class=\"footnote-bottom\"></span></span> The FDA is accepting RWE as part of regulatory submissions prior to official guidance to, in part, inform such future guidance. Poor-quality RWEreflecting data or analytic shortfallsposes the greatest risk to its broader adoption. A thoughtful collaboration between relevant stakeholders can help define what best practices look like in the development and use of RWE.</p>\n<div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"default\" data-module-background=\"transparent\" data-module-category=\"\" class=\"mck-c-disruptor1up mck-o-md-center mck-u-inline-module-border-top mck-u-inline-module-border-bottom mck-u-screen-only\" data-layer-region=\"disruptor-1up\"><div class=\"mdc-u-grid mdc-u-grid-gutter-md mdc-u-grid-col-lg-12 mdc-u-grid-col-md-12 \"><div class=\"mdc-u-grid-col-lg-span-4 mdc-u-grid-col-md-span-5 Disruptor1Up_mck-c-disruptor1up__image___2Gc4\"><picture data-component=\"mdc-c-picture\"><img alt=\"the Shortlist\" src=\"/~/media/mckinsey/email/shortlist/template/shortlist_promo-interrupter-849120982_1536x1536.jpg?cq=50&amp;mh=145&amp;car=16:9&amp;cpy=Center\" loading=\"lazy\"></picture></div><div class=\"mdc-u-grid-col-lg-span-8 mdc-u-grid-col-md-span-7\"><header data-component=\"mdc-c-header\" class=\"mdc-c-header\"><div class=\"mdc-c-header__block___i1Lg-_990311c\"><h3 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c\"><div>Subscribe to the Shortlist</div></h3><div data-component=\"mdc-c-description\" class=\"mdc-c-description___SrnQP_990311c mdc-u-ts-7\"><p><div>McKinseys new weekly newsletter, featuring must-read content on a range of topics, every Friday</div></p></div></div></header><div data-component=\"mdc-c-link-container\" class=\"mdc-c-link-container___xefGu_990311c mdc-c-link-container--display-column___X0HDD_990311c mck-c-disruptor1up__content Disruptor1Up_mck-c-disruptor1up__content--links__VV4lE mdc-u-grid-gutter-md\"><a data-component=\"mdc-c-link\" href=\"/user-registration/manage-account/edit-subscriptions\" class=\"mdc-c-link-cta___NBQVi_990311c\"><span class=\"mdc-c-link__label___Pfqtd_990311c\">Get the Shortlist in your inbox</span><span data-component=\"mdc-c-icon\" class=\"mdc-c-icon___oi7ef_990311c mck-link-arrow-right-icon\"></span></a></div></div></div></div>\n<h2>Realizing the potential of RWE</h2>\n<p>Biopharmaceutical companies that have successfully leveraged the potential of RWE have done so by coupling high-value use cases with an operating model that enables large-scale impact. In leading organizations, RWE is championed by an RWE group with a broader mandate than traditional health economics and outcomes research (HEOR) groups. These RWE groups exist within a next-generation clinical development model that positions RWE as central to a broader evidence generation strategy, ensuring its integration throughout a products development and life cycle, and not simply geared toward satisfying a health technology assessment. Proactive RWE groups seek out best-of-breed data partnerships that go beyond the limitations of commercially available data. These range from traditional partnerships with academic medical centers to more oncology-specific data curated by dedicated RWE groups. In short, these organizations have moved away from the legacy HEOR model to drive RWE on a large scale across many of the use cases described above. As RWE opportunities continue to expand and play a greater role in drug approvals, these biopharmaceutical companies will be best positioned to reap the benefits from RWE.</p>\n<h2>RWE and a new drug development paradigm</h2>\n<p>RWE, appropriately utilized, has the potential to dramatically improve drug development, inform clinical practice, and clarify the value of new therapies. <span>With its rapid pace of drug and clinical development</span>, oncology will, by necessity, be at the forefront of how RWE impacts drug development. Early adopters recognize this and are positioning a comprehensive RWE capability as a central component of their drug development infrastructure, investing in robust real-world data and analytic capabilities. Biopharmaceutical companies that are slow to implement comprehensive RWE capabilities risk finding themselves significantly disadvantaged in an increasingly competitive therapeutic space, unable to benefit from the new drug development paradigm. By acting decisively and collaborating with relevant stakeholders, biopharmaceutical companies can actively shape the role of RWE in oncology drug development, accelerating the next generation of innovative therapies.</p></div><div class=\"container-placeholder\"></div></div></div><div class=\"mdc-u-grid mdc-u-grid-gutter-xl\"><section role=\"contentinfo\" data-layer-region=\"article-about-authors\" class=\"mdc-u-grid mdc-u-grid-col-md-12 AboutAuthor_mck-c-about-author__nRJzu\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-3 mdc-u-grid-col-lg-end-11\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-c-heading--title___5qyOB_990311c mdc-c-heading--border___K8dj3_990311c mdc-u-align-center\">About the author(s)</h5><div data-component=\"mdc-c-description\" class=\"mdc-c-description___SrnQP_990311c mdc-u-ts-8 mck-u-links-inline mck-u-links-inline--secondary mdc-u-mt-5\"><div><p><strong>Arnaub Chatterjee</strong> is a senior expert in McKinseys North America Knowledge Center, where <strong>Joe Zabinski</strong> is an analyst;&nbsp;<strong>Sastry Chilukuri</strong> is a partner in the New Jersey office, where <strong>Adam Knepp</strong> is an associate partner;&nbsp;<strong><a href=\"/sitecore/service/notfound.aspx?item=web%3a%7be3799187-fa38-4262-a0a8-1aa6e0b32933%7d%40en\">Edd Fleming</a></strong> is a senior partner in the Silicon Valley office; and <strong>Saif Rathore</strong> is a senior expert in the Chicago office.</p></div></div></div></section><section class=\"mdc-u-grid mdc-u-grid-col-md-12 mck-u-screen-only\"><div class=\"mdc-u-grid-col-md-start-2 mdc-u-grid-col-md-end-12 mdc-u-grid-col-lg-start-5 mdc-u-grid-col-lg-end-9\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-c-heading--title___5qyOB_990311c mdc-c-heading--border___K8dj3_990311c mdc-u-align-center\">Explore a career with us</h5><div data-component=\"mdc-c-link-container\" class=\"mdc-c-link-container___xefGu_990311c mdc-c-link-container--align-center___ar3mu_990311c\"><a data-component=\"mdc-c-link\" href=\"/careers/search-jobs\" class=\"mdc-c-button___U4iY2_990311c mdc-c-button--secondary___Boipq_990311c mdc-c-button--size-large___jwpUy_990311c\" aria-label=\"Search Openings\" data-layer-event-prefix=\"CTA Link\" data-layer-action=\"click\" data-layer-category=\"careers\" data-layer-subcategory=\"search\" data-layer-text=\"Search Openings\"><span class=\"mdc-c-link__label___Pfqtd_990311c\">Search Openings</span></a></div></div></section></div></main></div><div data-component=\"mdc-c-module-wrapper\" data-module-theme=\"light\" data-module-background=\"lightest-grey\" data-module-category=\"StandalonePromo\" class=\"RelatedArticle_mck-c-article-related__GGA76 mck-u-screen-only\" data-layer-region=\"related-articles\"><div class=\"mdc-o-container__wrapper is-wrapped mdc-u-spaced-mobile\"><h5 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-c-heading--title___5qyOB_990311c mdc-u-align-center\">Related Articles</h5><div class=\"mdc-u-grid mdc-u-grid-col-md-3 RelatedArticle_items-container__s2uD0\"><div class=\"mdc-u-grid mdc-u-grid-gutter-lg Card_card__diA2r Card_hover-effect__RGb9b\"><div class=\"Card_wrapper-image__8b4P6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/pursuing-breakthroughs-in-cancer-drug-development\" class=\"mdc-c-link___lBbY1_990311c\"><picture data-component=\"mdc-c-picture\" class=\"Card_wrapper-image__8b4P6\"><style>.picture-uniqueKey-pursu-0 { aspect-ratio: 16/9 }</style><img alt=\"Pursuing breakthroughs in cancer-drug development\" class=\"picture-uniqueKey-pursu-0\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/pursuing%20breakthroughs%20in%20cancer%20drug%20development/pursuing-cancer-drug-1536x1536-0.jpg?cq=50&amp;mw=767&amp;car=16:9&amp;cpy=Center\" loading=\"lazy\"></picture></a></div><div class=\"Card_wrapper-text__U6Y3k\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c Card_content-block__pF6Z1\"><span>Article</span><h6 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/pursuing-breakthroughs-in-cancer-drug-development\" class=\"mdc-c-link-heading___Zggl8_990311c mdc-c-link___lBbY1_990311c\"><div>Pursuing breakthroughs in cancer-drug development</div></a></h6></div></div></div><div class=\"mdc-u-grid mdc-u-grid-gutter-lg Card_card__diA2r Card_hover-effect__RGb9b\"><div class=\"Card_wrapper-image__8b4P6\"><a data-component=\"mdc-c-link\" href=\"/industries/healthcare/our-insights/the-next-wave-of-innovation-in-oncology\" class=\"mdc-c-link___lBbY1_990311c\"><picture data-component=\"mdc-c-picture\" class=\"Card_wrapper-image__8b4P6\"><style>.picture-uniqueKey-then-0 { aspect-ratio: 16/9 }</style><img alt=\"The next wave of innovation in oncology\" class=\"picture-uniqueKey-then-0\" src=\"/~/media/mckinsey/industries/healthcare%20systems%20and%20services/our%20insights/the%20next%20wave%20of%20innovation%20in%20oncology/mck_cancer-center_next-wave_661788165_1536x1536.jpg?cq=50&amp;mw=767&amp;car=16:9&amp;cpy=Center\" loading=\"lazy\"></picture></a></div><div class=\"Card_wrapper-text__U6Y3k\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c Card_content-block__pF6Z1\"><span>Report</span><h6 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-6\"><a data-component=\"mdc-c-link\" href=\"/industries/healthcare/our-insights/the-next-wave-of-innovation-in-oncology\" class=\"mdc-c-link-heading___Zggl8_990311c mdc-c-link___lBbY1_990311c\"><div>The next wave of innovation in oncology</div></a></h6></div></div></div><div class=\"mdc-u-grid mdc-u-grid-gutter-lg Card_card__diA2r Card_hover-effect__RGb9b\"><div class=\"Card_wrapper-image__8b4P6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/real-world-evidence-from-activity-to-impact-in-healthcare-decision-making\" class=\"mdc-c-link___lBbY1_990311c\"><picture data-component=\"mdc-c-picture\" class=\"Card_wrapper-image__8b4P6\"><style>.picture-uniqueKey-real--0 { aspect-ratio: 16/9 }</style><img alt=\"Real-world evidence: From activity to impact\" class=\"picture-uniqueKey-real--0\" src=\"/~/media/mckinsey/industries/life%20sciences/our%20insights/real%20world%20evidence%20from%20activity%20to%20impact%20in%20healthcare%20decision%20making/real-world-evidence-1536x1536-100.jpg?cq=50&amp;mw=767&amp;car=16:9&amp;cpy=Center\" loading=\"lazy\"></picture></a></div><div class=\"Card_wrapper-text__U6Y3k\"><div data-component=\"mdc-c-content-block\" class=\"mdc-c-content-block___7p6Lu_990311c Card_content-block__pF6Z1\"><span>Article</span><h6 data-component=\"mdc-c-heading\" class=\"mdc-c-heading___0fM1W_990311c mdc-u-ts-6\"><a data-component=\"mdc-c-link\" href=\"/industries/life-sciences/our-insights/real-world-evidence-from-activity-to-impact-in-healthcare-decision-making\" class=\"mdc-c-link-heading___Zggl8_990311c mdc-c-link___lBbY1_990311c\"><div>Real-world evidence: From activity to impact in healthcare decision making</div></a></h6></div></div></div></div></div></div></div></main><div class=\"mck-u-sr-only\" role=\"log\" aria-live=\"polite\" aria-relevant=\"additions\" aria-atomic=\"true\"></div></div><script id=\"__NEXT_DATA__\" type=\"application/json\">{\"props\":{\"pageProps\":{\"locale\":\"en\",\"dictionary\":{},\"sitecoreContext\":{\"route\":{\"name\":\"Real world evidence Driving a new drug development paradigm in oncology\",\"displayName\":\"Real world evidence Driving a new drug development paradigm in oncology\",\"fields\":null,\"databaseName\":\"web\",\"deviceId\":\"fe5d7fdf-89c0-4d99-9aa3-b5fbd009c9f3\",\"itemId\":\"fe170b38-bd48-4955-8aba-7173563e1f6b\",\"itemLanguage\":\"en\",\"itemVersion\":2,\"layoutId\":\"ae753eb4-a035-40b4-83bf-4b4438df6742\",\"templateId\":\"683910db-02ba-40ba-92e7-726c880160a9\",\"templateName\":\"ArticleJSS\",\"placeholders\":{\"jss-main\":[{\"uid\":\"232bb7e9-289f-492d-a916-2b6185e44a84\",\"componentName\":\"ArticleTemplate\",\"dataSource\":\"\",\"fields\":{\"data\":{\"articleTemplate\":{\"title\":{\"jsonValue\":{\"value\":\"Real-world evidence: Driving a new drug-development paradigm in oncology\"}},\"sEOTitle\":{\"value\":\"\"},\"description\":{\"jsonValue\":{\"value\":\"The potential for real-world evidence is expanding, particularly in oncology drug development. To compete, some companies are investing in robust real-world data and analytic capabilities.\"}},\"sEODescription\":{\"value\":\"\"},\"displayDate\":{\"jsonValue\":{\"value\":\"2018-07-24T00:00:00Z\"}},\"body\":{\"value\":\"[[DownloadsSidebar]]\\n\\u003cp\\u003e\\u003cem\\u003eNote: some examples referenced in this white paper, including therapies, indications, and biopharmaceutical manufacturers, remain under review by regulatory agencies or health authorities; to preserve confidentiality, these are presented without identification.\\u003c/em\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eEvidence generation in oncology\\u003c/strong\\u003e is at a key inflection point. Given the rapid pace of scientific innovation, historical approaches to drug development are increasingly burdensome, with randomized controlled trials remaining incredibly costly and time intensive to conduct, and having a low certainty of success. Biopharmaceutical companies will collectively invest $50 billion to support oncology research and development in 2018, with an approximately 3 percent probability of success for any individual product from preclinical through registration phases.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote1\\\"\\u003e\\u003csup\\u003e1\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote1\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e1.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003eBj\\u0026ouml;rn Albrecht, Sandra Andersen, Keval Chauhan, Daina Graybosch, and Philippe Menu, \\u0026ldquo;\\u003ca href=\\\"/industries/life-sciences/our-insights/pursuing-breakthroughs-in-cancer-drug-development\\\"\\u003ePursuing breakthroughs in cancer-drug development\\u003c/a\\u003e,\\u0026rdquo; January 2018; Andrew W. Lo, Kien Wei Siah, and Chi Heem Wong, \\u0026ldquo;Estimation of clinical trial success rates and related parameters,\\u0026rdquo; \\u003cem\\u003eBiostatistics\\u003c/em\\u003e, 2018, mit.edu.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e Despite this investment, many completed trials fail to answer critical questions for payers and healthcare providers, exacerbating the wide evidence gap that already exists between clinical research.\\u003c/p\\u003e\\n\\u003cp\\u003ePatients, providers, and payers lack answers to fundamental questions: \\u0026ldquo;What treatment is best for me?\\u0026rdquo;, \\u0026ldquo;How do patients treated in the \\u0026lsquo;real world\\u0026rsquo; perform on this therapy?\\u0026rdquo;, \\u0026ldquo;What is the value of this therapy relative to other treatment options?\\u0026rdquo; The evidence gap persists despite a richness of available data, novel analytic methods, and inexpensive computing and genomic sequencing power. Real-world evidence (RWE)\\u0026mdash;insights generated from data collected during routine clinical practice\\u0026mdash;provides a platform with which to close the evidence gap between clinical research and practice.\\u003c/p\\u003e\\n\\u003cp\\u003eThe role of RWE in drug development is expanding, driven in part by biotechnology and pharmaceutical manufacturers\\u0026rsquo; embrace of digital solutions to realize gains in speed and efficiency from innovation. RWE teams have taken root across the pharmaceutical industry with industry-wide investments in talent and technical infrastructure. Successful biopharmaceutical companies have coupled investment with the belief that RWE is a critical component of development and life-cycle management, and committed to this by building RWE-generation capabilities on a large scale. Providers have similarly embraced RWE to inform clinical practice, and clinical guidelines (for example, National Comprehensive Cancer Network) increasingly incorporate RWE-generated insights. Recognizing the need for a more flexible framework for therapy evaluation, regulators are developing approaches to incorporate RWE in their decision making, as outlined in frameworks such as the 21st Century Cures Act. These changes are accompanied by the emergence of high-quality data providers, including those with distinct data sources and analytic approaches.\\u003c/p\\u003e\\n[[Disruptor1UP dis1]]\\n\\u003cp\\u003eThe potential for RWE is perhaps greatest in oncology. Cancer will soon overtake cardiovascular disease as the leading cause of death in the United States,\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote2\\\"\\u003e\\u003csup\\u003e2\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote2\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e2.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003e\\u0026ldquo;Leading Causes of Death,\\u0026rdquo; Centers for Disease Control and Prevention, March 2017, cdc.gov.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e with a similarly increasing disease burden in other geographies. Governmental support for addressing the burden of cancer has increased and includes record levels of federal funding (the National Cancer Institute is the most heavily funded of the 27 National Institutes of Health) and regulatory support through the creation of the Oncology Center of Excellence within the Food and Drug Administration (FDA).\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote3\\\"\\u003e\\u003csup\\u003e3\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote3\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e3.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003e\\u0026ldquo;HHS FY2016 Budget in Brief,\\u0026rdquo; Department of Health \\u0026amp; Human Services, February 2015, hhs.gov.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e Clinical breakthroughs have led to the development of novel modalities of therapy (that is, chimeric antigen receptor T (CAR-T)/cell therapy) that offer the potential for cure-like responses, but at financial costs that raise questions regarding the role and, ultimately, the value of such therapy. RWE is well positioned to help address these questions in a manner aligned with the interests of all stakeholders. Effectively deployed, RWE can accelerate the pace of discovery\\u0026mdash;and patient impact\\u0026mdash;of new oncology therapies.\\u003c/p\\u003e\\n\\u003ch2\\u003eHow is RWE driving impact?\\u003c/h2\\u003e\\n\\u003cp\\u003eRobust RWE has applications across the entire drug development life cycle, presenting numerous opportunities for biopharmaceutical companies to shorten development time lines, reduce the costs of clinical trials, and improve the probability of technical and regulatory success (PTRS). There are several applications for RWE \\u003cem\\u003ethroughout clinical development\\u003c/em\\u003e, including:\\u003c/p\\u003e\\n\\u003cul\\u003e\\n    \\u003cli\\u003e\\u003cem\\u003eEarly discovery.\\u003c/em\\u003e Oncology development is increasingly personalized and precise, with narrower and more nuanced indications characterized by genomic alterations and signatures. RWE can derisk elements of early discovery by focusing on identification of high-responding patient cohorts. Using robust genomic sequencing data and longitudinal clinical data, RWE analyses can identify biomarkers of therapeutic response and resistance to optimize a drug development strategy. For example, a top ten pharmaceutical company recently utilized a clinico-genomic database with tumor sequencing information from over 2,000 patients with advanced nonsmall cell lung cancer to identify and characterize genomic profiles of patients with rapid progression or otherwise poor prognosis.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote4\\\"\\u003e\\u003csup\\u003e4\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote4\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e4.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003eVineeta Agarwala et al, \\u0026ldquo;Identification of resistance mechanisms to EGFR treatment in the real world using a clinicogenomic database,\\u0026rdquo; AACR Annual Meeting, Chicago, IL, In 2018 ASCO Annual Meeting, June 1-4, 2018; Chicago, Illinois, April 16, 2018, abstractsonline.com.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e Application of such findings can inform biomarker targets of interest and, in the future, may support more targeted drug development.\\u003c/li\\u003e\\n    \\u003cli\\u003e\\u003cem\\u003eTrial design and feasibility.\\u003c/em\\u003e Targeted use of RWE derived from electronic health records (EHR) supports the design and optimization of clinical trials. RWE can be used to design a protocol that is generalizable to standard of care, assess the impact of eligibility criteria on trial feasibility, and inform the selection of trial sites. For example, a top five oncology drug developer designed a dosing study protocol with high external validity by using RWE to understand how standard of care was delivered in a metastatic cancer population in routine clinical practice. This included adjusting the frequency of assessments of diagnostic imaging and laboratory tests to match the patterns observed in the patient population in the real world. The resulting protocol was designed to be less onerous to patients and investigators, and to lower the cost to the sponsor while producing reliable evidence.\\u003c/li\\u003e\\n    \\u003cli\\u003e\\u003cem\\u003eTrial execution.\\u003c/em\\u003e Of particular relevance to oncology is the adoption of external control arms which may reduce trial size (that is, required number of patients), duration, and cost. In some scenarios, randomization of patients to standard of care will prolong recruitment, and may be difficult to recruit for if early signals show substantial benefit over standard of care. The traditional control arm, which provides a comparator to the experimental therapy, may evolve into an \\u0026ldquo;external\\u0026rdquo; control derived from historical or contemporaneous populations treated in a real-world setting. This opportunity is particularly striking in cases of rare malignancies where patient recruitment remains a challenge. External control arms may also serve as comparators to early-phase single-arm trials used for registration purposes, as seen in 11 of the last 12 oncology-related approvals through the FDA\\u0026rsquo;s Breakthrough Therapy Designation Pathway.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote5\\\"\\u003e\\u003csup\\u003e5\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote5\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e5.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003e\\u0026ldquo;2016 novel drugs summary,\\u0026rdquo; US Food \\u0026amp; Drug Administration, January 2017, fda.gov; \\u0026ldquo;2017 new drug therapy approvals,\\u0026rdquo; US Food \\u0026amp; Drug Administration, January 2018, fda.gov.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e Pfizer recently validated such an approach for a subset of clinical trial patients with HER2-negative/hormone-receptor-positive metastatic breast cancer. The real-world control arm replicated the clinical outcomes (progression-free survival and overall survival) observed in a subset of patients enrolled in a standard of care phase III control arm.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote6\\\"\\u003e\\u003csup\\u003e6\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote6\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e6.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003eC.H. Bartlett et al, \\u0026ldquo;Concordance of real world progression free survival (PFS) on endocrine therapy as first line treatment for metastatic breast cancer using electronic health record with proper quality control versus conventional PFS from a phase 3 trial,\\u0026rdquo; San Antonio Breast Cancer Symposium, December 5\\u0026ndash;9, 2017, San Antonio, Texas, cancerres.aacrjournals.org.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e Important questions regarding experimental design, appropriate use of external control arms, and role in the regulatory approval process remain to be elucidated.\\u003c/li\\u003e\\n\\u003c/ul\\u003e\\n\\u003cp\\u003eAs therapies move from investigation to regulatory approval and uptake, RWE can address additional evidence gaps. Postapproval, we see additional RWE applications, including:\\u003c/p\\u003e\\n\\u003cul\\u003e\\n    \\u003cli\\u003e\\n    \\u003cp\\u003e\\u003cem\\u003ePostmarketing studies.\\u003c/em\\u003e Real-world perspectives were first incorporated in the regulatory process through the mandate for postmarketing studies. These requirements have traditionally been satisfied through prospective patient registries or chart reviews, approaches requiring significant resources and time to enroll sufficient patients. As oncology therapies are increasingly approved through the FDA\\u0026rsquo;s Breakthrough Therapy Designation Pathway, the number and scope of resource intensive postmarketing studies is growing. RWE derived from retrospective capture of high-quality data sources represents an alternative means of satisfying this regulatory requirement that is faster, cheaper, and more representative of real-world populations. A recent example of the increased regulatory role of postmarketing studies was the FDA\\u0026rsquo;s Breakthrough Therapy Pathway designation and approval of osimertinib for second-line or later EGFR T790M+ nonsmall cell lung cancer.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote7\\\"\\u003e\\u003csup\\u003e7\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote7\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e7.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003e\\u0026ldquo;TAGRISSO\\u0026trade; (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer,\\u0026rdquo; AstraZeneca, November 13, 2015, astrazeneca.com.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e Upon approval, the FDA requested that AstraZeneca provide overall response-rate data from \\u0026ldquo;one or more real-world cohorts of a minimum of 100 patients who have been selected for treatment on the basis of an EGFR T790M mutation positive result.\\u0026rdquo;\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote8\\\"\\u003e\\u003csup\\u003e8\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote8\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e8.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003e\\u0026ldquo;Postmarket requirements and commitments,\\u0026rdquo; US Food \\u0026amp; Drug Administration, April 25, 2018, Retrieved from accessdata.fda.gov.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e While the FDA has previously required postmarketing studies to assess effectiveness and safety in real-world populations, the approval of osimertinib is notable in that RWE is explicitly requested by name in order to maintain the label. A top-ten oncology developer has gone a step further and adopted a portfolio-wide RWD approach using EHR data to track the effectiveness and safety of their on-market oncology products in near real time.\\u003c/p\\u003e\\n    \\u003cp\\u003eAs regulators explore how to incorporate RWE into approval processes, the conditional approach taken with osimertinib may represent an emerging regulatory mechanism. For instance, regulators may increase the use of postmarketing requirements to address evidence gaps from traditional clinical trials as guidelines solidify the use of RWE in this setting. This approach would be of the greatest value in understanding therapy performance in populations typically excluded from clinical trials (for example, mild chronic kidney disease, mild hepatic dysfunction, presence of brain metastases) where the risk-treatment benefit has not been studied.\\u003c/p\\u003e\\n    \\u003cp\\u003ePostmarketing studies are also critical in ex-US markets, and here too, RWE has been proven effective in addressing evidence gaps. For example, a European Health Technology Assessment authority recently requested data to evaluate the safety of a top-five oncology therapy manufacturer\\u0026rsquo;s new medication in patients with limited cardiac function. The patient population was excluded from the therapy\\u0026rsquo;s registration trials, so a retrospective analysis of real-world patients was submitted to clarify the safety profile associated with the use of the therapy in this patient subset. This analysis informed the specific European country\\u0026rsquo;s national coverage decision without the need for an additional costly trial.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote9\\\"\\u003e\\u003csup\\u003e9\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote9\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e9.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003e\\u0026ldquo;An observational study of cardiac events in patients with HER2-positive metastatic breast cancer who have a left ventricular ejection fraction (LVEF) between 40%-49% prior to initiating treatment with Kadcyla,\\u0026rdquo; European Network of Centers for Pharmacoepidemiology and Pharmacovigilance, April 27, 2018.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e As the ability to generate high-quality RWE expands, providers will be able to understand the performance of therapies in specific population segments, allowing clinicians and governing bodies (for example, guideline developers) to deliver more tailored therapy recommendations to patients.\\u003c/p\\u003e\\n    \\u003c/li\\u003e\\n    \\u003cli\\u003e\\u003cem\\u003eIndication expansion.\\u003c/em\\u003e Oncology therapies approved for a specific indication are frequently used for the treatment of related malignancies. RWE provides a means of leveraging the series of natural experiments that occur as part of off-label use to clarify\\u0026mdash;and where possible, broaden\\u0026mdash;indications or guidelines for previously approved therapies. Using high-quality RWE to secure broader indications or coverage helps biopharmaceutical companies by reducing obligations for costly randomized controlled trials. In doing so, the impact and scope of biopharmaceutical companies\\u0026rsquo; development budgets is increased. Indication expansion has tangible benefits for patients who often depend on labels to ensure treatment coverage. Moreover, indication expansion via RWE also benefits providers by creating a richer evidence dossier that can inform clinical practice.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote10\\\"\\u003e\\u003csup\\u003e10\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote10\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e10.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003eDerrick Gingery, \\u0026ldquo;Pink sheet: US FDA looks to proactively update old generic drug labels under pilot,\\u0026rdquo; Friends of Cancer Research, January 28, 2018, focr.org.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e The value of this benefit is demonstrated in Friends of Cancer Research\\u0026rsquo;s recent efforts to promote label updates for generic therapies whose labels no longer fully reflect how a therapy is used in practice. In an example from a commercial setting, a top-ten oncology drug developer recently submitted EHR-derived patient narratives\\u0026mdash;brief summaries of specific events experienced by patients during clinical trials\\u0026mdash;to support an indication expansion for a rare biomarker defined population. Aside from small populations, RWE can inform treatment in populations historically excluded from randomized controlled trials, including elderly patients and those with comorbidities.\\u003c/li\\u003e\\n    \\u003cli\\u003e\\u003cem\\u003eMarket access and reimbursement.\\u003c/em\\u003e In the face of increasing therapy costs, payers are increasingly asking for evidence of clinical value before providing coverage. These pressures are more prominent in oncology, where multiple high-cost agents with similar mechanisms of action compete for market share. For example, the PD-(L)1 inhibitor class includes five on-market therapies and several under development.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote11\\\"\\u003e\\u003csup\\u003e11\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote11\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e11.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003eKenji Chamoto et al, \\u0026ldquo;Cancer immunotherapies targeting the PD-1 signaling pathway,\\u0026rdquo; Journal of Biomedical Science, 2017, Volume 24, Number 26, jbiomedsci.biomedcentral.com.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e RWE provides a means for demonstration of value, ranging from confirming randomized trial benefits in real-world populations to a fuller characterization of resource impact. In the case of PD-(L)1s, RWE may be utilized as a means of differentiation. More recently, RWE has been used to facilitate value-based and other novel contracting structures by providing a mutually agreed upon measurement methodology for biopharmaceutical companies and providers. Novartis\\u0026rsquo;s decision to utilize an outcomes-based pricing contract with CMS for their CAR-T breakthrough Kymriah illustrates this emerging trend.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote12\\\"\\u003e\\u003csup\\u003e12\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote12\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e12.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003e\\u0026ldquo;Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah\\u0026trade; (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice,\\u0026rdquo; Novartis, August 30, 2017, novartis.com.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003c/li\\u003e\\n\\u003c/ul\\u003e\\n\\u003ch2\\u003eDefining quality RWE\\u003c/h2\\u003e\\n\\u003cp\\u003eWhile RWE promises to unlock significant value across the drug development life cycle, realizing its potential hinges on the quality of the data underlying RWE analyses. This raises the question of how stakeholders should define high-quality RWE. \\u003cspan\\u003ePoor-quality data risks incorrect conclusions\\u003c/span\\u003e through noise and/or potential bias. Clearly defining what data are considered sufficient, and for what purposes, is necessary to ensure confidence in RWE. Data used for hypothesis generation or internal development decision making purposes may not require the same quality standard as data directly informing patient, provider, payer, or regulator behavior.\\u003c/p\\u003e\\n\\u003cp\\u003eRegulatory grade RWE, or evidence derived from data and analyses intended for review by regulators such as the FDA and the European Medicines Agency, or for national payer reviews (Health Technology Assessment authorities), must withstand the highest level of scrutiny (that is, potential review by the FDA Office of Scientific Investigations). Regulatory guidance regarding the specific aspects of high-quality data and analytics is still in development. In the absence of official guidance, principles suggested by others\\u0026mdash;traceable/auditable, complete, transparent, generalizable, timely, and scalable\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote13\\\"\\u003e\\u003csup\\u003e13\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote13\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e13.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003eAmy P. Abernethy and Rebecca A. Miksad, \\u0026ldquo;Harnessing the power of real-world evidence (RWE): A checklist to ensure regulatory-grade data quality,\\u0026rdquo; Clinical Pharmacology and Therapeutics, February 2018, Volume 103, Issue 2, pp. 202-205.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u0026mdash;provide a good starting point. Ideally, such standards will be developed in a collaboration between biopharmaceutical companies, regulators, and RWE data providers. FDA demonstration projects with RWE providers such as ASCO\\u0026rsquo;s CancerLinQ and Flatiron Health, and industry roundtables through the Duke-Margolis Center for Health Policy Research RWE Collaborative represent ongoing efforts in this space.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote14\\\"\\u003e\\u003csup\\u003e14\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote14\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e14.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003eScott Gottlieb, \\u0026ldquo;Implementing the 21st Century Cures Act: An update from FDA and NIH,\\u0026rdquo; testimony before the Subcommittee on Health, Energy, and Commerce Committee, US House of Representatives, November 30, 2017, fda.gov.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e The FDA is accepting RWE as part of regulatory submissions prior to official guidance to, in part, inform such future guidance. Poor-quality RWE\\u0026mdash;reflecting data or analytic shortfalls\\u0026mdash;poses the greatest risk to its broader adoption. A thoughtful collaboration between relevant stakeholders can help define what best practices look like in the development and use of RWE.\\u003c/p\\u003e\\n[[Disruptor1UP shortlist]]\\n\\u003ch2\\u003eRealizing the potential of RWE\\u003c/h2\\u003e\\n\\u003cp\\u003eBiopharmaceutical companies that have successfully leveraged the potential of RWE have done so by coupling high-value use cases with an operating model that enables large-scale impact. In leading organizations, RWE is championed by an RWE group with a broader mandate than traditional health economics and outcomes research (HEOR) groups. These RWE groups exist within a next-generation clinical development model that positions RWE as central to a broader evidence generation strategy, ensuring its integration throughout a product\\u0026rsquo;s development and life cycle, and not simply geared toward satisfying a health technology assessment. Proactive RWE groups seek out \\u0026ldquo;best-of-breed\\u0026rdquo; data partnerships that go beyond the limitations of commercially available data. These range from traditional partnerships with academic medical centers to more oncology-specific data curated by dedicated RWE groups. In short, these organizations have moved away from the legacy HEOR model to drive RWE on a large scale across many of the use cases described above. As RWE opportunities continue to expand and play a greater role in drug approvals, these biopharmaceutical companies will be best positioned to reap the benefits from RWE.\\u003c/p\\u003e\\n\\u003ch2\\u003eRWE and a new drug development paradigm\\u003c/h2\\u003e\\n\\u003cp\\u003eRWE, appropriately utilized, has the potential to dramatically improve drug development, inform clinical practice, and clarify the value of new therapies. \\u003cspan\\u003eWith its rapid pace of drug and clinical development\\u003c/span\\u003e, oncology will, by necessity, be at the forefront of how RWE impacts drug development. Early adopters recognize this and are positioning a comprehensive RWE capability as a central component of their drug development infrastructure, investing in robust real-world data and analytic capabilities. Biopharmaceutical companies that are slow to implement comprehensive RWE capabilities risk finding themselves significantly disadvantaged in an increasingly competitive therapeutic space, unable to benefit from the new drug development paradigm. By acting decisively and collaborating with relevant stakeholders, biopharmaceutical companies can actively shape the role of RWE in oncology drug development, accelerating the next generation of innovative therapies.\\u003c/p\\u003e\"},\"isFullScreenInteractive\":{\"boolValue\":false},\"hideStickySocialShareBar\":{\"boolValue\":false},\"desktopID\":{\"value\":\"\"},\"mobileID\":{\"value\":\"\"},\"desktopURL\":{\"value\":\"\"},\"mobileURL\":{\"value\":\"\"},\"desktopPaddingPercentage\":{\"value\":\"\"},\"mobilePaddingPercentage\":{\"value\":\"\"},\"desktopOverrideHeight\":{\"value\":\"\"},\"mobileOverrideHeight\":{\"value\":\"\"},\"cerosOembedURL\":{\"value\":\"\"},\"cerosRenderMode\":{\"targetItem\":null},\"cerosBackgroundColor\":{\"targetItem\":null},\"hideByLine\":{\"boolValue\":false},\"tableOfContentsTitle\":{\"value\":\"TABLE OF CONTENTS\"},\"accessStatus\":{\"targetItem\":{\"key\":{\"value\":\"RegisteredUsers\"},\"value\":{\"value\":\"Registered Users\"}}},\"articleType\":{\"targetItem\":{\"displayName\":\"Article\"}},\"hasSpecialReport\":{\"boolValue\":false},\"contentType\":{\"targetItem\":{\"displayName\":\"Article\"}},\"sourcePublication\":{\"targetItem\":null},\"externalPublication\":{\"value\":\"\"},\"mobileReady\":{\"boolValue\":true},\"forClientsOnly\":{\"boolValue\":false},\"excludeFromClientLink\":{\"boolValue\":false},\"originalPublishDate\":{\"jsonValue\":{\"value\":\"2018-06-01T00:00:00Z\"}},\"footnotes\":{\"value\":\"\"},\"contributoryPractice\":{\"targetItems\":[]},\"aboutTheAuthors\":{\"value\":\"\\u003cp\\u003e\\u003cstrong\\u003eArnaub Chatterjee\\u003c/strong\\u003e is a senior expert in McKinsey\\u0026rsquo;s North America Knowledge Center, where \\u003cstrong\\u003eJoe Zabinski\\u003c/strong\\u003e is an analyst;\\u0026nbsp;\\u003cstrong\\u003eSastry Chilukuri\\u003c/strong\\u003e is a partner in the New Jersey office, where \\u003cstrong\\u003eAdam Knepp\\u003c/strong\\u003e is an associate partner;\\u0026nbsp;\\u003cstrong\\u003e\\u003ca href=\\\"/sitecore/service/notfound.aspx?item=web%3a%7be3799187-fa38-4262-a0a8-1aa6e0b32933%7d%40en\\\"\\u003eEdd Fleming\\u003c/a\\u003e\\u003c/strong\\u003e is a senior partner in the Silicon Valley office; and \\u003cstrong\\u003eSaif Rathore\\u003c/strong\\u003e is a senior expert in the Chicago office.\\u003c/p\\u003e\"},\"authors\":{\"targetItems\":[{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"B29561FE30F54A709979B812CA5DB9C7\",\"name\":\"Arnaub Chatterjee\",\"authorTitle\":{\"value\":\"Arnaub Chatterjee\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[]}},{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"DCE8D40A32DA4817A41FA131602B8030\",\"name\":\"Sastry Chilukuri\",\"authorTitle\":{\"value\":\"Sastry Chilukuri\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[]}},{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"4EA73E6F4BC94D25B9F48027FEF52535\",\"name\":\"Edd Fleming\",\"authorTitle\":{\"value\":\"Edd Fleming\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[]}},{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"0B445C8291B447579EE915958FA2C8CE\",\"name\":\"Adam Knepp\",\"authorTitle\":{\"value\":\"Adam Knepp\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[]}},{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"B9B5F33CD55A40418D55BA969102A7A9\",\"name\":\"Saif Rathore\",\"authorTitle\":{\"value\":\"Saif Rathore\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[]}},{\"template\":{\"id\":\"3FBABDB63A094F68B1F8E1BBE1BA124E\",\"name\":\"Author\"},\"id\":\"3F5F70D0CF9041649689579F43812628\",\"name\":\"Joe Zabinski\",\"authorTitle\":{\"value\":\"Joe Zabinski\"},\"description\":{\"value\":\"\"},\"thumbnailImage\":{\"alt\":\"\",\"src\":null},\"profile\":{\"targetItems\":[]}}]},\"nonPartnerAuthors\":{\"targetItems\":[]},\"interactiveToUse\":{\"targetItem\":null},\"enableArticleComponents\":{\"boolValue\":false},\"relatedArticles\":{\"targetItems\":[{\"sourcePublication\":{\"targetItem\":null},\"publicationSource\":null,\"externalPublication\":{\"value\":\"\"},\"title\":{\"value\":\"Pursuing breakthroughs in cancer-drug development\"},\"url\":{\"path\":\"/industries/life-sciences/our-insights/pursuing-breakthroughs-in-cancer-drug-development\"},\"eyebrow\":{\"targetItem\":{\"name\":\"Article\"}},\"articleType\":{\"targetItem\":{\"name\":\"Article\"}},\"contentType\":{\"targetItem\":{\"name\":\"Article\"}},\"description\":{\"value\":\"Here\\u0026rsquo;s how to get the right medicines to the right patients faster.\"},\"standardImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/pursuing breakthroughs in cancer drug development/pursuing-cancer-drug-1536x1536-0.jpg\",\"alt\":\"Pursuing breakthroughs in cancer-drug development\"},\"heroImage\":null,\"thumbnailImage\":null},{\"sourcePublication\":{\"targetItem\":null},\"publicationSource\":null,\"externalPublication\":{\"value\":\"\"},\"title\":{\"value\":\"The next wave of innovation in oncology\"},\"url\":{\"path\":\"/industries/healthcare/our-insights/the-next-wave-of-innovation-in-oncology\"},\"eyebrow\":{\"targetItem\":{\"name\":\"Report\"}},\"articleType\":{\"targetItem\":{\"name\":\"Report\"}},\"contentType\":{\"targetItem\":{\"name\":\"Article\"}},\"description\":{\"value\":\"A new wave of therapeutic and diagnostic technologies in oncology is becoming available. While many of these have the potential to transform oncology treatment in the future, manufacturers, regulators and care providers must address a number of topics\\u0026mdash;including clinical, regulatory and market access hurdles\\u0026mdash;to deliver on their promise.\"},\"standardImage\":{\"src\":\"/~/media/mckinsey/industries/healthcare systems and services/our insights/the next wave of innovation in oncology/mck_cancer-center_next-wave_661788165_1536x1536.jpg\",\"alt\":\"The next wave of innovation in oncology\"},\"heroImage\":null,\"thumbnailImage\":null},{\"sourcePublication\":{\"targetItem\":null},\"publicationSource\":null,\"externalPublication\":{\"value\":\"\"},\"title\":{\"value\":\"Real-world evidence: From activity to impact in healthcare decision making\"},\"url\":{\"path\":\"/industries/life-sciences/our-insights/real-world-evidence-from-activity-to-impact-in-healthcare-decision-making\"},\"eyebrow\":{\"targetItem\":{\"name\":\"Article\"}},\"articleType\":{\"targetItem\":{\"name\":\"Article\"}},\"contentType\":{\"targetItem\":{\"name\":\"Article\"}},\"description\":{\"value\":\"While there is general agreement that real-world evidence could significantly improve how healthcare stakeholders make decisions, expanding its use requires action by multiple stakeholders.\"},\"standardImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/real world evidence from activity to impact in healthcare decision making/real-world-evidence-1536x1536-100.jpg\",\"alt\":\"Real-world evidence: From activity to impact\"},\"heroImage\":null,\"thumbnailImage\":null}]},\"useEnhancedAuthors\":{\"boolValue\":false},\"acknowledgements\":{\"value\":\"\"},\"showSocialShareFooter\":{\"boolValue\":false},\"template\":{\"id\":\"683910db-02ba-40ba-92e7-726c880160a9\"},\"hideFromSearchEngines\":{\"boolValue\":false},\"heroFiftyFiftyBackground\":{\"targetItem\":null},\"backgroundColor\":{\"targetItem\":null},\"gradientDirection\":{\"targetItem\":{\"key\":{\"value\":\"Bottom Right\"},\"value\":{\"value\":\"bottom-right\"}}},\"hideStickySubscriptionBar\":{\"value\":false},\"enableRegWall\":{\"boolValue\":false},\"timer\":{\"value\":\"8\"},\"regWallHeading\":{\"value\":\"\"},\"showGoToHomeLink\":{\"boolValue\":true},\"regWallDescription\":{\"value\":\"\"},\"isInsightsStorePage\":{\"boolValue\":false},\"selectedModalSubscriptions\":{\"targetItems\":[]},\"link1\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"link2\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"link3\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"link4\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"link5\":{\"queryString\":\"\",\"className\":\"\",\"anchor\":\"\",\"linkType\":\"internal\",\"url\":\"\",\"text\":\"\",\"targetItem\":null},\"fullReportPDF\":{\"name\":\"Full Report PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"fullReportPDFDisplayName\":{\"value\":\"\"},\"appendixPDF\":{\"name\":\"Appendix PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"appendixPDFDisplayName\":{\"value\":\"\"},\"articlePDF\":{\"name\":\"Article PDF\",\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/real world evidence driving a new drug development paradigm in oncology/real-world-evidence-driving-a-new-drug-development-paradigm-in-oncology-final.pdf\",\"displayName\":\"Real-world-evidence-Driving-a-new-drug-development-paradigm-in-oncology-final\",\"title\":\"Real-world evidence: Driving a new drug-development paradigm in oncology\",\"keywords\":\"\",\"description\":\"\",\"extension\":\"pdf\",\"mimeType\":\"application/pdf\",\"size\":1131023,\"pageCount\":\"\",\"thumbnailImageSrc\":\"\"},\"briefingNotePDF\":{\"name\":\"Briefing Note PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"discussionPapersPDF\":{\"name\":\"Discussion Papers PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"executiveSummaryPDF\":{\"name\":\"Executive Summary PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"executiveSummaryPDFDisplayName\":{\"value\":\"\"},\"researchPreviewPDF\":{\"name\":\"Research Preview PDF\",\"src\":null,\"displayName\":null,\"title\":null,\"keywords\":null,\"description\":null,\"extension\":null,\"mimeType\":null,\"size\":null,\"pageCount\":null,\"thumbnailImageSrc\":\"\"},\"heroImage\":{\"src\":null,\"alt\":\"\"},\"standardImage\":{\"src\":\"/~/media/mckinsey/industries/life sciences/our insights/real world evidence driving a new drug development paradigm in oncology/real-world-evidence-driving-new-drug-1536x1536-800.jpg\",\"alt\":\"Real-world evidence: Driving a new drug development paradigm in oncology\"},\"heroImageTopOffset\":{\"value\":\"800\"},\"headerOverlayOpacity\":{\"targetItem\":null},\"heroType\":{\"targetItem\":{\"displayName\":\"Existing\"}},\"photoOverlayOpacity\":{\"targetItem\":null},\"hideHero\":{\"boolValue\":false},\"articleHeroVideoId\":{\"value\":\"\"},\"podcastHeroOmnyAudioID\":{\"value\":\"\"},\"heroBespokeInteractiveID\":{\"value\":\"\"},\"bespokeHeroRenderMode\":{\"targetItem\":null},\"audio\":{\"results\":[]},\"disruptor1up\":{\"results\":[{\"title\":{\"value\":\"Would you like to learn more about our \\u003ca href=\\\"/industries/life-sciences/how-we-help-clients\\\"\\u003eLife Sciences Practice\\u003c/a\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"LinkType\":\"internal\",\"Title\":\"\",\"Text\":\"Visit our Research \\u0026 Development page\",\"Url\":\"/industries/life-sciences/how-we-help-clients/research-and-development\",\"Target\":\"\",\"CssClass\":\"\",\"QueryString\":\"\",\"Anchor\":\"\",\"LinkTitle\":\"Research \\u0026amp; Development\"}]}},\"mediaID\":{\"value\":\"dis1\"},\"template\":{\"name\":\"Disruptor 1Up\"}},{\"mediaID\":{\"value\":\"cop28\"},\"title\":{\"value\":\"Explore COP28 with McKinsey\"},\"description\":{\"value\":\"Join us for a series of dynamic virtual events during COP28. Discover new research, practical strategies, and collaborations across sectors that propel climate action and growth towards net-zero.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/sustainability/how we help clients/cop/cop28/cop28-page-thumb_1536x1536.jpg\",\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/capabilities/sustainability/how-we-help-clients/cop/overview\"}]}}},{\"mediaID\":{\"value\":\"attheedge\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eAt the Edge\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/at-the-edge/id1612870236\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3SnUcezwM20nKnzqvUl6iF\"}]}}},{\"mediaID\":{\"value\":\"authortalks\"},\"title\":{\"value\":\"Visit \\u003cem\\u003e\\u003ca href=\\\"/featured-insights/mckinsey-on-books/author-talks\\\"\\u003eAuthor Talks\\u003c/a\\u003e\\u003c/em\\u003e to see the full series.\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/author talks/authortalks_1536x1536_v1.png\",\"alt\":\"Author Talks\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/author-talks\"}]}}},{\"mediaID\":{\"value\":\"COVID\"},\"title\":{\"value\":\"Explore McKinseys ongoing coverage of the pandemic\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/risk/our insights/covid 19 implications for business/implications-briefing-note-4-standard-1536x1536.jpg\",\"alt\":\"COVID-19: Implications for business\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Read more about the business impact of coronavirus and how organizations can respond\",\"Title\":\"\",\"Url\":\"/featured-insights/coronavirus-leading-through-the-crisis\"}]}}},{\"mediaID\":{\"value\":\"CE\"},\"title\":{\"value\":\"Customer experience\"},\"description\":{\"value\":\"More insight into creating competitive advantage by putting customers first and managing their journeys.\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/public and social sector/our insights/customer experience/customer-experience_22934010_1536x864.jpg\",\"alt\":\"Customer experience\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"\"}]}}},{\"mediaID\":{\"value\":\"driversofdisruption\"},\"title\":{\"value\":\"Want to subscribe to \\u003ca href=\\\"/features/mckinsey-center-for-future-mobility/our-insights/drivers-of-disruption\\\"\\u003e\\u003cem\\u003eDrivers of Disruption\\u003c/em\\u003e\\u003c/a\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/drivers-of-disruption/id1687257324\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5fWXzWmVKacc5I7u9CQsah?si=KQ-wUOSyQlqcnfexExiH9Q\\u0026nd=1\"}]}}},{\"mediaID\":{\"value\":\"JOL\"},\"title\":{\"value\":\"The Journey of Leadership\"},\"description\":{\"value\":\"\\u003cstrong\\u003eHow CEOs Learn to Lead from the Inside Out\\u003c/strong\\u003e\\u003cbr /\\u003e\\nBy \\u003ca href=\\\"/our-people/dana-maor\\\"\\u003eDana Maor\\u003c/a\\u003e, \\u003ca href=\\\"https://www.linkedin.com/in/hanswernerkaas\\\"\\u003eHans-Werner Kaas\\u003c/a\\u003e, \\u003ca href=\\\"/our-people/kurt-strovink\\\"\\u003eKurt Strovink\\u003c/a\\u003e, and \\u003ca href=\\\"/our-people/ramesh-srinivasan\\\"\\u003eRamesh Srinivasan\\u003c/a\\u003e\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/journey of leadership/journey-of-leadership-book-cover-1536x1536.jpg\",\"alt\":\"The Journey of Leadership book cover\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/journey-of-leadership\"}]}}},{\"mediaID\":{\"value\":\"surveys\"},\"title\":{\"value\":\"McKinsey\\u0026rsquo;s original survey research\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey global surveys/mck-global-survey-landing-1284442931-thumb-1536x1536.jpg\",\"alt\":\"McKinsey Global Surveys\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Read more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-global-surveys\"}]}}},{\"mediaID\":{\"value\":\"healthcarepodcast\"},\"title\":{\"value\":\"Want to subscribe to \\u003cem\\u003eMcKinsey on Healthcare\\u003c/em\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-healthcare/id1469979748\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3y1AgAilV4E5Jz0x4wD9O2?si=mLCTUQ2ORTS_LC5gW_htlA\\u0026dl_branch=1\"}]}}},{\"mediaID\":{\"value\":\"myleadershipjourney\"},\"title\":{\"value\":\"My Leadership Journey\"},\"description\":{\"value\":\"A series of conversations with leaders about the people and experiences that shaped them\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/our insights/my leadership journey/my leadership journey collection page_131575496_thumb_1536x1536.jpg\",\"alt\":\"My Leadership Journey\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/my-leadership-journey\"}]}}},{\"mediaID\":{\"value\":\"lessonsfromleaders\"},\"title\":{\"value\":\"State of Organizations: Lessons from leaders\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/our insights/state of org lessons from leaders/soo-chapter-2-872507320-standard-1536x1536.jpg\",\"alt\":\"\\\"\\\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore more interviews\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/lessons-from-leaders\"}]}}},{\"mediaID\":{\"value\":\"stateoforg\"},\"title\":{\"value\":\"The State of Organizations 2023\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Report overview\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/the-state-of-organizations-2023\"}]}}},{\"mediaID\":{\"value\":\"titaniumeconomy\"},\"title\":{\"value\":\"The Titanium Economy\"},\"description\":{\"value\":\"How Industrial Technology Can Create a Better, Faster, Stronger America\\u003cbr /\\u003e\\nBy \\u003ca href=\\\"/our-people/asutosh-padhi\\\"\\u003eAsutosh Padhi\\u003c/a\\u003e, Gaurav Batra, and \\u003ca href=\\\"https://fernweh.com/nick-santhanam/\\\"\\u003eNick Santhanam\\u003c/a\\u003e\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/the titanium economy/titanium_3d-1536x1536-hero-trans.png\",\"alt\":\"The Titanium Economy Book cover\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/the-titanium-economy\"}]}}},{\"mediaID\":{\"value\":\"GII\"},\"title\":{\"value\":\"Global Infrastructure Initiative\"},\"description\":{\"value\":\"Convening global leaders in infrastructure and capital projects in pursuit of new solutions\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/operations/our insights/the global infrastructure initiative/jpg-cpi-improving-construction-productivity-1536x864.jpg\",\"alt\":\"Improving construction productivity\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"http://www.globalinfrastructureinitiative.com/\"}]}}},{\"mediaID\":{\"value\":\"FOApodcast\"},\"title\":{\"value\":\"Subscribe to \\u003ca href=\\\"/featured-insights/future-of-asia/future-of-asia-podcasts\\\"\\u003e\\u003cem\\u003eFuture of Asia Podcasts\\u003c/em\\u003e\\u003c/a\\u003e\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/future-of-asia/id1480316959\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/2CZX4AR2DT4hQCFKJG0cCv?si=B20tkrOmQYymuCUhKCQOwA\"}]}}},{\"mediaID\":{\"value\":\"logisticsdisruptors\"},\"title\":{\"value\":\"Logistics Disruptors\"},\"description\":{\"value\":\"Meet the companies shaping how goods will move tomorrow.\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/travel logistics and infrastructure/our insights/logistics disruptors/tli-logistics-disruptors-1536x1536.jpeg\",\"alt\":\"illustration autonomous truck driving off into the future\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/travel-logistics-and-infrastructure/our-insights/logistics-disruptors\"}]}}},{\"mediaID\":{\"value\":\"mckinseyexplainers\"},\"title\":{\"value\":\"Looking for direct answers to other complex questions?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey explainers/mckinseyexplainers-flat-thumb-1536x1536.jpg\",\"alt\":\"Circular, white maze filled with white semicircles.\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore the full McKinsey Explainers series\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-explainers\"}]}}},{\"mediaID\":{\"value\":\"livesandlegacies\"},\"title\":{\"value\":\"\\u003cem\\u003e\\u003ca href=\\\"/featured-insights/mckinsey-on-lives-and-legacies\\\"\\u003eMcKinsey on Lives \\u0026amp; Legacies\\u003c/a\\u003e\\u003c/em\\u003e\"},\"description\":{\"value\":\"Highlighting the lasting impact of leaders and executives\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey on lives and legacies/lives-and-legacies-landing-page-thumb-1536x1536.jpg\",\"alt\":\"McKinsey on Lives \\u0026 Legacies\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore previous obituaries\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-lives-and-legacies\"}]}}},{\"mediaID\":{\"value\":\"Strategy\"},\"title\":{\"value\":\"Strategy in a digital age\"},\"description\":{\"value\":\"Our series on developing corporate and business-unit strategies in a digitally disrupted world.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/mckinsey digital/our insights/strategy in a digital age/digital-strategy_1536x864_flexpromoimage.jpg\",\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"View the collection\",\"Title\":\"\",\"Url\":\"/featured-insights/strategy-in-a-digital-age\"}]}}},{\"mediaID\":{\"value\":\"great\"},\"title\":{\"value\":\"The great re-make: Manufacturing for modern times\"},\"description\":{\"value\":\"This 21-article compendium gives practical insights for manufacturing leaders looking to keep a step ahead of today\\u0026rsquo;s disruptions.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/operations/our insights/the great remake manufacturing for modern times/jpg-ops-dm-compendium-cover-1536x864.jpg\",\"alt\":\"The great re-make: Manufacturing for modern times\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"View the collection\",\"Title\":\"\",\"Url\":\"/capabilities/operations/our-insights/the-great-re-make-manufacturing-for-modern-times-compendium\"}]}}},{\"mediaID\":{\"value\":\"futureofamerica\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eFuture of America\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/future-of-america/id1616517376\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/0FpeyjojJTKf2hVtQ3otah\"}]}}},{\"mediaID\":{\"value\":\"governmentpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Government\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-government/id1573645359\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/61XsO4B2ersroMft8t3KSq\"}]}}},{\"mediaID\":{\"value\":\"podcast\"},\"title\":{\"value\":\"Want to subscribe to the McKinsey Podcast?\\n\"},\"description\":{\"value\":\"\\u003cdiv class=\\\"cta-container -align-horizontal\\\"\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eGoogle Play\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eiTunes\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eStitcher\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn mck-rss-icon\\\"\\u003eRSS\\u003c/a\\u003e\\n\\u003c/div\\u003e\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[]}}},{\"mediaID\":{\"value\":\"operationspodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey Talks Operations\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-talks-operations/id1598128813\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/7LYQS2fxAoBmC3LgFNJbi8\"}]}}},{\"mediaID\":{\"value\":\"energyinsights\"},\"title\":{\"value\":\"Speak to an expert about our upstream capabilities\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/oil and gas/how we help clients/energy insights/newsletter-signup-promo-bar-1536x768.jpg\",\"alt\":\"EI newsletter sign up\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Contact us\",\"Title\":\"\",\"Url\":\"/industries/oil-and-gas/how-we-help-clients/energy-solutions/contact-us\"}]}}},{\"mediaID\":{\"value\":\"buildingproductspodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Building Products\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-building-product/id1735607317\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/79pncGJtBtzz7pFoR6OiH8\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/how-we-help-clients/mckinsey-academy/product-academy/mckinsey-on-building-product\"}]}}},{\"mediaID\":{\"value\":\"talentpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey Talks Talent\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-talks-talent/id1491112396\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5sW4eHEFMbOvAFJjMfN9a6\"}]}}},{\"mediaID\":{\"value\":\"outlook\"},\"title\":{\"value\":\"A longer, more comprehensive version of our Global Oil Supply \\u0026 Demand Outlook is available for purchase upon request.\\n\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Contact us\",\"Title\":\"\",\"Url\":\"/industries/oil-and-gas/how-we-help-clients/energy-solutions/contact-us\"}]}}},{\"mediaID\":{\"value\":\"talentpodcast2\"},\"title\":{\"value\":\"McKinsey Talks Talent Podcast\"},\"description\":{\"value\":\"Bryan Hancock, Brooke Weddle, and other talent experts help you navigate a fast-changing landscape and prepare for the future of work by making talent a competitive advantage.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/mckinsey talks talent/mck-mtt-disruptor-full-1536x864-smoke-may-2021.jpg\",\"alt\":\"McKinsey Talks Talent\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"See more episodes\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/mckinsey-talks-talent-podcast\"}]}}},{\"mediaID\":{\"value\":\"investing\"},\"title\":{\"value\":\"Subscribe to McKinsey on Investing\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/private-capital/our-insights/mckinsey-on-investing-issue-1/contact\"}]}}},{\"mediaID\":{\"value\":\"women matter\"},\"title\":{\"value\":\"Subscribe to McKinsey \\u003cem\\u003eWomen Matter Canada\\u003c/em\\u003e\"},\"description\":{\"value\":\"Please subscribe if your organization is interested in learning about participating in future research.\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"\"}]}}},{\"mediaID\":{\"value\":\"customs\"},\"title\":{\"value\":\"This article was written as part of a larger research effort to identify opportunities for improvement and innovation at customs agencies globally.\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/public-sector/our-insights/contact\"}]}}},{\"mediaID\":{\"value\":\"tech\"},\"title\":{\"value\":\"\\u003cspan class=\\\"disrupt-ab\\\"\\u003eCreating value beyond the hype\\u003c/span\\u003e\"},\"description\":{\"value\":\"Let\\u0026rsquo;s deliver on the promise of technology from strategy to scale.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/mckinsey digital/how we help clients/2024/never-just-tech_thumb_1536x1536.jpg\",\"alt\":\"Never just tech\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Get started\",\"Title\":\"\",\"Url\":\"https://www.mckinsey.com/capabilities/mckinsey-digital/how-we-help-clients?cid=njt-ste-crk-mbm-mbm--2403-promo01-njt-bam-web\"}]}}},{\"mediaID\":{\"value\":\"sust\"},\"title\":{\"value\":\"\\u003cspan class=\\\"disrupt-ab\\\"\\u003eMove from plans to progress.\\u003c/span\\u003e\"},\"description\":{\"value\":\"Sustainability matters. Together well make it real.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/sustainability/how we help clients/sustainability-campaign_promo-thumb_1536x1536.jpg\",\"alt\":\"Move from plans to progress.\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Get started\",\"Title\":\"\",\"Url\":\"https://www.mckinsey.com/capabilities/sustainability/how-we-help-clients/?cid=susti24-ste-crk-mbm-m01-other-glb-web\"}]}}},{\"mediaID\":{\"value\":\"nwowpodcast\"},\"title\":{\"value\":\"Subscribe to the New World of Work podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/the-new-world-of-work/id1319502839?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3S6fHLW6mcbDJDp1wkArKI\"}]}}},{\"mediaID\":{\"value\":\"globalpodcast\"},\"title\":{\"value\":\"Want to subscribe to \\u003cem\\u003eThe McKinsey Podcast\\u003c/em\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/the-mckinsey-podcast/id285260960?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/4dyjRTP9xzEUPgleo6XjXI\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"YouTube\",\"Title\":\"\",\"Url\":\"https://www.youtube.com/@McKinsey/podcasts\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-podcast\"}]}}},{\"mediaID\":{\"value\":\"Qaudio\"},\"title\":{\"value\":\"Discover and subscribe to McKinsey Quarterly Audio\"},\"description\":{\"value\":\"\\u003cstrong\\u003eFive ways to subscribe:\\u003c/strong\\u003e\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/mckinsey-quarterly-audio/id1437925222?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5mb2zYJnrPcRrML8gx5doD\"}]}}},{\"mediaID\":{\"value\":\"shortlist\"},\"title\":{\"value\":\"Subscribe to the Shortlist\"},\"description\":{\"value\":\"McKinsey\\u0026rsquo;s new weekly newsletter, featuring must-read content on a range of topics, every Friday\"},\"image\":{\"src\":\"/~/media/mckinsey/email/shortlist/template/shortlist_promo-interrupter-849120982_1536x1536.jpg\",\"alt\":\"the Shortlist\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Get the Shortlist in your inbox\",\"Title\":\"\",\"Url\":\"/user-registration/manage-account/edit-subscriptions\"}]}}},{\"mediaID\":{\"value\":\"retailpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Consumer and Retail\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-consumer-and-retail/id1526250428\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/41D4bro8PPDOGhEgOEJyHB?si=7l3SeYCZQD-7v3toqd9fHQ\"}]}}},{\"mediaID\":{\"value\":\"insurancepodcast\"},\"title\":{\"value\":\"Want to subscribe to the \\u003cem\\u003eMcKinsey on Insurance\\u003c/em\\u003e podcast?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-insurance/id1533196359\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5gZ6YKF7n7C9zWaER4mFZ5\"}]}}},{\"mediaID\":{\"value\":\"strategypodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eInside the Strategy Room\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/inside-the-strategy-room/id1422814215?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/4TcFfiQ0e6OYuc5kRDLxqj\"}]}}},{\"mediaID\":{\"value\":\"mgipodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eForward Thinking\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/forward-thinking/id1319502839\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3S6fHLW6mcbDJDp1wkArKI?si=0zvPmiCsQ7SBAPanfpY4aA\\u0026nd=1\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/mgi/forward-thinking\"}]}}}]},\"globalDisruptors\":{\"disruptor1up\":{\"results\":[{\"mediaID\":{\"value\":\"cop28\"},\"title\":{\"value\":\"Explore COP28 with McKinsey\"},\"description\":{\"value\":\"Join us for a series of dynamic virtual events during COP28. Discover new research, practical strategies, and collaborations across sectors that propel climate action and growth towards net-zero.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/sustainability/how we help clients/cop/cop28/cop28-page-thumb_1536x1536.jpg\",\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/capabilities/sustainability/how-we-help-clients/cop/overview\"}]}}},{\"mediaID\":{\"value\":\"attheedge\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eAt the Edge\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/at-the-edge/id1612870236\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3SnUcezwM20nKnzqvUl6iF\"}]}}},{\"mediaID\":{\"value\":\"authortalks\"},\"title\":{\"value\":\"Visit \\u003cem\\u003e\\u003ca href=\\\"/featured-insights/mckinsey-on-books/author-talks\\\"\\u003eAuthor Talks\\u003c/a\\u003e\\u003c/em\\u003e to see the full series.\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/author talks/authortalks_1536x1536_v1.png\",\"alt\":\"Author Talks\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/author-talks\"}]}}},{\"mediaID\":{\"value\":\"COVID\"},\"title\":{\"value\":\"Explore McKinseys ongoing coverage of the pandemic\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/risk/our insights/covid 19 implications for business/implications-briefing-note-4-standard-1536x1536.jpg\",\"alt\":\"COVID-19: Implications for business\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Read more about the business impact of coronavirus and how organizations can respond\",\"Title\":\"\",\"Url\":\"/featured-insights/coronavirus-leading-through-the-crisis\"}]}}},{\"mediaID\":{\"value\":\"CE\"},\"title\":{\"value\":\"Customer experience\"},\"description\":{\"value\":\"More insight into creating competitive advantage by putting customers first and managing their journeys.\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/public and social sector/our insights/customer experience/customer-experience_22934010_1536x864.jpg\",\"alt\":\"Customer experience\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"\"}]}}},{\"mediaID\":{\"value\":\"driversofdisruption\"},\"title\":{\"value\":\"Want to subscribe to \\u003ca href=\\\"/features/mckinsey-center-for-future-mobility/our-insights/drivers-of-disruption\\\"\\u003e\\u003cem\\u003eDrivers of Disruption\\u003c/em\\u003e\\u003c/a\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/drivers-of-disruption/id1687257324\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5fWXzWmVKacc5I7u9CQsah?si=KQ-wUOSyQlqcnfexExiH9Q\\u0026nd=1\"}]}}},{\"mediaID\":{\"value\":\"JOL\"},\"title\":{\"value\":\"The Journey of Leadership\"},\"description\":{\"value\":\"\\u003cstrong\\u003eHow CEOs Learn to Lead from the Inside Out\\u003c/strong\\u003e\\u003cbr /\\u003e\\nBy \\u003ca href=\\\"/our-people/dana-maor\\\"\\u003eDana Maor\\u003c/a\\u003e, \\u003ca href=\\\"https://www.linkedin.com/in/hanswernerkaas\\\"\\u003eHans-Werner Kaas\\u003c/a\\u003e, \\u003ca href=\\\"/our-people/kurt-strovink\\\"\\u003eKurt Strovink\\u003c/a\\u003e, and \\u003ca href=\\\"/our-people/ramesh-srinivasan\\\"\\u003eRamesh Srinivasan\\u003c/a\\u003e\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/journey of leadership/journey-of-leadership-book-cover-1536x1536.jpg\",\"alt\":\"The Journey of Leadership book cover\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/journey-of-leadership\"}]}}},{\"mediaID\":{\"value\":\"surveys\"},\"title\":{\"value\":\"McKinsey\\u0026rsquo;s original survey research\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey global surveys/mck-global-survey-landing-1284442931-thumb-1536x1536.jpg\",\"alt\":\"McKinsey Global Surveys\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Read more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-global-surveys\"}]}}},{\"mediaID\":{\"value\":\"healthcarepodcast\"},\"title\":{\"value\":\"Want to subscribe to \\u003cem\\u003eMcKinsey on Healthcare\\u003c/em\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-healthcare/id1469979748\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3y1AgAilV4E5Jz0x4wD9O2?si=mLCTUQ2ORTS_LC5gW_htlA\\u0026dl_branch=1\"}]}}},{\"mediaID\":{\"value\":\"myleadershipjourney\"},\"title\":{\"value\":\"My Leadership Journey\"},\"description\":{\"value\":\"A series of conversations with leaders about the people and experiences that shaped them\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/our insights/my leadership journey/my leadership journey collection page_131575496_thumb_1536x1536.jpg\",\"alt\":\"My Leadership Journey\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/my-leadership-journey\"}]}}},{\"mediaID\":{\"value\":\"lessonsfromleaders\"},\"title\":{\"value\":\"State of Organizations: Lessons from leaders\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/our insights/state of org lessons from leaders/soo-chapter-2-872507320-standard-1536x1536.jpg\",\"alt\":\"\\\"\\\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore more interviews\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/lessons-from-leaders\"}]}}},{\"mediaID\":{\"value\":\"stateoforg\"},\"title\":{\"value\":\"The State of Organizations 2023\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Report overview\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/our-insights/the-state-of-organizations-2023\"}]}}},{\"mediaID\":{\"value\":\"titaniumeconomy\"},\"title\":{\"value\":\"The Titanium Economy\"},\"description\":{\"value\":\"How Industrial Technology Can Create a Better, Faster, Stronger America\\u003cbr /\\u003e\\nBy \\u003ca href=\\\"/our-people/asutosh-padhi\\\"\\u003eAsutosh Padhi\\u003c/a\\u003e, Gaurav Batra, and \\u003ca href=\\\"https://fernweh.com/nick-santhanam/\\\"\\u003eNick Santhanam\\u003c/a\\u003e\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey books/the titanium economy/titanium_3d-1536x1536-hero-trans.png\",\"alt\":\"The Titanium Economy Book cover\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-books/the-titanium-economy\"}]}}},{\"mediaID\":{\"value\":\"GII\"},\"title\":{\"value\":\"Global Infrastructure Initiative\"},\"description\":{\"value\":\"Convening global leaders in infrastructure and capital projects in pursuit of new solutions\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/operations/our insights/the global infrastructure initiative/jpg-cpi-improving-construction-productivity-1536x864.jpg\",\"alt\":\"Improving construction productivity\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"http://www.globalinfrastructureinitiative.com/\"}]}}},{\"mediaID\":{\"value\":\"FOApodcast\"},\"title\":{\"value\":\"Subscribe to \\u003ca href=\\\"/featured-insights/future-of-asia/future-of-asia-podcasts\\\"\\u003e\\u003cem\\u003eFuture of Asia Podcasts\\u003c/em\\u003e\\u003c/a\\u003e\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/future-of-asia/id1480316959\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/2CZX4AR2DT4hQCFKJG0cCv?si=B20tkrOmQYymuCUhKCQOwA\"}]}}},{\"mediaID\":{\"value\":\"logisticsdisruptors\"},\"title\":{\"value\":\"Logistics Disruptors\"},\"description\":{\"value\":\"Meet the companies shaping how goods will move tomorrow.\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/travel logistics and infrastructure/our insights/logistics disruptors/tli-logistics-disruptors-1536x1536.jpeg\",\"alt\":\"illustration autonomous truck driving off into the future\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/travel-logistics-and-infrastructure/our-insights/logistics-disruptors\"}]}}},{\"mediaID\":{\"value\":\"mckinseyexplainers\"},\"title\":{\"value\":\"Looking for direct answers to other complex questions?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey explainers/mckinseyexplainers-flat-thumb-1536x1536.jpg\",\"alt\":\"Circular, white maze filled with white semicircles.\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore the full McKinsey Explainers series\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-explainers\"}]}}},{\"mediaID\":{\"value\":\"livesandlegacies\"},\"title\":{\"value\":\"\\u003cem\\u003e\\u003ca href=\\\"/featured-insights/mckinsey-on-lives-and-legacies\\\"\\u003eMcKinsey on Lives \\u0026amp; Legacies\\u003c/a\\u003e\\u003c/em\\u003e\"},\"description\":{\"value\":\"Highlighting the lasting impact of leaders and executives\"},\"image\":{\"src\":\"/~/media/mckinsey/featured insights/mckinsey on lives and legacies/lives-and-legacies-landing-page-thumb-1536x1536.jpg\",\"alt\":\"McKinsey on Lives \\u0026 Legacies\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Explore previous obituaries\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-on-lives-and-legacies\"}]}}},{\"mediaID\":{\"value\":\"Strategy\"},\"title\":{\"value\":\"Strategy in a digital age\"},\"description\":{\"value\":\"Our series on developing corporate and business-unit strategies in a digitally disrupted world.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/mckinsey digital/our insights/strategy in a digital age/digital-strategy_1536x864_flexpromoimage.jpg\",\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"View the collection\",\"Title\":\"\",\"Url\":\"/featured-insights/strategy-in-a-digital-age\"}]}}},{\"mediaID\":{\"value\":\"great\"},\"title\":{\"value\":\"The great re-make: Manufacturing for modern times\"},\"description\":{\"value\":\"This 21-article compendium gives practical insights for manufacturing leaders looking to keep a step ahead of today\\u0026rsquo;s disruptions.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/operations/our insights/the great remake manufacturing for modern times/jpg-ops-dm-compendium-cover-1536x864.jpg\",\"alt\":\"The great re-make: Manufacturing for modern times\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"View the collection\",\"Title\":\"\",\"Url\":\"/capabilities/operations/our-insights/the-great-re-make-manufacturing-for-modern-times-compendium\"}]}}},{\"mediaID\":{\"value\":\"futureofamerica\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eFuture of America\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/future-of-america/id1616517376\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/0FpeyjojJTKf2hVtQ3otah\"}]}}},{\"mediaID\":{\"value\":\"governmentpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Government\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-government/id1573645359\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/61XsO4B2ersroMft8t3KSq\"}]}}},{\"mediaID\":{\"value\":\"podcast\"},\"title\":{\"value\":\"Want to subscribe to the McKinsey Podcast?\\n\"},\"description\":{\"value\":\"\\u003cdiv class=\\\"cta-container -align-horizontal\\\"\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eGoogle Play\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eiTunes\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn btn-fill\\\"\\u003eStitcher\\u003c/a\\u003e\\n    \\u003ca href=\\\"#\\\" class=\\\"btn mck-rss-icon\\\"\\u003eRSS\\u003c/a\\u003e\\n\\u003c/div\\u003e\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[]}}},{\"mediaID\":{\"value\":\"operationspodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey Talks Operations\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-talks-operations/id1598128813\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/7LYQS2fxAoBmC3LgFNJbi8\"}]}}},{\"mediaID\":{\"value\":\"energyinsights\"},\"title\":{\"value\":\"Speak to an expert about our upstream capabilities\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":\"/~/media/mckinsey/industries/oil and gas/how we help clients/energy insights/newsletter-signup-promo-bar-1536x768.jpg\",\"alt\":\"EI newsletter sign up\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Contact us\",\"Title\":\"\",\"Url\":\"/industries/oil-and-gas/how-we-help-clients/energy-solutions/contact-us\"}]}}},{\"mediaID\":{\"value\":\"buildingproductspodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Building Products\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-building-product/id1735607317\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/79pncGJtBtzz7pFoR6OiH8\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/how-we-help-clients/mckinsey-academy/product-academy/mckinsey-on-building-product\"}]}}},{\"mediaID\":{\"value\":\"talentpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey Talks Talent\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-talks-talent/id1491112396\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5sW4eHEFMbOvAFJjMfN9a6\"}]}}},{\"mediaID\":{\"value\":\"outlook\"},\"title\":{\"value\":\"A longer, more comprehensive version of our Global Oil Supply \\u0026 Demand Outlook is available for purchase upon request.\\n\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Contact us\",\"Title\":\"\",\"Url\":\"/industries/oil-and-gas/how-we-help-clients/energy-solutions/contact-us\"}]}}},{\"mediaID\":{\"value\":\"talentpodcast2\"},\"title\":{\"value\":\"McKinsey Talks Talent Podcast\"},\"description\":{\"value\":\"Bryan Hancock, Brooke Weddle, and other talent experts help you navigate a fast-changing landscape and prepare for the future of work by making talent a competitive advantage.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/people and organizational performance/mckinsey talks talent/mck-mtt-disruptor-full-1536x864-smoke-may-2021.jpg\",\"alt\":\"McKinsey Talks Talent\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"See more episodes\",\"Title\":\"\",\"Url\":\"/capabilities/people-and-organizational-performance/mckinsey-talks-talent-podcast\"}]}}},{\"mediaID\":{\"value\":\"investing\"},\"title\":{\"value\":\"Subscribe to McKinsey on Investing\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/private-capital/our-insights/mckinsey-on-investing-issue-1/contact\"}]}}},{\"mediaID\":{\"value\":\"women matter\"},\"title\":{\"value\":\"Subscribe to McKinsey \\u003cem\\u003eWomen Matter Canada\\u003c/em\\u003e\"},\"description\":{\"value\":\"Please subscribe if your organization is interested in learning about participating in future research.\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"\"}]}}},{\"mediaID\":{\"value\":\"customs\"},\"title\":{\"value\":\"This article was written as part of a larger research effort to identify opportunities for improvement and innovation at customs agencies globally.\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Learn more\",\"Title\":\"\",\"Url\":\"/industries/public-sector/our-insights/contact\"}]}}},{\"mediaID\":{\"value\":\"tech\"},\"title\":{\"value\":\"\\u003cspan class=\\\"disrupt-ab\\\"\\u003eCreating value beyond the hype\\u003c/span\\u003e\"},\"description\":{\"value\":\"Let\\u0026rsquo;s deliver on the promise of technology from strategy to scale.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/mckinsey digital/how we help clients/2024/never-just-tech_thumb_1536x1536.jpg\",\"alt\":\"Never just tech\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Get started\",\"Title\":\"\",\"Url\":\"https://www.mckinsey.com/capabilities/mckinsey-digital/how-we-help-clients?cid=njt-ste-crk-mbm-mbm--2403-promo01-njt-bam-web\"}]}}},{\"mediaID\":{\"value\":\"sust\"},\"title\":{\"value\":\"\\u003cspan class=\\\"disrupt-ab\\\"\\u003eMove from plans to progress.\\u003c/span\\u003e\"},\"description\":{\"value\":\"Sustainability matters. Together well make it real.\"},\"image\":{\"src\":\"/~/media/mckinsey/business functions/sustainability/how we help clients/sustainability-campaign_promo-thumb_1536x1536.jpg\",\"alt\":\"Move from plans to progress.\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Get started\",\"Title\":\"\",\"Url\":\"https://www.mckinsey.com/capabilities/sustainability/how-we-help-clients/?cid=susti24-ste-crk-mbm-m01-other-glb-web\"}]}}},{\"mediaID\":{\"value\":\"nwowpodcast\"},\"title\":{\"value\":\"Subscribe to the New World of Work podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/the-new-world-of-work/id1319502839?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3S6fHLW6mcbDJDp1wkArKI\"}]}}},{\"mediaID\":{\"value\":\"globalpodcast\"},\"title\":{\"value\":\"Want to subscribe to \\u003cem\\u003eThe McKinsey Podcast\\u003c/em\\u003e?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/the-mckinsey-podcast/id285260960?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/4dyjRTP9xzEUPgleo6XjXI\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"YouTube\",\"Title\":\"\",\"Url\":\"https://www.youtube.com/@McKinsey/podcasts\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/featured-insights/mckinsey-podcast\"}]}}},{\"mediaID\":{\"value\":\"Qaudio\"},\"title\":{\"value\":\"Discover and subscribe to McKinsey Quarterly Audio\"},\"description\":{\"value\":\"\\u003cstrong\\u003eFive ways to subscribe:\\u003c/strong\\u003e\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/mckinsey-quarterly-audio/id1437925222?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5mb2zYJnrPcRrML8gx5doD\"}]}}},{\"mediaID\":{\"value\":\"shortlist\"},\"title\":{\"value\":\"Subscribe to the Shortlist\"},\"description\":{\"value\":\"McKinsey\\u0026rsquo;s new weekly newsletter, featuring must-read content on a range of topics, every Friday\"},\"image\":{\"src\":\"/~/media/mckinsey/email/shortlist/template/shortlist_promo-interrupter-849120982_1536x1536.jpg\",\"alt\":\"the Shortlist\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Get the Shortlist in your inbox\",\"Title\":\"\",\"Url\":\"/user-registration/manage-account/edit-subscriptions\"}]}}},{\"mediaID\":{\"value\":\"retailpodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eMcKinsey on Consumer and Retail\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-consumer-and-retail/id1526250428\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/41D4bro8PPDOGhEgOEJyHB?si=7l3SeYCZQD-7v3toqd9fHQ\"}]}}},{\"mediaID\":{\"value\":\"insurancepodcast\"},\"title\":{\"value\":\"Want to subscribe to the \\u003cem\\u003eMcKinsey on Insurance\\u003c/em\\u003e podcast?\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/mckinsey-on-insurance/id1533196359\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/5gZ6YKF7n7C9zWaER4mFZ5\"}]}}},{\"mediaID\":{\"value\":\"strategypodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eInside the Strategy Room\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://itunes.apple.com/us/podcast/inside-the-strategy-room/id1422814215?mt=2\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/4TcFfiQ0e6OYuc5kRDLxqj\"}]}}},{\"mediaID\":{\"value\":\"mgipodcast\"},\"title\":{\"value\":\"Subscribe to the \\u003cem\\u003eForward Thinking\\u003c/em\\u003e podcast\"},\"description\":{\"value\":\"\"},\"image\":{\"src\":null,\"alt\":\"\"},\"moreLinks\":{\"jsonValue\":{\"value\":[{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Apple Podcasts\",\"Title\":\"\",\"Url\":\"https://podcasts.apple.com/us/podcast/forward-thinking/id1319502839\"},{\"CssClass\":\"btn btn-fill\",\"LinkType\":\"external\",\"Target\":\"_blank\",\"Text\":\"Spotify\",\"Title\":\"\",\"Url\":\"https://open.spotify.com/show/3S6fHLW6mcbDJDp1wkArKI?si=0zvPmiCsQ7SBAPanfpY4aA\\u0026nd=1\"},{\"CssClass\":\"\",\"LinkType\":\"internal\",\"Target\":\"\",\"Text\":\"Listen to previous episodes\",\"Title\":\"\",\"Url\":\"/mgi/forward-thinking\"}]}}}]},\"disruptorsignup\":{\"results\":[{\"mediaID\":{\"value\":\"full-width\"},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"fullwidth\"},\"value\":{\"value\":\"Full Width\"}}},\"callToAction\":{\"url\":\"/user-registration/register-mvc\",\"text\":\"Subscribe\"},\"title\":{\"jsonValue\":{\"value\":\"Stay current on your favorite topics\"}}},{\"mediaID\":{\"value\":\"left\"},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"left\"},\"value\":{\"value\":\"Left\"}}},\"callToAction\":{\"url\":\"/user-registration/register-mvc\",\"text\":\"Subscribe\"},\"title\":{\"jsonValue\":{\"value\":\"Stay current on your favorite topics\"}}}]}},\"ceros\":{\"results\":[]},\"exhibit\":{\"results\":[]},\"image\":{\"results\":[]},\"exhibitcarousel\":{\"results\":[]},\"pullquote\":{\"results\":[]},\"disruptorsignup\":{\"results\":[{\"mediaID\":{\"value\":\"full-width\"},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"fullwidth\"},\"value\":{\"value\":\"Full Width\"}}},\"callToAction\":{\"url\":\"/user-registration/register-mvc\",\"text\":\"Subscribe\"},\"title\":{\"jsonValue\":{\"value\":\"Stay current on your favorite topics\"}}},{\"mediaID\":{\"value\":\"left\"},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"left\"},\"value\":{\"value\":\"Left\"}}},\"callToAction\":{\"url\":\"/user-registration/register-mvc\",\"text\":\"Subscribe\"},\"title\":{\"jsonValue\":{\"value\":\"Stay current on your favorite topics\"}}}]},\"articlesidebar\":{\"results\":[{\"mediaID\":{\"value\":\"RWE\"},\"description\":{\"jsonValue\":{\"value\":\"\\u003cp\\u003e\\u003cem\\u003e\\u003cstrong\\u003eSituation.\\u003c/strong\\u003e\\u003c/em\\u003e Alecensa (alectinib), Roche\\u0026rsquo;s new ALK inhibitor, received Breakthrough Therapy Designation from the FDA for the treatment of ALK+ advanced nonsmall cell lung cancer in patients who failed or were intolerant to crizotinib. US approval was based on data from a 138-patient global single-arm phase II trial (NCT01801111). Alecensa subsequently received conditional approval in the EU in February 2017 based on pooled data from this trial and an additional 87 patients evaluated in a North American single-arm phase II trial (NCT01871805).\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote21\\\"\\u003e\\u003csup\\u003e1\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote21\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e1.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003e\\u0026ldquo;Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer,\\u0026rdquo; Roche, February 21, 2017, roche.com.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e National Health Technology Assessment authorities in the EU requested additional evidence of the effectiveness of Alecensa relative to standard of care (ceritinib) in order to provide a coverage decision.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cem\\u003e\\u003cstrong\\u003eRWE application/impact.\\u003c/strong\\u003e\\u003c/em\\u003e To meet this requirement,\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote22\\\"\\u003e\\u003csup\\u003e2\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote22\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e2.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003e\\u0026ldquo;Roche CEO O\\u0026rsquo;Day: Our investment in Flatiron will accelerate their mission,\\u0026rdquo; Cancer Letter, March 2, 2018, cancerletter.com.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e in addition to initiating a phase III randomized controlled trial (ALEX),\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote23\\\"\\u003e\\u003csup\\u003e3\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote23\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e3.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003eD. Ross Camidge et al, \\u0026ldquo;Alectinib versus Crizotinib in Untreated ALK-Positive Non\\u0026ndash;Small-Cell Lung Cancer,\\u0026rdquo; \\u003cem\\u003eNew England Journal of Medicine\\u003c/em\\u003e, Volume 377, pp. 829-838, nejm.org.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e Roche collaborated with Flatiron Health to conduct a retrospective analysis of EHRs of patients treated with ceritinib (standard of care). The real-world external control arm cohort of 77 ceritinib-treated patients was compared to the phase II single-arm alectinib patients and submitted to several European Health Technology Assessment authorities, satisfying coverage requirements. Use of an RWE-generated external control arm allowed alectinib to obtain coverage approximately 18 months earlier than if Roche had waited for the completion of the ALEX trial. Based on current usage, this resulted in an earlier realization of significant revenue and enabled access to this breakthrough therapy for many patients.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote24\\\"\\u003e\\u003csup\\u003e4\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote24\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e4.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003e\\u0026ldquo;Investor update,\\u0026rdquo; Roche, February 1, 2018, roche.com.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e In addition, this demonstrated the ability of RWE to be used in a transnational fashion, with evidence generated in one geography informing decision-making in another.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote25\\\"\\u003e\\u003csup\\u003e5\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote25\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e5.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003eOlivia Cavlan, Sastry Chilukuri, Matthias Evers, and Ann Westra, \\u0026ldquo;\\u003ca href=\\\"/industries/life-sciences/our-insights/real-world-evidence-from-activity-to-impact-in-healthcare-decision-making\\\"\\u003eReal-world evidence: From activity to impact in healthcare decision making\\u003c/a\\u003e,\\u0026rdquo; May 2018.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cem\\u003e\\u003cstrong\\u003eValidation.\\u003c/strong\\u003e\\u003c/em\\u003e To confirm the accuracy of the RWE external control generated by Flatiron, Roche compared the ceritinib-treated control arm from the ASCEND-2 randomized controlled trial, which utilized the same inclusion and exclusion criteria as the Flatiron control arm. Propensity score analysis comparing the Flatiron-generated real-world cohort of ceritinib treated patients to the ASCEND-2 enrolled ceritinib control arm demonstrated a high degree of concordance of the OS endpoint (median OS 15.6 months in RW cohort versus 14.9 months for the ASCEND-2 arm), validating the use of this control arm methodology.\\u003ca href=\\\"#\\\" class=\\\"link-footnote\\\" onclick=\\\"return false;\\\" rel=\\\"#footnote26\\\"\\u003e\\u003csup\\u003e6\\u003c/sup\\u003e\\u003c/a\\u003e \\u003cspan class=\\\"tooltip\\\" id=\\\"footnote26\\\" style=\\\"display: none;\\\"\\u003e\\u003cspan class=\\\"footnote-content\\\"\\u003e\\u003cspan class=\\\"footnote-number\\\"\\u003e6.\\u003c/span\\u003e\\u003cspan class=\\\"footnote-text\\\"\\u003eM. Coudert et al, \\u0026ldquo;Retrospective indirect comparison of alectinib phase II data vs ceritinib real-world data in ALK+ NSCLC after progression on crizotinib,\\u0026rdquo; \\u003cem\\u003eAnnals of Oncology\\u003c/em\\u003e, May 2017, Volume 28, academic.oup.com.\\u003c/span\\u003e\\u003cspan class=\\\"clear\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003cspan class=\\\"footnote-bottom\\\"\\u003e\\u003c/span\\u003e\\u003c/span\\u003e\\u003c/p\\u003e\"}},\"aboutTheAuthors\":{\"jsonValue\":{\"value\":\"\"}},\"headline\":{\"jsonValue\":{\"value\":\"RWE case example: Employing a real-world external control arm to accelerate reimbursement in more than 20 European markets\"}},\"footnotes\":{\"value\":\"\"},\"showShareTools\":{\"boolValue\":true},\"backgroundColor\":{\"targetItem\":{\"key\":{\"value\":\"Lightest Grey\"},\"value\":{\"value\":\"lightest-grey\"}}},\"gradientDirection\":{\"targetItem\":{\"key\":{\"value\":\"Bottom Right\"},\"value\":{\"value\":\"bottom-right\"}}},\"renderMode\":{\"targetItem\":{\"key\":{\"value\":\"Collapsible\"},\"value\":{\"value\":\"default\"}}},\"isAboutAuthor\":{\"boolValue\":false},\"background\":{\"targetItem\":null},\"image\":{\"src\":null,\"alt\":\"\"}}]},\"globalsidebar\":{\"results\":[]},\"video\":{\"results\":[]},\"scrollycontainer\":{\"results\":[]},\"bespokeinteractive\":{\"results\":[]},\"storycontainer\":{\"results\":[]},\"interactive\":{\"results\":[]},\"sectionheader\":{\"results\":[]},\"statementdisruptor\":{\"results\":[]},\"fullbleedphoto\":{\"results\":[]},\"tocitem\":{\"results\":[]},\"quizcontainer\":{\"results\":[]},\"generalup\":{\"results\":[]},\"twoupmedium\":{\"results\":[]},\"accordion\":{\"results\":[]},\"factoid\":{\"results\":[]},\"promobarwithquote\":{\"results\":[]},\"oneupmedium\":{\"results\":[]},\"oneupmediumquote\":{\"results\":[]},\"gridwall\":{\"results\":[]},\"twoupsmall\":{\"results\":[]},\"oneclicksubscribe\":{\"results\":[]},\"promobar\":{\"results\":[]},\"promobanner\":{\"results\":[]},\"sectionhero\":{\"results\":[]},\"threeuplinklist\":{\"results\":[]},\"table\":{\"results\":[]},\"isFiveFiftyHorizontalArticle\":{\"boolValue\":false},\"fiveFifty\":{\"results\":[]}},\"contextItem\":{\"ancestors\":[{\"breadCrumbUrl\":{\"path\":\"/industries/life-sciences/our-insights\"},\"breadCrumbTitle\":{\"value\":\"Our Insights\"},\"isMiniSite\":{\"boolValue\":false},\"displayName\":\"Insights on Life Sciences\",\"template\":{\"id\":\"85FF05307883480F9A4C82123F72FFD8\"}},{\"breadCrumbUrl\":{\"path\":\"/industries/life-sciences/how-we-help-clients\"},\"breadCrumbTitle\":null,\"isMiniSite\":{\"boolValue\":true},\"displayName\":\"Life Sciences\",\"template\":{\"id\":\"414C6C64AD35440E9668CF39D8A18CCF\"}},{\"breadCrumbUrl\":{\"path\":\"/industries\"},\"breadCrumbTitle\":{\"value\":\"Industries\"},\"isMiniSite\":{\"boolValue\":false},\"displayName\":\"Industries\",\"template\":{\"id\":\"85FF05307883480F9A4C82123F72FFD8\"}},{\"breadCrumbUrl\":{\"path\":\"/\"},\"breadCrumbTitle\":{\"value\":\"\"},\"isMiniSite\":{\"boolValue\":false},\"displayName\":\"Home\",\"template\":{\"id\":\"85FF05307883480F9A4C82123F72FFD8\"}}]}}},\"placeholders\":{\"main-area\":[],\"sidebar-area\":[]}}]}},\"itemId\":\"fe170b38-bd48-4955-8aba-7173563e1f6b\",\"pageEditing\":false,\"site\":{\"name\":\"website\"},\"pageState\":\"normal\",\"language\":\"en\",\"pageMetaData\":{\"alternateLanguages\":[{\"languageCode\":\"en\",\"displayName\":\"English\",\"url\":\"/industries/life-sciences/our-insights/real-world-evidence-driving-a-new-drug-development-paradigm-in-oncology\"}],\"currentLanguage\":\"en\",\"navigationLink\":\"industries\",\"activeItemId\":\"{BB8498AC-8CC4-4BFB-8832-53C76F3E61CF}\",\"miniSiteId\":\"{CDBF3A89-AE60-459E-ACF8-786E31307534}\",\"officeCode\":\"\",\"officeDisplayName\":\"\",\"subscriptionPracticeData\":null,\"isAlaisedPage\":false,\"originalHostName\":\"www.mckinsey.com\",\"updatedDate\":\"2023-03-04T09:17:43Z\",\"createdDate\":\"2018-07-18T20:41:57Z\",\"practice\":{\"isDefaultPractice\":false,\"name\":\"Life Sciences\",\"code\":\"N20\",\"stickyTitle\":\"Sign up for emails on new Life Sciences articles\",\"stickySubtitle\":\"Never miss an insight. We'll email you when new articles are published on this topic.\",\"previewLink\":\"\",\"previewLinkLabel\":\"Preview\",\"description\":null,\"descriptionText\":\"Get the latest articles on this topic delivered to your inbox\",\"frequency\":\"Alert\",\"regFormTitle\":null},\"url\":\"/industries/life-sciences/our-insights/real-world-evidence-driving-a-new-drug-development-paradigm-in-oncology\",\"isCareersPage\":false,\"officePath\":\"\",\"hideAppPromo\":false,\"itemInfo\":{\"id\":\"fe170b38-bd48-4955-8aba-7173563e1f6b\",\"fullPath\":\"/sitecore/content/McKinsey/Home/Industries/Life Sciences/Our Insights/Real world evidence Driving a new drug development paradigm in oncology\",\"templateName\":\"ArticleJSS\",\"templateID\":\"683910db-02ba-40ba-92e7-726c880160a9\"}},\"defaultSettings\":{\"McKinsey Quarterly\":\"\\u003cem\\u003eMcKinsey Quarterly\\u003c/em\\u003e\",\"FacebookCID\":\"soc-web\",\"LinkedInCID\":\"soc-web\",\"TwitterCID\":\"soc-web\",\"Home Page SEO Details\":{\"Description\":\"McKinsey \\u0026 Company is the trusted advisor and counselor to many of the world's most influential businesses and institutions.\",\"Image_Url\":\"/~/media/images/global/seoimageplaceholder.jpg\",\"Image_Alt\":\"\"}},\"alumniDatalayerChunk\":\"static/chunks/alumnidatalayer.2eb8cbe055d39895.js\"},\"componentProps\":{},\"notFound\":false,\"noAccess\":false},\"__N_PREVIEW\":true,\"__N_SSP\":true},\"page\":\"/[[...path]]\",\"query\":{\"timestamp\":\"1729761740429\",\"path\":[\"industries\",\"life-sciences\",\"our-insights\",\"real-world-evidence-driving-a-new-drug-development-paradigm-in-oncology\"]},\"buildId\":\"AymXir4ImcRSnB3UIpSL6\",\"runtimeConfig\":{\"CONFIG_ENV\":\"production\",\"CURRENT_ENV\":\"production\",\"PUBLIC_URL\":\"https://www.mckinsey.com\",\"PUBLIC_CMS_URL\":\"https://cms-prod.mckinsey.com\",\"RECAPTCHA_V3_KEY\":\"6LdC5twSAAAAAF0dePIbY_ckeF05mKdYYJXn7uTg\",\"INVISIBLE_RECAPTCHA_KEY\":\"6LcWCs0UAAAAAEik2NaGkfGH8mGHo1ThxIt-qUoE\",\"USER_SERVICE_API_HOST\":\"https://prd-api.mckinsey.com\",\"MOBILE_SERVICES_HOST\":\"https://mobileservices.mckinsey.com\",\"SEARCH_SERVICE_API_HOST\":\"https://mckapi.mckinsey.com\",\"OT_DATA_DOMAIN_SCRIPT_COM\":\"915b5091-0d7e-44d2-a8c4-cf08267e52fe\",\"OT_DATA_DOMAIN_SCRIPT_DE\":\"13f50396-9d33-4d95-ba3e-1f108fa91009\",\"OT_DATA_DOMAIN_SCRIPT_BR\":\"679eae24-1d5c-4f33-8aae-b35aa8269966\",\"ADOBE_LAUNCH\":\"a400cfbb2fd3\",\"BCOV_POLICY\":\"BCpkADawqM3Xn1B8iTmHawNytUSk0kXaQKMSM51CBVsYKHfwlRhZimTJqbOOq0NuyxTKQnvb4V9myMVRjwGkyGtJQO2HrUPOJHcsgkpbB-jyHwswonskf6XnZaF0TyyKkAQgbymSMtudeD9CLk-xCpqAzTaNUm7a3M3QKLN4pdLRNJ9_HbVMWzNpiUr5ezAVdMciDMwsD-gxNl43d7bfVP3wRhTNWbWUYn3WK7-Oz2gbxV6mMTm0jJU3SjK_x0meTprYUgdUWA-iDgwVglsnfJ_SVtVDPZypUokKv85GzFLM-ywjWlPM2Hg1ucemwwOpa-qvYBGfeMV7zP3n6s22hFCBveiWtHEBpV9N8f4rjmunMlxBx7kSlxIRjWquZm70hLRXMoxAgQ22BC86tBhgR_d1l9_-FzZuZIlZhzJwJi3ug1HszooHM8uEMOkHmB5nYj5XEgVk5JFYGcSwFSnMnNzE1ej2J3jcEiE3eSWHcremWjCZ0s9bs_8R08WpGWkBp8WMXUFfmhPBMk-MGixR_yIu7nJ6B_hYBnVhqKnnoW-xxEmRxgwG0Ev0S96cAcBG8qdlChGN7o1qN0heGTUIYnDk703q3lt9j7X4FgaITrlcPZOWZ96EHytVKUAtmtVp5BVGpiLn4viuUpEdAM_CLSBIaPVunk-39L8tm6m8iUYmbMX_KXPyaL900bQtVQgK39FCa0pUEZ_jSBOGNj1FH8NUPN2TS8_csNWfpN7gsaD9FBN3wUtawAD_RPdJ952odfwJqyvrkN89AyKnFdFMvUh6_4LCIQVYd4M5KC_k1WNLYb11KZhq6O4UaoyD4X1pV4-x0jBzEnc4VQTkL_04dw2xdPJ1uqUrmHuUcIBO0SKaEk6_5HYc3GKfYwmPz1oxMpOi-Rzw1QPyWIdbrcZdFbIHoVZ8FKfyslEv392pJMiKzUnVWL_3mZ0UqnGtddwlXYVdSs57AUdlrfOe7TVaaIMZ_kL7FSrbWrsaSufitSYr62xD1K1-qeb4wkx8QQEorxGJ3RG1Vpn97Pn5JEC_jvj0s7uzFgidYR9bp80EMmPCHUmRg-Hm1Aq1B4YMNc1ARnFz6UvT_8_pMhJEwKuypA-nPoJu4JZJNLVUdw\",\"sitecoreApiKey\":\"{AD59BE63-BA20-47D4-A1B0-ECF30588E2E2}\",\"sitecoreApiHost\":\"https://prod.mckinsey.com\",\"FB_APP_ID\":\"1382278882079245\",\"ARTICLE_API_HOST\":\"https://prd-api.mckinsey.com\",\"SITECORE_FORMS_SERVICES_API_HOST\":\"https://prd-api.mckinsey.com\",\"FEATURE_TOGGLES\":\"{\\\"stack_adapt_pixel\\\": true, \\\"article_seo_schema\\\":true, \\\"remember_me\\\": true, \\\"gql_promo_banner\\\": true, \\\"gql_highlight_bar\\\": true, \\\"gql_ceros_placeholder\\\": true, \\\"gql_two_up_medium\\\": true, \\\"gql_hero_with_partnership_mark\\\": true, \\\"gql_brightcove_gallery\\\": true, \\\"gql_one_up_medium\\\": true, \\\"gql_promo_bar_with_quote\\\": true, \\\"gql_fifty_fifty_hero\\\": true, \\\"gql_enhanched_hero\\\": true, \\\"gql_two_up_small\\\": true, \\\"gql_general_up\\\": true, \\\"gql_full_bleed_hero\\\": true, \\\"passwordless_login_enabled\\\": true, \\\"sso_enabled\\\": true, \\\"article_id\\\": \\\"\\\", \\\"personalisation_enabled\\\":true, \\\"hide_student_sticky_footer\\\":true, \\\"email_domain_validation_enabled\\\":true}\",\"HEADER_SCRIPT_HASH\":\"abcd1234\",\"OKTA_AUTH_CLIENT_ID\":\"0oa8ppb3ypQ8uOI8y697\",\"OKTA_AUTH_ISSUER\":\"https://dotcomidp.mckinsey.com/oauth2/aus2byav0jTElyFDD697/\",\"AUTO_REDIRECTION_DURATION\":\"5\",\"LINKEDIN_IDP\":\"0oaecyj1byxnfrfFk697\",\"APPLE_IDP\":\"0oaeg2lxy6mq4PX5F697\",\"GOOGLE_IDP\":\"0oaeczfkb03XL3E4O697\",\"ALUMNI_BASE_API_URL\":\"https://dev-gateway.intranet.mckinsey.com/:apiKey/v1\",\"ALUMNI_AUTHENTICATE_API_URL\":\"https://dev-ac3-okta-auth.intranet.mckinsey.com/authenticate\",\"ALUMNI_OKTA_URL\":\"\",\"ALUMNI_OKTA_ENABLED\":\"true\",\"GOOGLE_MAP_API_KEY\":\"AIzaSyDqrGDNMDjy9pXHkMf-_Ut33LoC725GSe4\",\"AWS_GATEWAY\":\"https://dev-gateway.mckinsey.com\",\"AWS_API_GATEWAY_ID\":\"o63viscaj4\",\"AWS_PERSONALIZATION_TRACKING_ID\":\"f3f97bc3-4ca7-4960-9e49-0bcff6294ab4\",\"AWS_PERSONALIZATION_CID\":\"recommendations-onw-onw-mck-mck-art-2410-v1-user-ext-web\",\"EVENTS_MODULE_CARDS_COUNT\":\"8\",\"RECOMMENDATIONS_OFFER_ACTIVITY\":\"Article Recommendations\"},\"isFallback\":false,\"dynamicIds\":[70281,73769,76731,32991],\"gssp\":true,\"locale\":\"en\",\"locales\":[\"en\",\"da-DK\"],\"defaultLocale\":\"en\",\"isPreview\":true,\"scriptLoader\":[]}</script><script type=\"text/javascript\" src=\"/1sISTh/L/u/nAoEgpNcfg7J/GaO3tL2mVXLX7b/BVlZblY_cBA/SXAe/KgkXcSUB\"></script><div id=\"floating-ui-root\"></div><script src=\"https://assets.adobedtm.com/b0dfb38aec8a/63974894e9a9/launch-a400cfbb2fd3.min.js?l=1\" data-nscript=\"afterInteractive\"></script><script id=\"data-layer\" data-nscript=\"afterInteractive\">eventDataLayer.pageLoadCompleted()</script><next-route-announcer><p aria-live=\"assertive\" id=\"__next-route-announcer__\" role=\"alert\" style=\"border: 0px; clip: rect(0px, 0px, 0px, 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap; overflow-wrap: normal;\"></p></next-route-announcer></body></html>"
}